

PD-L2 is a second ligand for PD-1 and inhibits T cell acti

Nature Immunology

2, 261-268

DOI: 10.1038/85330

Citation Report

#	ARTICLE	IF	CITATIONS
1	Costimulation of Memory T-Cells by ICOS: A Potential Therapeutic Target for Autoimmunity?. <i>Clinical Immunology</i> , 2001, 100, 263-269.	1.4	29
2	PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. <i>Trends in Immunology</i> , 2001, 22, 265-268.	2.9	428
3	Manipulation of costimulatory pathways in autoimmune diseases. <i>Modern Rheumatology</i> , 2001, 11, 184-191.	0.9	1
4	Active immunization against cancer with dendritic cells: The near future. <i>International Journal of Cancer</i> , 2001, 94, 459-473.	2.3	285
5	The expanding B7 superfamily: Increasing complexity in costimulatory signals regulating T cell function. <i>Nature Immunology</i> , 2001, 2, 203-209.	7.0	372
6	T-cell regulation by CD28 and CTLA-4. <i>Nature Reviews Immunology</i> , 2001, 1, 220-228.	10.6	740
7	B7H Costimulates Clonal Expansion of, and Cognate Destruction of Tumor Cells by, CD8+ T Lymphocytes In Vivo. <i>Journal of Experimental Medicine</i> , 2001, 194, 1339-1348.	4.2	111
8	Cutting Edge: NKG2D Receptors Induced by IL-15 Costimulate CD28-Negative Effector CTL in the Tissue Microenvironment. <i>Journal of Immunology</i> , 2001, 167, 5527-5530.	0.4	295
9	Docking Protein Gab2 Is Phosphorylated by ZAP-70 and Negatively Regulates T Cell Receptor Signaling by Recruitment of Inhibitory Molecules. <i>Journal of Biological Chemistry</i> , 2001, 276, 45175-45183.	1.6	80
10	CD4+CD25high Regulatory Cells in Human Peripheral Blood. <i>Journal of Immunology</i> , 2001, 167, 1245-1253.	0.4	1,655
11	PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 13866-13871.	3.3	732
12	Cross-linking the B7 Family Molecule B7-DC Directly Activates Immune Functions of Dendritic Cells. <i>Journal of Experimental Medicine</i> , 2002, 196, 1393-1398.	4.2	96
13	Expression of Programmed Death 1 Ligands by Murine T Cells and APC. <i>Journal of Immunology</i> , 2002, 169, 5538-5545.	0.4	831
14	B7-H1 Is Expressed by Human Endothelial Cells and Suppresses T Cell Cytokine Synthesis. <i>Journal of Immunology</i> , 2002, 169, 3581-3588.	0.4	300
15	Characterization of Mouse and Human B7-H3 Genes. <i>Journal of Immunology</i> , 2002, 168, 6294-6297.	0.4	235
16	Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 12293-12297.	3.3	2,563
17	Programmed Death-1 Targeting Can Promote Allograft Survival. <i>Journal of Immunology</i> , 2002, 169, 6546-6553.	0.4	219
18	Failure of B7.1-modified tumor to evoke full activation of CD8+ tumor-infiltrating lymphocytes in the central nervous system: prevention of parental tumor growth in the subcutaneous environment. <i>Journal of Neurosurgery</i> , 2002, 97, 432-440.	0.9	2

#	ARTICLE	IF	CITATIONS
19	Immunomodulatory Effects of Antigen-Pulsed Macrophages in a Murine Model of Allergic Asthma. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2002, 27, 257-264.	1.4	24
20	CD8+ T Cell Tolerance to a Tumor-associated Antigen Is Maintained at the Level of Expansion Rather than Effector Function. <i>Journal of Experimental Medicine</i> , 2002, 195, 1407-1418.	4.2	96
21	Blockade of B7/CD28 in mixed lymphocyte reaction cultures results in the generation of alternatively activated macrophages, which suppress T-cell responses. <i>Blood</i> , 2002, 99, 1465-1473.	0.6	53
22	Heavy chain ferritin activates regulatory T cells by induction of changes in dendritic cells. <i>Blood</i> , 2002, 99, 3326-3334.	0.6	106
23	The role of SAP in murine CD150 (SLAM)-mediated T-cell proliferation and interferon $\hat{I}^3$ production. <i>Blood</i> , 2002, 100, 2899-2907.	0.6	67
24	A Cell-Based Artificial Antigen-Presenting Cell Coated with Anti-CD3 and CD28 Antibodies Enables Rapid Expansion and Long-Term Growth of CD4 T Lymphocytes. <i>Clinical Immunology</i> , 2002, 105, 259-272.	1.4	84
25	Costimulatory Molecules and Autoimmune Thyroid Diseases. <i>Autoimmunity</i> , 2002, 35, 159-167.	1.2	44
26	THE B7 FAMILY OF LIGANDS AND ITS RECEPTORS: New Pathways for Costimulation and Inhibition of Immune Responses. <i>Annual Review of Immunology</i> , 2002, 20, 29-53.	9.5	792
27	The Combination of Chemotherapy and Systemic Immunotherapy and the Concept of Cure in Murine Leukemia and Lymphoma. <i>Leukemia and Lymphoma</i> , 2002, 43, 2075-2082.	0.6	6
28	T-Cell costimulatory pathways relevant to transplant rejection and tolerance. <i>Transplantation Reviews</i> , 2002, 16, 205-219.	1.2	4
29	B7 Family Molecules: Novel Immunomodulators at the Maternal-Fetal Interface. <i>Placenta</i> , 2002, 23, S95-S101.	0.7	101
30	T-cell activation: a multidimensional signaling network. <i>Current Opinion in Cell Biology</i> , 2002, 14, 575-580.	2.6	69
31	CTLA-4 regulates cell cycle progression during a primary immune response. <i>European Journal of Immunology</i> , 2002, 32, 366-373.	1.6	115
32	PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2. <i>European Journal of Immunology</i> , 2002, 32, 634.	1.6	612
33	T $\hat{I}$ lymphocytes express B7 family molecules following interaction with dendritic cells and acquire bystander costimulatory properties. <i>European Journal of Immunology</i> , 2002, 32, 3092-3101.	1.6	31
34	Antigen-presenting cells and tolerance induction. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2002, 57, 2-8.	2.7	2
35	Negative co-receptors on lymphocytes. <i>Current Opinion in Immunology</i> , 2002, 14, 391-396.	2.4	152
36	The right place at the right time: novel B7 family members regulate effector T cell responses. <i>Current Opinion in Immunology</i> , 2002, 14, 384-390.	2.4	107

#	ARTICLE	IF	CITATIONS
37	New regulatory co-receptors: inducible co-stimulator and PD-1. <i>Current Opinion in Immunology</i> , 2002, 14, 779-782.	2.4	221
38	CD80 Expression is Induced on Activated B Cells Following Stimulation by CD86. <i>Scandinavian Journal of Immunology</i> , 2002, 55, 577-584.	1.3	22
39	Beyond Self and Nonself: Fuzzy Recognition of the Immune System. <i>Scandinavian Journal of Immunology</i> , 2002, 56, 224-232.	1.3	31
40	Microanatomical localization of PD-1 in human tonsils. <i>Immunology Letters</i> , 2002, 83, 215-220.	1.1	69
41	Structural mechanisms of costimulation. <i>Nature Immunology</i> , 2002, 3, 427-434.	7.0	123
42	Homeostasis and anergy of CD4+CD25+ suppressor T cells in vivo. <i>Nature Immunology</i> , 2002, 3, 33-41.	7.0	589
43	Protect the killer: CTLs need defenses against the tumor. <i>Nature Medicine</i> , 2002, 8, 787-789.	15.2	22
44	The enemy within: keeping self-reactive T cells at bay in the periphery. <i>Nature Reviews Immunology</i> , 2002, 2, 11-19.	10.6	503
45	The B7-CD28 superfamily. <i>Nature Reviews Immunology</i> , 2002, 2, 116-126.	10.6	1,513
46	Spinning molecular immunology into successful immunotherapy. <i>Nature Reviews Immunology</i> , 2002, 2, 227-238.	10.6	341
47	Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. <i>Immunology Letters</i> , 2002, 84, 57-62.	1.1	249
48	Cytotoxic T-Lymphocyte Antigen-4 and Programmed Death-1 Function as Negative Regulators of Lymphocyte Activation. <i>Immunologic Research</i> , 2003, 28, 49-60.	1.3	32
49	Interaction of B7RP-1 with ICOS negatively regulates antigen presentation by B cells. <i>Inflammation</i> , 2003, 27, 191-200.	1.7	3
50	Immunology of B7-H1 and Its Roles in Human Diseases. <i>International Journal of Hematology</i> , 2003, 78, 321-328.	0.7	34
51	Modulation of costimulation to enhance tumor immunity. <i>Cancer Immunology, Immunotherapy</i> , 2003, 52, 663-669.	2.0	18
52	B7-H1 pathway and its role in the evasion of tumor immunity. <i>Journal of Molecular Medicine</i> , 2003, 81, 281-287.	1.7	249
53	Negative T cell costimulation and islet tolerance. <i>Diabetes/Metabolism Research and Reviews</i> , 2003, 19, 179-185.	1.7	19
54	Preferential contribution of B7-H1 to programmed death-1-mediated regulation of hapten-specific allergic inflammatory responses. <i>European Journal of Immunology</i> , 2003, 33, 2773-2782.	1.6	119

#	ARTICLE	IF	CITATIONS
55	Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. <i>European Journal of Immunology</i> , 2003, 33, 2706-2716.	1.6	551
56	Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytotoxicity. <i>European Journal of Immunology</i> , 2003, 33, 3117-3126.	1.6	413
57	Some interfaces of dendritic cell biology. <i>Apmis</i> , 2003, 111, 675-697.	0.9	259
58	Negative feedback of T cell activation through inhibitory adapters and costimulatory receptors. <i>Immunological Reviews</i> , 2003, 192, 143-160.	2.8	64
59	Apoptosis and transplantation tolerance. <i>Immunological Reviews</i> , 2003, 193, 124-145.	2.8	22
60	T-Helper Cell Tolerance to Ubiquitous Nuclear Antigens. <i>Scandinavian Journal of Immunology</i> , 2003, 58, 478-492.	1.3	6
61	B cell inhibitory receptors and autoimmunity. <i>Immunology</i> , 2003, 108, 263-273.	2.0	93
62	T-cell costimulatory pathways in allograft rejection and tolerance. <i>Immunological Reviews</i> , 2003, 196, 85-108.	2.8	202
63	Mouse B7-H3 induces antitumor immunity. <i>Gene Therapy</i> , 2003, 10, 1728-1734.	2.3	112
64	TIP, a T-cell factor identified using high-throughput screening increases survival in a graft-versus-host disease model. <i>Nature Biotechnology</i> , 2003, 21, 302-307.	9.4	40
65	BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. <i>Nature Immunology</i> , 2003, 4, 670-679.	7.0	768
66	Costimulation through the inducible costimulator ligand is essential for both T helper and B cell functions in T cell-dependent B cell responses. <i>Nature Immunology</i> , 2003, 4, 765-772.	7.0	185
67	The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. <i>Nature Immunology</i> , 2003, 4, 899-906.	7.0	479
68	DOES THE IMMUNE SYSTEM SEE TUMORS AS FOREIGN OR SELF?. <i>Annual Review of Immunology</i> , 2003, 21, 807-839.	9.5	688
69	Role of costimulatory pathways in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. <i>Journal of Allergy and Clinical Immunology</i> , 2003, 112, 837-849.	1.5	50
70	Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma. <i>Journal of Experimental Medicine</i> , 2003, 198, 851-862.	4.2	1,002
71	B7 Family Molecules Are Favorably Positioned at the Human Maternal-Fetal Interface. <i>Biology of Reproduction</i> , 2003, 68, 1496-1504.	1.2	189
72	The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice. <i>Journal of Experimental Medicine</i> , 2003, 198, 63-69.	4.2	697

#	ARTICLE	IF	CITATIONS
73	Differential binding properties of B7-H1 and B7-DC to programmed death-1. <i>Biochemical and Biophysical Research Communications</i> , 2003, 307, 672-677.	1.0	181
74	A set of genes selectively expressed in murine dendritic cells: utility of related cis-acting sequences for lentiviral gene transfer. <i>Molecular Immunology</i> , 2003, 40, 35-47.	1.0	13
75	Graft immunogenicity and treatment of kidney donors. <i>Transplantation Reviews</i> , 2003, 17, 131-139.	1.2	1
76	Informatics and the immune system: the expanding IL-1 and B7 protein families. <i>Seminars in Immunology</i> , 2003, 15, 225-231.	2.7	2
77	B7S1, a Novel B7 Family Member that Negatively Regulates T Cell Activation. <i>Immunity</i> , 2003, 18, 863-873.	6.6	386
78	B7-H4, a Molecule of the B7 Family, Negatively Regulates T Cell Immunity. <i>Immunity</i> , 2003, 18, 849-861.	6.6	623
79	Finding genes for SLE: complex interactions and complex populations. <i>Journal of Autoimmunity</i> , 2003, 21, 117-120.	3.0	8
80	Regulation of immune and autoimmune responses by ICOS. <i>Journal of Autoimmunity</i> , 2003, 21, 255-260.	3.0	86
81	Current Perspective on the Pathogenesis of Gravesâ€™ Disease and Ophthalmopathy. <i>Endocrine Reviews</i> , 2003, 24, 802-835.	8.9	415
82	Blockade of B7-H1 Suppresses the Development of Chronic Intestinal Inflammation. <i>Journal of Immunology</i> , 2003, 171, 4156-4163.	0.4	163
83	B7DC/PDL2 Promotes Tumor Immunity by a PD-1-independent Mechanism. <i>Journal of Experimental Medicine</i> , 2003, 197, 1721-1730.	4.2	130
84	Molecular Modeling and Functional Mapping of B7-H1 and B7-DC Uncouple Costimulatory Function from PD-1 Interaction. <i>Journal of Experimental Medicine</i> , 2003, 197, 1083-1091.	4.2	259
85	Gene Array and Protein Expression Profiles Suggest Post-transcriptional Regulation during CD8+ T Cell Differentiation. <i>Journal of Biological Chemistry</i> , 2003, 278, 17044-17052.	1.6	29
86	PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 5336-5341.	3.3	536
87	Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies. <i>FASEB Journal</i> , 2003, 17, 1-16.	0.2	95
88	B7-H1 (Programmed Death-1 Ligand) on Dendritic Cells Is Involved in the Induction and Maintenance of T Cell Anergy. <i>Journal of Immunology</i> , 2003, 170, 3637-3644.	0.4	242
89	Cooperative B7-1/2 (CD80/CD86) and B7-DC Costimulation of CD4+ T Cells Independent of the PD-1 Receptor. <i>Journal of Experimental Medicine</i> , 2003, 198, 31-38.	4.2	144
90	Blockade of Programmed Death-1 Engagement Accelerates Graft-Versus-Host Disease Lethality by an IFN-Î³-Dependent Mechanism. <i>Journal of Immunology</i> , 2003, 171, 1272-1277.	0.4	305

#	ARTICLE	IF	CITATIONS
91	Critical Role of the Programmed Death-1 (PD-1) Pathway in Regulation of Experimental Autoimmune Encephalomyelitis. <i>Journal of Experimental Medicine</i> , 2003, 198, 71-78.	4.2	461
92	PD-1 Inhibits Antiviral Immunity at the Effector Phase in the Liver. <i>Journal of Experimental Medicine</i> , 2003, 198, 39-50.	4.2	353
93	T Cell Rewiring in Differentiation and Disease. <i>Journal of Immunology</i> , 2003, 171, 3325-3331.	0.4	57
94	B7x: A widely expressed B7 family member that inhibits T cell activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 10388-10392.	3.3	362
95	Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production. <i>Journal of Immunology</i> , 2003, 170, 1257-1266.	0.4	842
96	Blocking the Monocyte Chemoattractant Protein-1/CCR2 Chemokine Pathway Induces Permanent Survival of Islet Allografts through a Programmed Death-1 Ligand-1-Dependent Mechanism. <i>Journal of Immunology</i> , 2003, 171, 6929-6935.	0.4	100
97	Naturally Occurring Human IgM Antibody That Binds B7-DC and Potentiates T Cell Stimulation by Dendritic Cells. <i>Journal of Immunology</i> , 2003, 170, 1830-1838.	0.4	65
98	Absence of Programmed Death Receptor 1 Alters Thymic Development and Enhances Generation of CD4/CD8 Double-Negative TCR-Transgenic T Cells. <i>Journal of Immunology</i> , 2003, 171, 4574-4581.	0.4	99
99	Program Death-1 Engagement Upon TCR Activation Has Distinct Effects on Costimulation and Cytokine-Driven Proliferation: Attenuation of ICOS, IL-4, and IL-21, But Not CD28, IL-7, and IL-15 Responses. <i>Journal of Immunology</i> , 2003, 170, 711-718.	0.4	248
100	T cell costimulatory pathways: blockade for autoimmunity. <i>Expert Opinion on Biological Therapy</i> , 2003, 3, 227-236.	1.4	28
101	BOOSTING T CELL COSTIMULATION IN CANCER: THE POSSIBILITIES SEEM ENDLESS. <i>International Reviews of Immunology</i> , 2003, 22, 173-194.	1.5	10
102	Development of new strategies to prevent type 1 diabetes: the role of animal models. <i>Annals of Medicine</i> , 2003, 35, 546-563.	1.5	15
103	Role of novel T-cell costimulatory pathways in transplantation. <i>Current Opinion in Organ Transplantation</i> , 2003, 8, 25-33.	0.8	0
104	Stimulating PD-1 <sup>hi</sup> negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival <sup>1</sup> . <i>Transplantation</i> , 2003, 76, 994-999.	0.5	140
105	Impaired germinal center formation and recall T-cell <sup>hi</sup> dependent immune responses in mice lacking the costimulatory ligand B7-H2. <i>Blood</i> , 2003, 102, 1381-1388.	0.6	72
106	B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. <i>Blood</i> , 2003, 101, 2514-2520.	0.6	157
107	Molecular and Cellular Mechanisms Associated with Autoimmune Diseases. <i>International Journal of Environmental Research and Public Health</i> , 2004, 1, 39-73.	1.2	8
108	PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. <i>International Immunology</i> , 2004, 17, 133-144.	1.8	413

#	ARTICLE	IF	CITATIONS
109	B7-H1-targeted immunotherapy for head and neck cancer. <i>Expert Opinion on Biological Therapy</i> , 2004, 4, 1577-1583.	1.4	3
110	Specific Regulation of T Helper Cell $\alpha$ -mediated Murine Colitis by CEACAM1. <i>Journal of Experimental Medicine</i> , 2004, 199, 471-482.	4.2	103
111	CTLA-4+CD8+ T Cells That Encounter B7-2+ Iris Pigment Epithelial Cells Express Their Own B7-2 to Achieve Global Suppression of T Cell Activation. <i>Journal of Immunology</i> , 2004, 172, 4184-4194.	0.4	43
112	The genetic basis of systemic lupus erythematosus—knowledge of today and thoughts for tomorrow. <i>Human Molecular Genetics</i> , 2004, 13, 143R-148.	1.4	49
113	Human Recombinant B7-H3 Expressed in <i>E. coli</i> Enhances T Lymphocyte Proliferation and IL-10 Secretion <i>In Vitro</i> . <i>Acta Biochimica Et Biophysica Sinica</i> , 2004, 36, 430-436.	0.9	25
114	Immunotherapeutic Potential of B7-DC (PD-L2) Cross-Linking Antibody In Conferring Antitumor Immunity. <i>Cancer Research</i> , 2004, 64, 4965-4972.	0.4	61
115	B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression. <i>Clinical Cancer Research</i> , 2004, 10, 5094-5100.	3.2	633
116	CD28 Signals in the Immature Immunological Synapse. <i>Journal of Immunology</i> , 2004, 172, 5880-5886.	0.4	53
117	Acquisition of anergic and suppressive activities in transforming growth factor- $\beta$ -costimulated CD4+CD25- T cells. <i>International Immunology</i> , 2004, 16, 1203-1213.	1.8	102
118	Refolding and Characterization of Recombinant Human GST-PD-1 Fusion Protein Expressed in <i>Escherichia coli</i> . <i>Acta Biochimica Et Biophysica Sinica</i> , 2004, 36, 141-146.	0.9	9
119	B7-DC Regulates Asthmatic Response by an IFN- $\beta$ -Dependent Mechanism. <i>Journal of Immunology</i> , 2004, 172, 2530-2541.	0.4	136
120	Altering immune tolerance therapeutically: the power of negative thinking. <i>Journal of Leukocyte Biology</i> , 2004, 75, 586-599.	1.5	18
121	Blockade of Allergic Airway Inflammation Following Systemic Treatment with a B7-Dendritic Cell (PD-L2) Cross-Linking Human Antibody. <i>Journal of Immunology</i> , 2004, 173, 1360-1365.	0.4	34
122	<i>Schistosoma mansoni</i> Worms Induce Anergy of T Cells via Selective Up-Regulation of Programmed Death Ligand 1 on Macrophages. <i>Journal of Immunology</i> , 2004, 173, 1240-1248.	0.4	180
123	Blocking Programmed Death-1 Ligand-PD-1 Interactions by Local Gene Therapy Results in Enhancement of Antitumor Effect of Secondary Lymphoid Tissue Chemokine. <i>Journal of Immunology</i> , 2004, 173, 4919-4928.	0.4	111
124	SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation. <i>Journal of Immunology</i> , 2004, 173, 945-954.	0.4	989
125	Molecular Characterization of Human 4Ig-B7-H3, a Member of the B7 Family with Four Ig-Like Domains. <i>Journal of Immunology</i> , 2004, 172, 2352-2359.	0.4	228
126	The Ability of Two <i>Listeria monocytogenes</i> Vaccines Targeting Human Papillomavirus-16 E7 to Induce an Antitumor Response Correlates with Myeloid Dendritic Cell Function. <i>Journal of Immunology</i> , 2004, 172, 6030-6038.	0.4	45



#	ARTICLE	IF	CITATIONS
127	Regulation of Postsurgical Fibrosis by the Programmed Death-1 Inhibitory Pathway. <i>Journal of Immunology</i> , 2004, 172, 5774-5781.	0.4	24
128	PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells. <i>Cancer Research</i> , 2004, 64, 1140-1145.	0.4	679
129	PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 10691-10696.	3.3	556
130	Suppression of expression and function of negative immune regulator PD-1 by certain pattern recognition and cytokine receptor signals associated with immune system danger. <i>International Immunology</i> , 2004, 16, 1181-1188.	1.8	27
131	Cloning and Identification of Two Novel Splice Variants of Human PD-L2. <i>Acta Biochimica Et Biophysica Sinica</i> , 2004, 36, 284-289.	0.9	31
132	Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjogren's syndrome and systemic sclerosis. <i>Clinical and Experimental Immunology</i> , 2004, 136, 388-392.	1.1	54
133	An innately interesting decade of research in immunology. <i>Nature Medicine</i> , 2004, 10, 1307-1320.	15.2	127
134	Co-inhibitory molecules of the B7/CD28 family in the control of T-cell immunity. <i>Nature Reviews Immunology</i> , 2004, 4, 336-347.	10.6	1,110
135	Inducible-costimulator-mediated suppression of human immunodeficiency virus type 1 replication in CD4+ T lymphocytes. <i>Virology</i> , 2004, 325, 252-263.	1.1	8
136	PD-1 ligands, negative regulators for activation of naïve, memory, and recently activated human CD4+ T cells. <i>Cellular Immunology</i> , 2004, 230, 89-98.	1.4	64
137	Immunology of Pregnancy: Implications for the Mother. <i>Clinical Reviews in Allergy and Immunology</i> , 2004, 26, 161-170.	2.9	117
138	Reflections on CD8 T-Cell Activation and Memory. <i>Immunologic Research</i> , 2004, 29, 151-160.	1.3	50
139	Investigation on the effects of soluble programmed death-1 (sPD-1) enhancing anti-tumor immune response. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2004, 24, 531-534.	1.0	10
140	The role of ICOS and other costimulatory molecules in allergy and asthma. <i>Seminars in Immunopathology</i> , 2004, 25, 349-359.	4.0	53
141	Costimulation-based immunotherapy for head and neck cancer. <i>Current Treatment Options in Oncology</i> , 2004, 5, 27-33.	1.3	12
142	Association of a programmed death 1 gene polymorphism with the development of rheumatoid arthritis, but not systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2004, 50, 770-775.	6.7	148
143	Paradoxical role of programmed death-1 ligand?2 in Th2 immune responses in vitro and in a mouse asthma model in vivo. <i>European Journal of Immunology</i> , 2004, 34, 3326-3336.	1.6	47
144	Frontline: Characterization of B7 molecules belonging to the B7 family expressed on immune cells. <i>European Journal of Immunology</i> , 2004, 34, 2089-2099.	1.6	90

#	ARTICLE	IF	CITATIONS
145	Commentary: Regulated equilibrium between opposite signals: a general paradigm for T cell function?. European Journal of Immunology, 2004, 34, 2084-2088.	1.6	10
146	Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses. Microbes and Infection, 2004, 6, 759-766.	1.0	112
147	Microparticulate Î²-glucan upregulates the expression of B7.1, B7.2, B7-H1, but not B7-DC on cultured murine peritoneal macrophages. Immunology Letters, 2004, 93, 71-78.	1.1	21
148	The expression of B7-H1 on keratinocytes in chronic inflammatory mucocutaneous disease and its regulatory role. Immunology Letters, 2004, 94, 215-222.	1.1	67
149	T Lymphocyte-Endothelial Cell Interactions. Annual Review of Immunology, 2004, 22, 683-709.	9.5	179
150	Co-signaling molecules of the B7-CD28 family in positive and negative regulation of T lymphocyte responses. Microbes and Infection, 2004, , .	1.0	0
151	The expression and function of costimulatory molecules B7H and B7-H1 on colonic epithelial cells. Gastroenterology, 2004, 126, 1347-1357.	0.6	141
152	The deficiency of immunoregulatory receptor PD-1 causes mild osteopetrosis. Bone, 2004, 35, 1059-1068.	1.4	28
153	PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3Î¶ signalosome and downstream signaling to PKCÎ¶. FEBS Letters, 2004, 574, 37-41.	1.3	643
154	Molecular cloning and characterization of canine ICOS. Genomics, 2004, 84, 730-736.	1.3	4
155	Immunological Unresponsiveness Characterized by Increased Expression of CD5 on Peripheral T Cells Induced by Dendritic Cells In Vivo. Immunity, 2004, 20, 695-705.	6.6	204
156	Degenerate recognition of T cell epitopes: impact of T cell receptor reserve and stability of peptide:MHC complexes. Molecular Immunology, 2004, 40, 1019-1025.	1.0	22
157	B7-H1 Determines Accumulation and Deletion of Intrahepatic CD8+ T Lymphocytes. Immunity, 2004, 20, 327-336.	6.6	352
158	Structural and Functional Analysis of the Costimulatory Receptor Programmed Death-1. Immunity, 2004, 20, 337-347.	6.6	331
159	The Roles of the New Negative T Cell Costimulatory Pathways in Regulating Autoimmunity. Immunity, 2004, 20, 529-538.	6.6	202
160	Molecular Profiling Provides Evidence of Primary Mediastinal Large B-Cell Lymphoma as a Distinct Entity Related to Classic Hodgkin Lymphoma. Advances in Anatomic Pathology, 2004, 11, 227-238.	2.4	71
161	Programmed death-1- programmed death-L1 interaction is essential for induction of regulatory cells by intratracheal delivery of alloantigen. Transplantation, 2004, 77, 6-12.	0.5	34
162	The quantal theory of how the immune system discriminates between "self and non-self". Medical Immunology, 2004, 3, 3.	2.1	27

#	ARTICLE	IF	CITATIONS
163	T-Cell Costimulatory Pathways in Allograft Rejection and Tolerance. <i>Transplantation</i> , 2005, 80, 555-563.	0.5	108
164	T and B Cell Cooperation: A Dance of Life and Death. <i>Transplantation</i> , 2005, 79, S8-S11.	0.5	21
165	The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. <i>Blood</i> , 2005, 105, 13-21.	0.6	276
166	THE B7 FAMILY REVISITED. <i>Annual Review of Immunology</i> , 2005, 23, 515-548.	9.5	2,104
167	Characterization and application of two novel monoclonal antibodies against 2IgB7-H3: expression analysis of 2IgB7-H3 on dendritic cells and tumor cells. <i>Tissue Antigens</i> , 2005, 66, 83-92.	1.0	31
168	PD-L2+ dendritic cells and PD-1+ CD4+ T cells in schistosomiasis correlate with morbidity. <i>Parasite Immunology</i> , 2005, 27, 45-53.	0.7	20
169	Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily. <i>British Journal of Haematology</i> , 2005, 130, 809-824.	1.2	46
170	Co-stimulatory molecules as potential targets for therapeutic intervention in allergic airway disease. <i>Clinical and Experimental Allergy</i> , 2005, 35, 1521-1534.	1.4	18
171	Correlation of disease evolution with progressive inflammatory cell activation and migration in the IL-4 transgenic mouse model of atopic dermatitis. <i>Clinical and Experimental Immunology</i> , 2005, 139, 189-201.	1.1	38
172	B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. <i>Nature Immunology</i> , 2005, 6, 90-98.	7.0	543
173	Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. <i>Nature Immunology</i> , 2005, 6, 280-286.	7.0	478
174	TIM-1 induces T cell activation and inhibits the development of peripheral tolerance. <i>Nature Immunology</i> , 2005, 6, 447-454.	7.0	278
175	PDCD1: a tissue-specific susceptibility locus for inherited inflammatory disorders. <i>Genes and Immunity</i> , 2005, 6, 430-437.	2.2	42
176	Identification of a novel splice variant of human PD-L1 mRNA encoding an isoform-lacking Igv-like domain1. <i>Acta Pharmacologica Sinica</i> , 2005, 26, 462-468.	2.8	59
177	Migratory Langerhans Cells in Mouse Lymph Nodes in Steady State and Inflammation. <i>Journal of Investigative Dermatology</i> , 2005, 125, 116-125.	0.3	79
178	The B7/CD28 costimulatory family in autoimmunity. <i>Immunological Reviews</i> , 2005, 204, 128-143.	2.8	129
179	Alternative splice variants of the human PD-1 gene. <i>Cellular Immunology</i> , 2005, 235, 109-116.	1.4	171
180	Time courses of B7 family molecules expressed on activated T-cells and their biological significance. <i>Cellular Immunology</i> , 2005, 236, 146-153.	1.4	26

#	ARTICLE	IF	CITATIONS
181	Role of the programmed Death-1 pathway in the suppressive activity of alternatively activated macrophages in experimental cysticercosis. <i>International Journal for Parasitology</i> , 2005, 35, 1349-1358.	1.3	118
182	Immune interactions at the maternal-fetal interface. <i>Journal of Reproductive Immunology</i> , 2005, 68, 1-13.	0.8	64
183	Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. <i>European Journal of Immunology</i> , 2005, 35, 1482-1490.	1.6	637
184	Switching from a restricted to an effective CD4 T cell response by activating CD8+ murine dendritic cells with a Toll-like receptor ligand. <i>European Journal of Immunology</i> , 2005, 35, 3209-3220.	1.6	9
185	PD-L2:PD-1 involvement in T cell proliferation, cytokine production, and integrin-mediated adhesion. <i>European Journal of Immunology</i> , 2005, 35, 3561-3569.	1.6	113
186	Antibody-mediated signaling through PD-1 costimulates T cells and enhances CD28-dependent proliferation. <i>European Journal of Immunology</i> , 2005, 35, 3545-3560.	1.6	28
187	Biliary epithelial cells regulate autoreactive T cells: Implications for biliary-specific diseases. <i>Hepatology</i> , 2005, 41, 151-159.	3.6	55
188	A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. <i>Arthritis and Rheumatism</i> , 2005, 52, 1058-1062.	6.7	131
189	A PD-1 polymorphism is associated with disease progression in multiple sclerosis. <i>Annals of Neurology</i> , 2005, 58, 50-57.	2.8	203
190	The adaptive immune response in neonatal cerebral white matter damage. <i>Annals of Neurology</i> , 2005, 58, 821-828.	2.8	77
191	Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 307-314.	2.0	509
192	Dendritic cell-mediated T cell polarization. <i>Seminars in Immunopathology</i> , 2005, 26, 289-307.	4.0	296
193	The balance of immune responses: costimulation versus coinhibition. <i>Journal of Molecular Medicine</i> , 2005, 83, 193-202.	1.7	69
194	Costimulation: critical pathways in the immunologic regulation of asthma. <i>Current Allergy and Asthma Reports</i> , 2005, 5, 149-154.	2.4	19
195	Immune Modulations. , 2005, , 475-490.		0
196	Immunity at the Maternal-Fetal Interface. , 2005, , 1735-1745.		1
197	Role of the Programmed Death-1 Pathway in Regulation of Alloimmune Responses In Vivo. <i>Journal of Immunology</i> , 2005, 174, 3408-3415.	0.4	164
198	Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD). <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2005, 360, 1747-1767.	1.8	56

#	ARTICLE	IF	CITATIONS
199	Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 2947-2953.	3.2	714
200	B and T Lymphocyte Attenuator Exhibits Structural and Expression Polymorphisms and Is Highly Induced in Anergic CD4+ T Cells. <i>Journal of Immunology</i> , 2005, 174, 3377-3385.	0.4	169
201	In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses. <i>Journal of Experimental Medicine</i> , 2005, 201, 1531-1541.	4.2	140
202	Constitutive and Inducible Expression of B7 Family of Ligands by Human Airway Epithelial Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2005, 33, 280-289.	1.4	129
203	PD-1/PD-L pathway and autoimmunity. <i>Autoimmunity</i> , 2005, 38, 353-357.	1.2	85
204	Blockade of B7-H1 on Macrophages Suppresses CD4+ T Cell Proliferation by Augmenting IFN- $\gamma$ -Induced Nitric Oxide Production. <i>Journal of Immunology</i> , 2005, 175, 1586-1592.	0.4	129
205	ICOS-B7 Homologous Protein Interactions Are Necessary for Mercury-Induced Autoimmunity. <i>Journal of Immunology</i> , 2005, 174, 3117-3121.	0.4	24
206	Lyn-Deficient Mice Develop Severe, Persistent Asthma: Lyn Is a Critical Negative Regulator of Th2 Immunity. <i>Journal of Immunology</i> , 2005, 175, 1867-1875.	0.4	77
207	Analysis of the Role of Negative T Cell Costimulatory Pathways in CD4 and CD8 T Cell-Mediated Alloimmune Responses In Vivo. <i>Journal of Immunology</i> , 2005, 174, 6648-6656.	0.4	139
208	Microglial Expression of the B7 Family Member B7 Homolog 1 Confers Strong Immune Inhibition: Implications for Immune Responses and Autoimmunity in the CNS. <i>Journal of Neuroscience</i> , 2005, 25, 2537-2546.	1.7	150
209	B7-DC cross-linking restores antigen uptake and augments antigen-presenting cell function by matured dendritic cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 11438-11443.	3.3	39
210	Programmed Death-1 (PD-1):PD-Ligand 1 Interactions Inhibit TCR-Mediated Positive Selection of Thymocytes. <i>Journal of Immunology</i> , 2005, 175, 7372-7379.	0.4	122
211	CD80 Cytoplasmic Domain Controls Localization of CD28, CTLA-4, and Protein Kinase C $\zeta$ in the Immunological Synapse. <i>Journal of Immunology</i> , 2005, 175, 7829-7836.	0.4	57
212	Activated Macrophages Infected with <i>Legionella</i> Inhibit T Cells by Means of MyD88-Dependent Production of Prostaglandins. <i>Journal of Immunology</i> , 2005, 175, 8181-8190.	0.4	24
213	A critical role for the programmed death ligand 1 in fetomaternal tolerance. <i>Journal of Experimental Medicine</i> , 2005, 202, 231-237.	4.2	375
214	The Biology of Human Lymphoid Malignancies Revealed by Gene Expression Profiling. <i>Advances in Immunology</i> , 2005, 87, 163-208.	1.1	218
215	Pathogenic roles of cardiac autoantibodies in dilated cardiomyopathy. <i>Trends in Molecular Medicine</i> , 2005, 11, 322-326.	3.5	40
216	Oscillating CD8+ T Cell Effector Functions after Antigen Recognition in the Liver. <i>Immunity</i> , 2005, 23, 53-63.	6.6	174

#	ARTICLE	IF	CITATIONS
217	Sinomenine inhibits B7-H1 and B7-DC expression on human renal tubular epithelial cells. <i>International Immunopharmacology</i> , 2005, 5, 1446-1457.	1.7	22
218	Expression of B7-H1 and B7-DC on the airway epithelium is enhanced by double-stranded RNA. <i>Biochemical and Biophysical Research Communications</i> , 2005, 330, 263-270.	1.0	40
219	PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis. <i>Clinical Immunology</i> , 2005, 115, 184-191.	1.4	86
220	B7-H1 (CD274) inhibits the development of herpetic stromal keratitis (HSK). <i>FEBS Letters</i> , 2005, 579, 6259-6264.	1.3	35
221	The Immunomodulatory Proteins B7-DC, B7-H2, and B7-H3 Are Differentially Expressed across Gestation in the Human Placenta. <i>American Journal of Pathology</i> , 2005, 167, 465-473.	1.9	77
222	Inhibitors of mitogen-activated protein kinases differentially regulate costimulated T cell cytokine production and mouse airway eosinophilia. <i>Respiratory Research</i> , 2005, 6, 36.	1.4	45
224	The B7 family of immune-regulatory ligands. <i>Genome Biology</i> , 2005, 6, 223.	13.9	256
225	Association of the programmed cell death 1 (PDCD1) gene polymorphism with ankylosing spondylitis in the Korean population. <i>Arthritis Research and Therapy</i> , 2006, 8, R163.	1.6	70
226	Checkpoint Blockade in Cancer Immunotherapy. <i>Advances in Immunology</i> , 2006, 90, 297-339.	1.1	498
227	Immunology of Pregnancy. , 2006, , .		11
228	Cancer Drug Resistance. , 2006, , .		21
229	Aberrant Regulation of Synovial T Cell Activation by Soluble Costimulatory Molecules in Rheumatoid Arthritis. <i>Journal of Immunology</i> , 2006, 177, 8844-8850.	0.4	194
230	Therapeutic potential of adenovirus as a vaccine vector for chronic virus infections. <i>Expert Opinion on Biological Therapy</i> , 2006, 6, 63-72.	1.4	10
231	Tissue expression of PD-L1 mediates peripheral T cell tolerance. <i>Journal of Experimental Medicine</i> , 2006, 203, 883-895.	4.2	1,042
233	PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. <i>Journal of Experimental Medicine</i> , 2006, 203, 2281-2292.	4.2	808
234	No cancer in cancers: Evolutionary trade-off between successful viviparity and tumor escape from the adaptive immune system. <i>Medical Hypotheses</i> , 2006, 66, 888-897.	0.8	21
235	PD-L1 is induced in hepatocytes by viral infection and by interferon- $\alpha$ and $\beta$ and mediates T cell apoptosis. <i>Journal of Hepatology</i> , 2006, 45, 520-528.	1.8	331
236	Turning on the off switch: Regulation of anti-viral T cell responses in the liver by the PD-1/PD-L1 pathway. <i>Journal of Hepatology</i> , 2006, 45, 468-472.	1.8	46

#	ARTICLE	IF	CITATIONS
237	Negative costimulatory molecules: The proximal of regulatory T cells?. Medical Hypotheses, 2006, 67, 841-847.	0.8	1
238	Immune Accessory Functions of Human Endothelial Cells Are Modulated by Overexpression of B7-H1 (PDL1). Human Immunology, 2006, 67, 568-578.	1.2	25
239	SHP1 Phosphatase-Dependent T Cell Inhibition by CEACAM1 Adhesion Molecule Isoforms. Immunity, 2006, 25, 769-781.	6.6	123
240	The PD-1/PD-L pathway in immunological tolerance. Trends in Immunology, 2006, 27, 195-201.	2.9	632
241	A genetic library screen for signaling proteins that interact with phosphorylated T cell costimulatory receptors. Genomics, 2006, 88, 841-845.	1.3	12
242	Mycophenolic Acid Upregulates B7-DC Expression on Dendritic Cells, Which Is Associated With Impaired Allostimulatory Capacity of Dendritic Cells. Transplantation Proceedings, 2006, 38, 1622-1624.	0.3	5
243	Expression of Costimulatory Molecules on Human Retinoblastoma Cells Y-79: Functional Expression of CD40 and B7H1. , 2006, 47, 4607.		14
244	Immunobiology of Human Pregnancy. , 2006, , 2759-2785.		8
245	Peroxisome proliferator-activated receptor $\gamma$ (PPAR $\gamma$ ) ligands reverse CTL suppression by alternatively activated (M2) macrophages in cancer. Blood, 2006, 108, 525-535.	0.6	114
246	DIgR2, dendritic cell-derived immunoglobulin receptor 2, is one representative of a family of IgSF inhibitory receptors and mediates negative regulation of dendritic cell-initiated antigen-specific T-cell responses. Blood, 2006, 108, 2678-2686.	0.6	44
247	Manipulating Immunological Checkpoints to Maximize Antitumor Immunity. , 2006, , 331-353.		0
248	Coinhibitory T-Cell Signaling in Islet Allograft Rejection and Tolerance. Cell Transplantation, 2006, 15, 105-119.	1.2	65
249	Suppression of Human T-Cell Responses to $\beta$ 2-Cells by Activation of B7-H4 Pathway. Cell Transplantation, 2006, 15, 399-410.	1.2	41
250	Gene Transfer of Programmed Death Ligand-1.Ig Prolongs Cardiac Allograft Survival. Transplantation, 2006, 82, 1733-1737.	0.5	42
251	Interaction of keratinocytes with infiltrating lymphocytes in allergic eczematous skin diseases. Current Opinion in Allergy and Clinical Immunology, 2006, 6, 329-334.	1.1	50
253	Costimulation blockade and its possible future use in clinical transplantation. Transplant International, 2006, 19, 693-704.	0.8	45
254	B7-H1 expression is upregulated in peripheral blood CD14+ monocytes of patients with chronic hepatitis B virus infection, which correlates with higher serum IL-10 levels. Journal of Viral Hepatitis, 2006, 13, 725-733.	1.0	32
255	Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nature Medicine, 2006, 12, 1198-1202.	15.2	1,376

#	ARTICLE	IF	CITATIONS
256	Balancing co-stimulation and inhibition with BTLA and HVEM. <i>Nature Reviews Immunology</i> , 2006, 6, 671-681.	10.6	270
257	Expression of the novel co-stimulatory molecule B7-H4 by renal tubular epithelial cells. <i>Kidney International</i> , 2006, 70, 2092-2099.	2.6	23
258	Immune privilege induced by regulatory T cells in transplantation tolerance. <i>Immunological Reviews</i> , 2006, 213, 239-255.	2.8	127
259	CD28 and ICOS: Similar or separate costimulators of T cells?. <i>Immunology Letters</i> , 2006, 105, 115-122.	1.1	63
260	Role of CEACAM1 as a Regulator of T Cells. <i>Annals of the New York Academy of Sciences</i> , 2006, 1072, 155-175.	1.8	43
261	Programmed Death-1 Gene Polymorphisms in Patients With Systemic Lupus Erythematosus in Taiwan. <i>Journal of Clinical Immunology</i> , 2006, 26, 506-511.	2.0	49
262	Low interleukin-10 production is associated with diabetes in HIV-infected patients undergoing antiviral therapy. <i>Medical Microbiology and Immunology</i> , 2006, 195, 125-132.	2.6	7
263	The genetics of systemic lupus erythematosus: understanding how SNPs confer disease susceptibility. <i>Seminars in Immunopathology</i> , 2006, 28, 109-117.	4.0	12
264	Physiologic regulation of central and peripheral T cell tolerance: lessons for therapeutic applications. <i>Journal of Molecular Medicine</i> , 2006, 84, 887-899.	1.7	24
265	Co-inhibitory role of T-cell-associated B7-H1 and B7-DC in the T-cell immune response. <i>Immunology Letters</i> , 2006, 102, 222-228.	1.1	47
266	Putting T cells to sleep: A new paradigm for immune evasion by persistent viruses. <i>Journal of Biosciences</i> , 2006, 31, 497-501.	0.5	2
267	Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. <i>Oral Oncology</i> , 2006, 42, 268-274.	0.8	86
268	Targeting memory Th2 cells for the treatment of allergic asthma. , 2006, 109, 107-136.		41
269	No evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activation. <i>European Journal of Immunology</i> , 2006, 36, 1104-1113.	1.6	45
270	PD-L1 and PD-L2 have distinct roles in regulating host immunity to cutaneous leishmaniasis. <i>European Journal of Immunology</i> , 2006, 36, 58-64.	1.6	78
271	Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation. <i>European Journal of Immunology</i> , 2006, 36, 2472-2482.	1.6	164
272	Human ILT2 receptor associates with murine MHC class I molecules in vivo and impairs T cell function. <i>European Journal of Immunology</i> , 2006, 36, 2457-2471.	1.6	42
273	The liver as an immunological organ. <i>Hepatology</i> , 2006, 43, S54-S62.	3.6	1,076



#	ARTICLE	IF	CITATIONS
274	Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. <i>International Journal of Cancer</i> , 2006, 119, 317-327.	2.3	276
275	Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of treg cells, and enhanced expression of the PD-1 costimulatory pathway. <i>Journal of Neuroscience Research</i> , 2006, 84, 370-378.	1.3	205
276	High-level expression of B7-H1 molecules by dendritic cells suppresses the function of activated T cells and desensitizes allergen-primed animals. <i>Journal of Leukocyte Biology</i> , 2006, 79, 686-695.	1.5	35
277	Costimulatory Molecules as Targets for the Induction of Transplantation Tolerance. <i>Current Molecular Medicine</i> , 2006, 6, 843-857.	0.6	21
278	Differential Role of Programmed Death-Ligand 1 and Programmed Death-Ligand 2 in Regulating the Susceptibility and Chronic Progression of Experimental Autoimmune Encephalomyelitis. <i>Journal of Immunology</i> , 2006, 176, 3480-3489.	0.4	122
279	Reinvigorating exhausted HIV-specific T cells via PD-1 ligand blockade. <i>Journal of Experimental Medicine</i> , 2006, 203, 2223-2227.	4.2	374
280	Generation and Characterization of B7-H4/B7S1/B7x-Deficient Mice. <i>Molecular and Cellular Biology</i> , 2006, 26, 6403-6411.	1.1	72
281	B7-H1-Induced Apoptosis as a Mechanism of Immune Privilege of Corneal Allografts. <i>Journal of Immunology</i> , 2006, 177, 5928-5935.	0.4	190
282	Modulation of Immune Response by B7 Family Molecules in Tumor Microenvironments. <i>Immunological Investigations</i> , 2006, 35, 395-418.	1.0	14
283	Involvement of programmed death-ligand 2 (PD-L2) in the development of experimental allergic conjunctivitis in mice. <i>British Journal of Ophthalmology</i> , 2006, 90, 1040-1045.	2.1	28
284	Expression of B7-H1 in Inflammatory Renal Tubular Epithelial Cells. <i>Nephron Experimental Nephrology</i> , 2006, 102, e81-e92.	2.4	39
285	Regulation of T cell activation and tolerance by PDL2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 11695-11700.	3.3	151
286	Roadmap to a Better Therapeutic Tumor Vaccine. <i>International Reviews of Immunology</i> , 2006, 25, 415-443.	1.5	56
287	The Biochemical Mechanisms of T-Cell Anergy. <i>Current Immunology Reviews</i> , 2006, 2, 73-99.	1.2	0
288	Differential Effects of Costimulatory Pathway Modulation on Corneal Allograft Survival. , 2006, 47, 3417.		51
289	Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 3360-3365.	3.3	1,308
290	B7-DC/PD-L2 Cross-Linking Induces NF- $\kappa$ B-Dependent Protection of Dendritic Cells from Cell Death. <i>Journal of Immunology</i> , 2007, 178, 1426-1432.	0.4	28
291	Induction of Tolerance in CD8+ T Cells to a Transgenic Autoantigen Expressed in the Liver Does Not Require Cross-Presentation. <i>Journal of Immunology</i> , 2007, 178, 6849-6860.	0.4	24

#	ARTICLE	IF	CITATIONS
292	BTNL2, a Butyrophilin/B7-Like Molecule, Is a Negative Costimulatory Molecule Modulated in Intestinal Inflammation. <i>Journal of Immunology</i> , 2007, 178, 1523-1533.	0.4	116
293	Characterization of Human Lung Tumor-Associated Fibroblasts and Their Ability to Modulate the Activation of Tumor-Associated T Cells. <i>Journal of Immunology</i> , 2007, 178, 5552-5562.	0.4	223
294	Liver-Infiltrating Lymphocytes in Chronic Human Hepatitis C Virus Infection Display an Exhausted Phenotype with High Levels of PD-1 and Low Levels of CD127 Expression. <i>Journal of Virology</i> , 2007, 81, 2545-2553.	1.5	431
295	PD-1:PD-L1 Interactions Contribute to the Functional Suppression of Virus-Specific CD8+ T Lymphocytes in the Liver. <i>Journal of Immunology</i> , 2007, 178, 2714-2720.	0.4	214
296	PDL1 Is Required for Peripheral Transplantation Tolerance and Protection from Chronic Allograft Rejection. <i>Journal of Immunology</i> , 2007, 179, 5204-5210.	0.4	176
297	Programmed Death 1 Ligand (PD-L) 1 and PD-L2 Limit Autoimmune Kidney Disease: Distinct Roles. <i>Journal of Immunology</i> , 2007, 179, 7466-7477.	0.4	73
298	T Cell Costimulatory and Inhibitory Receptors as Therapeutic Targets for Inducing Anti-Tumor Immunity. <i>Current Cancer Drug Targets</i> , 2007, 7, 55-70.	0.8	43
299	Specific and high-affinity binding of tetramerized PD-L1 extracellular domain to PD-1-expressing cells: possible application to enhance T cell function. <i>International Immunology</i> , 2007, 19, 881-890.	1.8	11
300	Costimulation, Coinhibition and Cancer. <i>Current Cancer Drug Targets</i> , 2007, 7, 15-30.	0.8	86
301	T-cell costimulation blockade in immunologic diseases: role of CD28 family members. <i>Expert Review of Clinical Immunology</i> , 2007, 3, 383-393.	1.3	0
302	Histone Deacetylase 7 Functions as a Key Regulator of Genes Involved in both Positive and Negative Selection of Thymocytes. <i>Molecular and Cellular Biology</i> , 2007, 27, 5184-5200.	1.1	58
303	Master switches of T-cell activation and differentiation. <i>European Respiratory Journal</i> , 2007, 29, 804-812.	3.1	38
304	The Function of Donor versus Recipient Programmed Death-Ligand 1 in Corneal Allograft Survival. <i>Journal of Immunology</i> , 2007, 179, 3672-3679.	0.4	101
305	Endothelial Programmed Death-1 Ligand 1 (PD-L1) Regulates CD8 <sup>+</sup> T-Cell-Mediated Injury in the Heart. <i>Circulation</i> , 2007, 116, 2062-2071.	1.6	221
306	Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 17765-17770.	3.3	97
307	Induction of a Th1 Response from Th2-Polarized T Cells by Activated Dendritic Cells: Dependence on TCR:Peptide-MHC Interaction, ICAM-1, IL-12, and IFN- $\gamma$ . <i>Journal of Immunology</i> , 2007, 178, 3583-3592.	0.4	28
308	Elevated Expression Levels of Inhibitory Receptor Programmed Death 1 on Simian Immunodeficiency Virus-Specific CD8 T Cells during Chronic Infection but Not after Vaccination. <i>Journal of Virology</i> , 2007, 81, 5819-5828.	1.5	119
309	Blockade of IDO Inhibits Nasal Tolerance Induction. <i>Journal of Immunology</i> , 2007, 179, 894-900.	0.4	39

#	ARTICLE	IF	CITATIONS
310	Syndecan-4 Mediates the Coinhibitory Function of DC-HIL on T Cell Activation. <i>Journal of Immunology</i> , 2007, 179, 5778-5784.	0.4	94
311	Effects of Specific Immunotherapy on the B7 Family of Costimulatory Molecules in Allergic Inflammation. <i>Journal of Immunology</i> , 2007, 178, 1931-1937.	0.4	16
312	Roles of programmed death-1 (PD-1)/PD-1 ligands pathway in the development of murine acute myocarditis caused by coxsackievirus B3. <i>Cardiovascular Research</i> , 2007, 75, 158-167.	1.8	51
313	Chronic Rhinosinusitis. , 0, , .		5
314	Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 2151-2157.	3.2	783
315	12-O-tetradecanoyl phorbol 13-acetate induces the expression of B7-DC, -H1, -H2, and -H3 in K562 cells. <i>International Journal of Oncology</i> , 2007, , .	1.4	2
316	DC-HIL is a negative regulator of T lymphocyte activation. <i>Blood</i> , 2007, 109, 4320-4327.	0.6	109
317	Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy. <i>Blood</i> , 2007, 110, 180-185.	0.6	209
318	Involvement of the Programmed Death-1/Programmed Death-1 Ligand Pathway in CD4+CD25+ Regulatory T-Cell Activity to Suppress Alloimmune Responses. <i>Transplantation</i> , 2007, 83, 774-782.	0.5	112
319	The New B7s: Playing a Pivotal Role in Tumor Immunity. <i>Journal of Immunotherapy</i> , 2007, 30, 251-260.	1.2	178
320	Programmed death 1: a critical regulator of T-cell function and a strong target for immunotherapies for chronic viral infections. <i>Current Opinion in HIV and AIDS</i> , 2007, 2, 219-227.	1.5	17
321	PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status. <i>Aids</i> , 2007, 21, 2005-2013.	1.0	151
322	PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. <i>Blood</i> , 2007, 109, 4671-4678.	0.6	259
323	Costimulatory receptors in jawed vertebrates: Conserved CD28, odd CTLA4 and multiple BTLAs. <i>Developmental and Comparative Immunology</i> , 2007, 31, 255-271.	1.0	79
324	Expression of programmed-death receptor ligands 1 and 2 may contribute to the poor stimulatory potential of murine immature dendritic cells. <i>Immunobiology</i> , 2007, 212, 159-165.	0.8	26
325	Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses. <i>Immunity</i> , 2007, 27, 111-122.	6.6	1,464
326	“Vive la Résistance!”™ “ the PI3K/Akt pathway can determine target sensitivity to regulatory T cell suppression. <i>Trends in Immunology</i> , 2007, 28, 154-160.	2.9	42
327	B7-1 mediated costimulation regulates pancreatic autoimmunity. <i>Molecular Immunology</i> , 2007, 44, 2616-2624.	1.0	12

#	ARTICLE	IF	CITATIONS
328	PD-1 and PD-1 ligands: from discovery to clinical application. <i>International Immunology</i> , 2007, 19, 813-824.	1.8	1,064
329	General Principles of Tumor Immunotherapy. , 2007, , .		3
330	Understanding Gene Expression Patterns in Immune-Mediated Disorders. <i>Journal of Immunotoxicology</i> , 2007, 4, 201-207.	0.9	7
331	The B7 Family and Cancer Therapy: Costimulation and Coinhibition. <i>Clinical Cancer Research</i> , 2007, 13, 5271-5279.	3.2	308
332	Programmed Death 1 Expression on HIV-Specific CD4+ T Cells Is Driven by Viral Replication and Associated with T Cell Dysfunction. <i>Journal of Immunology</i> , 2007, 179, 1979-1987.	0.4	234
333	Dendritic Cells and Coregulatory Signals: Immune Checkpoint Blockade to Stimulate Immunotherapy. , 2007, , 257-275.		0
335	Inhibitory Receptors and Autoimmunity in the Mouse. , 2007, , 261-273.		0
337	Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice. <i>Journal of Clinical Investigation</i> , 2007, 117, 2974-2982.	3.9	174
338	Programmed cell death 1 gene (PDCD1) polymorphism and pemphigus foliaceus (fogo selvagem) disease susceptibility. <i>Genetics and Molecular Biology</i> , 2007, 30, 314-321.	0.6	14
339	Immunotherapy and Cancer Therapeutics: Why Partner?. , 2007, , 207-233.		5
340	Mini-review of conventional and hypofractionated radiation therapy combined with immunotherapy for non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2007, 6, 220-229.	1.3	10
341	Transplant tolerance through costimulation blockade - are we there yet?. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 2935.	3.0	6
342	Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4 <sup>+</sup> T cells in adult T cell leukemia/lymphoma. <i>International Journal of Cancer</i> , 2007, 121, 2585-2590.	2.3	82
343	The tyrosine phosphatase SHP-2 regulates differentiation and apoptosis of individual primary T <sub>H</sub> 1 lymphocytes. <i>European Journal of Immunology</i> , 2007, 37, 1072-1086.	1.6	14
344	PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for V <sub>H</sub> 11/V <sub>H</sub> 12 and phosphatidylcholine binding. <i>European Journal of Immunology</i> , 2007, 37, 2405-2410.	1.6	173
345	Programmed cell death-1 (PD-1) and its ligand PD-L1 are required for allograft tolerance. <i>European Journal of Immunology</i> , 2007, 37, 2983-2990.	1.6	68
346	Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7-homolog 1-dependent CD8+ T cell tolerance. <i>Hepatology</i> , 2008, 47, 296-305.	3.6	242
347	The sound of silence: modulating energy in T lymphocytes. <i>Current Opinion in Immunology</i> , 2007, 19, 658-664.	2.4	32

#	ARTICLE	IF	CITATIONS
348	The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. <i>Nature Immunology</i> , 2007, 8, 239-245.	7.0	1,286
349	Immunostimulatory monoclonal antibodies for cancer therapy. <i>Nature Reviews Cancer</i> , 2007, 7, 95-106.	12.8	564
350	The contribution of immunology to the rational design of novel antibacterial vaccines. <i>Nature Reviews Microbiology</i> , 2007, 5, 491-504.	13.6	144
351	No evidence of association between genetic variants of the PDCD1 ligands and SLE. <i>Genes and Immunity</i> , 2007, 8, 69-74.	2.2	16
352	PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies. <i>Tissue Antigens</i> , 2007, 69, 19-27.	1.0	68
353	Characterization and application of three novel monoclonal antibodies against human 4â€BB: distinct epitopes of human 4â€BB on lung tumor cells and immune cells. <i>Tissue Antigens</i> , 2007, 70, 470-479.	1.0	17
354	The divergent roles of alternatively activated macrophages in helminthic infections. <i>Parasite Immunology</i> , 2007, 29, 609-619.	0.7	113
355	From Tâ€cell activation signals to signaling control of antiâ€cancer immunity. <i>Immunological Reviews</i> , 2007, 220, 151-168.	2.8	69
356	Virusâ€based immunotherapy of cancer: what do we know and where are we going?. <i>Apmsis</i> , 2007, 115, 1177-1193.	0.9	4
357	Intrahepatic expression of the coâ€stimulatory molecules programmed deathâ€1, and its ligands in autoimmune liver disease. <i>Pathology International</i> , 2007, 57, 485-492.	0.6	54
358	Mechanisms of PDL1-mediated regulation of autoimmune diabetes. <i>Clinical Immunology</i> , 2007, 125, 16-25.	1.4	111
359	Inhibitory costimulation and anti-tumor immunity. <i>Seminars in Cancer Biology</i> , 2007, 17, 288-298.	4.3	27
360	Immune suppression in renal cell carcinoma. <i>Seminars in Cancer Biology</i> , 2007, 17, 330-343.	4.3	35
361	PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2007, 182, 124-134.	1.1	175
362	The PD-1/PD-L pathway is up-regulated during IL-12-induced suppression of EAE mediated by IFN-gamma. <i>Journal of Neuroimmunology</i> , 2007, 185, 75-86.	1.1	63
363	Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1173-1182.	2.0	413
364	Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 739-745.	2.0	412
365	Lymphocyte tracking and interactions in secondary lymphoid organs. <i>Inflammation Research</i> , 2007, 56, 391-401.	1.6	20

#	ARTICLE	IF	CITATIONS
366	Potent Systemic Antitumor Immunity Induced by Vaccination with Chemotactic-Prostate Tumor Associated Antigen Gene-Modified Tumor Cell and Blockade of B7-H1. <i>Journal of Clinical Immunology</i> , 2007, 27, 117-130.	2.0	12
367	Polymorphisms of Genes for Programmed Cell Death 1 Ligands in Patients with Rheumatoid Arthritis. <i>Journal of Clinical Immunology</i> , 2007, 27, 563-567.	2.0	15
368	PD-1 gene haplotype is associated with the development of type 1 diabetes mellitus in Japanese children. <i>Human Genetics</i> , 2007, 121, 223-232.	1.8	63
369	Artificial phosphatidylserine liposome mimics apoptotic cells in inhibiting maturation and immunostimulatory function of murine myeloid dendritic cells in response to 1-chloro-2,4-dinitrobenzene in vitro. <i>Archives of Dermatological Research</i> , 2007, 299, 327-336.	1.1	27
370	Immunotherapeutic strategies employing RNA interference technology for the control of cancers. <i>Journal of Biomedical Science</i> , 2007, 14, 15-29.	2.6	20
371	Glucocorticoids impair microglia ability to induce T cell proliferation and Th1 polarization. <i>Immunology Letters</i> , 2007, 109, 129-137.	1.1	25
372	Modulating Co-Stimulation. <i>Neurotherapeutics</i> , 2007, 4, 666-675.	2.1	8
373	TLR-mediated induction of negative regulatory ligands on dendritic cells. <i>Journal of Molecular Medicine</i> , 2008, 86, 443-455.	1.7	30
374	B7-1 restricts neuroantigen-specific T cell responses and confines inflammatory CNS damage: Implications for the lesion pathogenesis of multiple sclerosis. <i>European Journal of Immunology</i> , 2008, 38, 1734-1744.	1.6	72
375	PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T cell responses in EAE. <i>European Journal of Immunology</i> , 2008, 38, 2706-2717.	1.6	103
376	PD-1 and Its Ligands in Tolerance and Immunity. <i>Annual Review of Immunology</i> , 2008, 26, 677-704.	9.5	4,462
377	Cell intrinsic mechanisms of T cell inhibition and application to cancer therapy. <i>Immunological Reviews</i> , 2008, 224, 141-165.	2.8	207
378	Control of peripheral T cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. <i>Immunological Reviews</i> , 2008, 224, 166-182.	2.8	840
379	Fine-Tuned Expression of Programmed Death 1 Ligands in Mature Dendritic Cells Stimulated by CD40 Ligand Is Critical for the Induction of an Efficient Tumor Specific Immune Response. <i>Cellular and Molecular Immunology</i> , 2008, 5, 33-39.	4.8	9
380	How tumours escape mass destruction. <i>Oncogene</i> , 2008, 27, 5894-5903.	2.6	175
381	PD-1/PD-L1, PD-1/PD-L2, and other co-inhibitory signaling pathways in transplantation. <i>Transplant International</i> , 2008, 21, ???-???	0.8	40
382	Programmed death-1 ligands-transfected dendritic cells loaded with glutamic acid decarboxylase 65 (GAD65) inhibit both the alloresponse and the GAD65-reactive lymphocyte response. <i>Clinical and Experimental Immunology</i> , 2007, 151, 86-93.	1.1	8
383	Soluble CD276 (B7-3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum. <i>Immunology</i> , 2008, 123, 538-546.	2.0	143

#	ARTICLE	IF	CITATIONS
384	Special regulatory T cell review: The resurgence of the concept of contrasuppression in immunoregulation. <i>Immunology</i> , 2008, 123, 40-44.	2.0	68
385	Costimulation and allergic responses: Immune and bioinformatic analyses. , 2008, 117, 385-392.		7
386	Immune modulation in corneal transplantation. <i>Transplantation Reviews</i> , 2008, 22, 105-115.	1.2	27
387	PD-1 Ligand Expression by Human Colonic Myofibroblasts/Fibroblasts Regulates CD4+ T-Cell Activity. <i>Gastroenterology</i> , 2008, 135, 1228-1237.e2.	0.6	147
388	Effects of interferon- $\beta$ on co-signaling molecules: upregulation of CD40, CD86 and PD-L2 on monocytes in relation to clinical response to interferon- $\beta$ treatment in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 166-176.	1.4	45
389	Trophoblast Immune Receptors in Maternal-Fetal Tolerance. <i>Immunological Investigations</i> , 2008, 37, 395-426.	1.0	36
391	The complex role of B7 molecules in tumor immunology. <i>Trends in Molecular Medicine</i> , 2008, 14, 550-559.	3.5	84
392	Novel strategies to eliminate persistent viral infections. <i>Trends in Immunology</i> , 2008, 29, 116-124.	2.9	29
393	Human Immunodeficiency Virus Type 1 Nef Induces Programmed Death 1 Expression through a p38 Mitogen-Activated Protein Kinase-Dependent Mechanism. <i>Journal of Virology</i> , 2008, 82, 11536-11544.	1.5	71
394	Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer. <i>Cancer Letters</i> , 2008, 268, 98-109.	3.2	126
395	Functional expression of B7H1 on retinal pigment epithelial cells. <i>Experimental Eye Research</i> , 2008, 86, 52-59.	1.2	53
396	Interferon-sensitive response element (ISRE) is mainly responsible for IFN- $\gamma$ -induced upregulation of programmed death-1 (PD-1) in macrophages. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2008, 1779, 811-819.	0.9	75
397	B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma. <i>Biochemical and Biophysical Research Communications</i> , 2008, 365, 170-175.	1.0	47
398	Anti-tumor immunotherapy by blockade of the PD-1/PD-L1 pathway with recombinant human PD-1 $\alpha$ IgV. <i>Cytotherapy</i> , 2008, 10, 711-719.	0.3	16
399	Primary mediastinal B-cell lymphoma: Treatment and therapeutic targets. <i>Leukemia and Lymphoma</i> , 2008, 49, 1050-1061.	0.6	15
400	Cyclosporin A Up-regulates B7-DC Expression on Dendritic Cells in an IL-4-dependent Manner In Vitro, Which is Associated with Decreased Allostimulatory Capacity of Dendritic Cells. <i>Immunopharmacology and Immunotoxicology</i> , 2008, 30, 399-409.	1.1	6
401	Mouse Sertoli Cells Display Phenotypical and Functional Traits of Antigen-Presenting Cells in Response to Interferon Gamma. <i>Biology of Reproduction</i> , 2008, 78, 234-242.	1.2	59
402	Active systemic lupus erythematosus is associated with failure of antigen-presenting cells to express programmed death ligand-1. <i>Rheumatology</i> , 2008, 47, 1335-1341.	0.9	72

#	ARTICLE	IF	CITATIONS
403	Viral replication and paracrine effects result in distinct, functional responses of dendritic cells following infection with dengue 2 virus. <i>Journal of Leukocyte Biology</i> , 2008, 84, 1028-1038.	1.5	62
404	Detrimental Contribution of the Immuno-Inhibitor B7-H1 to Rabies Virus Encephalitis. <i>Journal of Immunology</i> , 2008, 180, 7506-7515.	0.4	89
405	Programmed Death (PD)-1:PD-Ligand 1/PD-Ligand 2 Pathway Inhibits T Cell Effector Functions during Human Tuberculosis. <i>Journal of Immunology</i> , 2008, 181, 116-125.	0.4	234
406	Impaired Hepatitis C Virus (HCV)-Specific Effector CD8 <sup>+</sup> T Cells Undergo Massive Apoptosis in the Peripheral Blood during Acute HCV Infection and in the Liver during the Chronic Phase of Infection. <i>Journal of Virology</i> , 2008, 82, 9808-9822.	1.5	93
407	The Role of Negative Costimulators During Parasitic Infections. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2008, 8, 279-288.	0.6	11
408	Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2008, 14, 3044-3051.	3.2	634
409	The Common $\beta$ -Chain Cytokines IL-2, IL-7, IL-15, and IL-21 Induce the Expression of Programmed Death-1 and Its Ligands. <i>Journal of Immunology</i> , 2008, 181, 6738-6746.	0.4	447
410	The Kidney-Renal Lymph Node-System Contributes to Cross-Tolerance against Innocuous Circulating Antigen. <i>Journal of Immunology</i> , 2008, 180, 706-715.	0.4	70
411	Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3 <sup>+</sup> CD4 <sup>+</sup> regulatory T cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 9331-9336.	3.3	348
412	Up-Regulation of Programmed Death-1 Expression on Beryllium-Specific CD4 <sup>+</sup> T Cells in Chronic Beryllium Disease. <i>Journal of Immunology</i> , 2008, 180, 2704-2712.	0.4	39
413	Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 10483-10488.	3.3	176
414	Dendritic Cell Programming by Cytomegalovirus Stunts Naive T Cell Responses via the PD-L1/PD-1 Pathway. <i>Journal of Immunology</i> , 2008, 180, 4836-4847.	0.4	78
415	Cosignaling Complexity Gets More Convoluted: The Emerging Importance of the B7-Like Butyrophilin Family of Immune Regulators. <i>Current Immunology Reviews</i> , 2008, 4, 43-52.	1.2	1
417	Protective Role of Programmed Death 1 Ligand 1 (PD-L1) in Nonobese Diabetic Mice. <i>Diabetes</i> , 2008, 57, 1861-1869.	0.3	73
418	The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 3011-3016.	3.3	357
419	Critical Role of Donor Tissue Expression of Programmed Death Ligand-1 in Regulating Cardiac Allograft Rejection and Vasculopathy. <i>Circulation</i> , 2008, 117, 660-669.	1.6	89
420	The PD-1/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungus <i>Histoplasma capsulatum</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 2658-2663.	3.3	107
422	TREM-2 Mediated Signaling Induces Antigen Uptake and Retention in Mature Myeloid Dendritic Cells. <i>Journal of Immunology</i> , 2008, 181, 7863-7872.	0.4	13



#	ARTICLE	IF	CITATIONS
423	Expression and Function of PDCD1 at the Human Maternal-Fetal Interface. <i>Biology of Reproduction</i> , 2008, 79, 562-569.	1.2	79
424	High-Programmed Death-1 Levels on Hepatitis C Virus-Specific T Cells during Acute Infection Are Associated with Viral Persistence and Require Preservation of Cognate Antigen during Chronic Infection. <i>Journal of Immunology</i> , 2008, 181, 8215-8225.	0.4	114
425	Association of an A/C single nucleotide polymorphism in programmed cell death-ligand 1 gene with Graves' disease in Japanese patients.. <i>European Journal of Endocrinology</i> , 2008, 158, 817-822.	1.9	48
426	The Programmed Death-1 and Interleukin-10 Pathways Play a Down-Modulatory Role in LP-BM5 Retrovirus-Induced Murine Immunodeficiency Syndrome. <i>Journal of Virology</i> , 2008, 82, 2456-2469.	1.5	16
427	Clinical significance of B7-H1 and PD-L1 expression in human acute leukemia. <i>Cancer Biology and Therapy</i> , 2008, 7, 622-627.	1.5	107
428	B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. <i>Blood</i> , 2008, 111, 3635-3643.	0.6	438
429	Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway. <i>Blood</i> , 2008, 112, 2149-2155.	0.6	63
430	Telomerase activity of HIV-specific CD8+ T cells: constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1 in progressors. <i>Blood</i> , 2008, 112, 3679-3687.	0.6	75
431	Transplantation of NIT-1 Cells Expressing pD-L1 for Treatment of Streptozotocin-Induced Diabetes. <i>Transplantation</i> , 2008, 86, 1596-1602.	0.5	12
432	The Use of the Inhibitory Receptors for Modulating the Immune Responses. <i>Current Pharmaceutical Design</i> , 2008, 14, 2643-2650.	0.9	20
433	Programmed death-1 as a factor in immune exhaustion and activation in HIV infection. <i>Current Opinion in HIV and AIDS</i> , 2008, 3, 362-367.	1.5	44
434	PD-L1/PD-1 Signal Deficiency Promotes Allogeneic Immune Responses and Accelerates Heart Allograft Rejection. <i>Transplantation</i> , 2008, 86, 836-844.	0.5	29
436	PD-L1: PD-1 Interaction Contributes to the Functional Suppression of T-Cell Responses to Human Uveal Melanoma Cells In Vitro. , 2008, 49, 2518.		105
437	PD-L1 Expression on Human Ocular Cells and Its Possible Role in Regulating Immune-Mediated Ocular Inflammation. , 2009, 50, 273.		78
438	Costimulatory Pathways in Multiple Sclerosis: Distinctive Expression of PD-1 and PD-L1 in Patients with Different Patterns of Disease. <i>Journal of Immunology</i> , 2009, 183, 4984-4993.	0.4	83
439	Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2009, 15, 971-979.	3.2	725
440	Herpesvirus Entry Mediator-Ig Treatment during Immunization Aggravates Rheumatoid Arthritis in the Collagen-Induced Arthritis Model. <i>Journal of Immunology</i> , 2009, 182, 3139-3145.	0.4	32
441	Teleost B7 Expressed on Monocytes Regulates T Cell Responses. <i>Journal of Immunology</i> , 2009, 182, 6799-6806.	0.4	49

#	ARTICLE	IF	CITATIONS
443	Human decidual stromal cells suppress cytokine secretion by allogenic CD4+ T cells via PD-1 ligand interactions. <i>Human Reproduction</i> , 2009, 24, 3160-3171.	0.4	63
444	Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. <i>International Journal of Oncology</i> , 2009, 35, 741-9.	1.4	68
445	Future therapeutics for the induction of peripheral immune tolerance in autoimmune disease and organ transplantation. <i>Immunotherapy</i> , 2009, 1, 447-460.	1.0	7
446	Healthy but not RSV-infected lung epithelial cells profoundly inhibit T cell activation. <i>Thorax</i> , 2009, 64, 283-290.	2.7	36
447	Naturally Occurring and Inducible T-Regulatory Cells Modulating Immune Response in Allergic Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 180, 211-225.	2.5	60
448	Recent Patents on the Treatment of Type 1 Diabetes. <i>Recent Patents on Endocrine, Metabolic &amp; Immune Drug Discovery</i> , 2009, 3, 1-10.	0.7	1
449	Variable Increased Expression of Program Death-1 and Program Death-1 Ligands on Peripheral Mononuclear Cells Is Not Impaired in Patients with Systemic Lupus Erythematosus. <i>Journal of Biomedicine and Biotechnology</i> , 2009, 2009, 1-6.	3.0	19
450	PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients. <i>Journal of Immunology</i> , 2009, 182, 5240-5249.	0.4	158
451	Subversion of Pulmonary Dendritic Cell Function by Paramyxovirus Infections. <i>Journal of Immunology</i> , 2009, 182, 3072-3083.	0.4	70
452	The co-inhibitory molecule PD-1 modulates disease severity in a model for an inherited, demyelinating neuropathy. <i>Neurobiology of Disease</i> , 2009, 33, 96-103.	2.1	13
453	Differentiation-Induced Post-Transcriptional Control of B7-H1 in Human Trophoblast Cells. <i>Placenta</i> , 2009, 30, 48-55.	0.7	16
454	Immune escape mechanisms of intraocular tumors. <i>Progress in Retinal and Eye Research</i> , 2009, 28, 329-347.	7.3	91
455	Altered availability of PD-1/PD ligands is associated with the failure to control autoimmunity in NOD mice. <i>Cellular Immunology</i> , 2009, 258, 161-171.	1.4	15
456	Chronically inflamed livers up-regulate expression of inhibitory B7 family members. <i>Hepatology</i> , 2009, 50, 1625-1637.	3.6	128
457	Structural immunology and crystallography help immunologists see the immune system in action: How T and NK cells touch their ligands. <i>IUBMB Life</i> , 2009, 61, 579-590.	1.5	28
458	The DCâ€HIL/syndecanâ€4 pathway inhibits human allogeneic Tâ€cell responses. <i>European Journal of Immunology</i> , 2009, 39, 965-974.	1.6	63
459	B7â€H3 is a potent inhibitor of human Tâ€cell activation: No evidence for B7â€H3 and TREML2 interaction. <i>European Journal of Immunology</i> , 2009, 39, 1754-1764.	1.6	231
460	Induction of Treg by monocyteâ€derived DC modulated by vitamin D<sub>3</sub> or dexamethasone: Differential role for PDâ€L1. <i>European Journal of Immunology</i> , 2009, 39, 3147-3159.	1.6	377

#	ARTICLE	IF	CITATIONS
461	B7-DC-silenced dendritic cells induce stronger anti-HBV immunity in transgenic mice. <i>Archives of Virology</i> , 2009, 154, 1813-1821.	0.9	3
462	Polymorphisms of PTPN11 Coding SHP-2 as Biomarkers for Ulcerative Colitis Susceptibility in the Japanese Population. <i>Journal of Clinical Immunology</i> , 2009, 29, 303-310.	2.0	24
463	siRNA Knockdown of PD-L1 and PD-L2 in Monocyte-Derived Dendritic Cells only Modestly Improves Proliferative Responses to Gag by CD8+ T Cells from HIV-1-Infected Individuals. <i>Journal of Clinical Immunology</i> , 2009, 29, 637-645.	2.0	25
464	Adoptiver Transfer tumorantigenspezifischer T-Zellen in der Onkologie. <i>Onkopipeline</i> , 2009, 2, 11-15.	0.0	0
465	Regulated Expression of CCL21 in the Prostate Tumor Microenvironment Inhibits Tumor Growth and Metastasis in an Orthotopic Model of Prostate Cancer. <i>Cancer Microenvironment</i> , 2009, 2, 59-67.	3.1	23
466	Polymorphisms in PDCD1 gene are not associated with Wegener's granulomatosis. <i>Rheumatology International</i> , 2009, 29, 1247-1250.	1.5	9
467	Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 687-697.	2.0	99
468	Leucocyte-associated immunoglobulin-like receptor 1 is an inhibitory regulator of contact hypersensitivity. <i>Immunology</i> , 2009, 128, 543-555.	2.0	14
469	SHP1 and SHP2 in T cells: two phosphatases functioning at many levels. <i>Immunological Reviews</i> , 2009, 228, 342-359.	2.8	309
470	Negative regulators of T cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. <i>Immunological Reviews</i> , 2009, 229, 67-87.	2.8	150
471	PD1 signaling in primary T cells. <i>Immunological Reviews</i> , 2009, 229, 114-125.	2.8	655
472	Yin-Yang of costimulation: crucial controls of immune tolerance and function. <i>Immunological Reviews</i> , 2009, 229, 88-100.	2.8	138
473	Costimulatory and coinhibitory receptors in anti-tumor immunity. <i>Immunological Reviews</i> , 2009, 229, 126-144.	2.8	246
474	Programmed death-1 receptor negatively regulates LPS-mediated IL-12 production and differentiation of murine macrophage RAW264.7 cells. <i>Immunology Letters</i> , 2009, 127, 39-47.	1.1	44
475	Immunoregulatory effects of indoleamine 2, 3-dioxygenase in transplantation. <i>Transplant Immunology</i> , 2009, 21, 18-22.	0.6	19
476	Memory T cells need CD28 costimulation to remember. <i>Seminars in Immunology</i> , 2009, 21, 69-77.	2.7	100
477	Contributions of PD-1/PD-L1 pathway to interactions of myeloid DCs with T cells in atherosclerosis. <i>Journal of Molecular and Cellular Cardiology</i> , 2009, 46, 169-176.	0.9	68
478	Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. <i>Human Pathology</i> , 2009, 40, 1715-1722.	1.1	145

#	ARTICLE	IF	CITATIONS
479	Immune barriers to successful gene therapy. Trends in Molecular Medicine, 2009, 15, 32-39.	3.5	48
480	Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses. Expert Review of Anticancer Therapy, 2009, 9, 1317-1332.	1.1	61
481	Accelerated Course of Experimental Autoimmune Encephalomyelitis in PD-1-Deficient Central Nervous System Myelin Mutants. American Journal of Pathology, 2009, 174, 2290-2299.	1.9	39
482	Interaction of Programmed Death-1 and Programmed Death-1 Ligand-1 Contributes to Testicular Immune Privilege. Transplantation, 2009, 87, 1778-1786.	0.5	60
483	PD-1 on dendritic cells impedes innate immunity against bacterial infection. Blood, 2009, 113, 5811-5818.	0.6	179
484	PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood, 2009, 114, 1545-1552.	0.6	354
485	Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. Blood, 2009, 114, 5062-5070.	0.6	123
486	Programmed Death-1 Signaling Is Essential for the Skin Allograft Protection by Alternatively Activated Dendritic Cell Infusion in Mice. Transplantation, 2009, 88, 864-873.	0.5	22
487	Update on ICOS: A Possible Target for Turning-Off Autoimmunity. Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, 2009, 3, 205-213.	0.7	0
488	The Inhibitory Co-Receptors: A Way to Save from Anergy the HIVSpecific T Cells. Current HIV Research, 2009, 7, 266-272.	0.2	16
489	Beyond IL-17: new cytokines in the pathogenesis of HIV infection. Current Opinion in HIV and AIDS, 2010, 5, 184-188.	1.5	12
490	Co-signals in organ transplantation. Current Opinion in Organ Transplantation, 2010, 15, 474-480.	0.8	15
491	Cellular Vaccine Approaches. Cancer Journal (Sudbury, Mass ), 2010, 16, 304-310.	1.0	117
492	Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood, 2010, 116, 2484-2493.	0.6	263
493	Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. Journal of Experimental Medicine, 2010, 207, 2187-2194.	4.2	1,652
494	Generation and Characterization of Four Novel Monoclonal Antibodies Against Human Programmed Death-1 Molecule. Hybridoma, 2010, 29, 153-160.	0.5	7
495	Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. Cancer Immunology, Immunotherapy, 2010, 59, 1163-1171.	2.0	141
496	RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells. Cancer Immunology, Immunotherapy, 2010, 59, 1173-1183.	2.0	47

#	ARTICLE	IF	CITATIONS
497	Structural immunology of costimulatory and coinhibitory molecules. <i>Science China Life Sciences</i> , 2010, 53, 183-189.	2.3	8
498	Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence. <i>Immunologic Research</i> , 2010, 47, 216-227.	1.3	63
499	Ligation of the B7 molecules, members of the B7 family, enhance the proinflammatory responses of human monocytes and monocyte-derived dendritic cells. <i>Molecular Immunology</i> , 2010, 48, 109-118.	1.0	17
500	Overexpression of programmed death-1 ligand-1 on NIT cells lead to negative regulation of allogeneic lymphocyte activation. <i>Cellular Immunology</i> , 2010, 263, 122-128.	1.4	2
501	GM-CSF induces bone marrow precursors of NOD mice to skew into tolerogenic dendritic cells that protect against diabetes. <i>Cellular Immunology</i> , 2010, 265, 31-36.	1.4	27
502	PD-1/B7-1 Interaction Contribute to the Spontaneous Acceptance of Mouse Liver Allograft. <i>American Journal of Transplantation</i> , 2010, 10, 40-46.	2.6	100
503	<i>PTPN22</i> , <i>PDCD1</i> and <i>CYP27B1</i> polymorphisms and susceptibility to type 1 diabetes in Polish patients. <i>International Journal of Immunogenetics</i> , 2010, 37, 367-372.	0.8	37
504	The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. <i>Arthritis and Rheumatism</i> , 2010, 62, 1870-1880.	6.7	126
505	Cytokine induced expression of programmed death ligands in human neutrophils. <i>Immunology Letters</i> , 2010, 129, 100-107.	1.1	32
506	Partial restoration of T cell function in aged mice by <i>in vitro</i> blockade of the PD-1/SPD-1 pathway. <i>Aging Cell</i> , 2010, 9, 785-798.	3.0	105
507	The PD-1 pathway in tolerance and autoimmunity. <i>Immunological Reviews</i> , 2010, 236, 219-242.	2.8	1,902
508	REVIEW ARTICLE: B7 Family Molecules as Regulators of the Maternal Immune System in Pregnancy. <i>American Journal of Reproductive Immunology</i> , 2010, 63, 506-519.	1.2	55
509	PD-1 signalling in CD4 <sup>+</sup> T cells restrains their clonal expansion to an immunogenic stimulus, but is not critically required for peptide-induced tolerance. <i>Immunology</i> , 2010, 130, 92-102.	2.0	30
510	PD-1/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection. <i>Journal of Viral Hepatitis</i> , 2010, 17, no-no.	1.0	78
511	The immunotherapeutic potential of dendritic cells in type 1 diabetes. <i>Clinical and Experimental Immunology</i> , 2010, 161, 197-207.	1.1	28
512	Increased programmed death-ligand-1 expression in human gastric epithelial cells in <i>Helicobacter pylori</i> infection. <i>Clinical and Experimental Immunology</i> , 2010, 161, 551-559.	1.1	70
513	Octamer binding protein 2 (Oct2) regulates PD-L2 gene expression in B-1 cells through lineage-specific activity of a unique, intronic promoter. <i>Genes and Immunity</i> , 2010, 11, 55-66.	2.2	16
514	PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. <i>Nature Immunology</i> , 2010, 11, 535-542.	7.0	583

#	ARTICLE	IF	CITATIONS
515	Diagnostic and Prognostic Utility of PD-1 In B Cell Lymphomas. <i>Disease Markers</i> , 2010, 29, 47-53.	0.6	87
516	Dendritic Cells in Chronic Mycobacterial Granulomas Restrict Local Anti-Bacterial T Cell Response in a Murine Model. <i>PLoS ONE</i> , 2010, 5, e11453.	1.1	42
517	Programmed Death-1 Expression on Epstein Barr Virus Specific CD8+ T Cells Varies by Stage of Infection, Epitope Specificity, and T-Cell Receptor Usage. <i>PLoS ONE</i> , 2010, 5, e12926.	1.1	35
518	Suppression of Bystander T Helper 1 Cells by Iris Pigment Epithelium-Inducing Regulatory T Cells via Negative Costimulatory Signals. , 2010, 51, 2529.		16
519	Programmed death-1 (PD-1)â€“deficient mice are extraordinarily sensitive to tuberculosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 13402-13407.	3.3	275
520	Inhibitory TCR Coreceptor PD-1 Is a Sensitive Indicator of Low-Level Replication of SIV and HIV-1. <i>Journal of Immunology</i> , 2010, 184, 476-487.	0.4	41
521	Th1 Cytokine Responses Fail to Effectively Control <i>Chlamydia</i> Lung Infection in ICOS Ligand Knockout Mice. <i>Journal of Immunology</i> , 2010, 184, 3780-3788.	0.4	18
522	The Role of Costimulatory Molecules in Allergic Disease and Asthma. <i>International Archives of Allergy and Immunology</i> , 2010, 151, 179-189.	0.9	70
523	Arginase in Parasitic Infections: Macrophage Activation, Immunosuppression, and Intracellular Signals. <i>Journal of Biomedicine and Biotechnology</i> , 2010, 2010, 1-10.	3.0	70
524	DC-HIL/Glycoprotein Nmb Promotes Growth of Melanoma in Mice by Inhibiting the Activation of Tumor-Reactive T Cells. <i>Cancer Research</i> , 2010, 70, 5778-5787.	0.4	61
525	NK cells in the eye. , 2010, , 385-401.		6
526	Mechanisms of T-cell inhibition: implications for cancer immunotherapy. <i>Expert Review of Vaccines</i> , 2010, 9, 89-105.	2.0	27
527	A Butyrophilin Family Member Critically Inhibits T Cell Activation. <i>Journal of Immunology</i> , 2010, 185, 5907-5914.	0.4	48
528	Î²-Cells Step Up in Controlling the Autoimmune Response. <i>Diabetes</i> , 2010, 59, 1861-1864.	0.3	2
529	Immunobiology of Cancer Therapies Targeting CD137 and B7-H1/PD-1 Cosignal Pathways. <i>Current Topics in Microbiology and Immunology</i> , 2010, 344, 245-267.	0.7	44
530	T Follicular Helper Cells During Immunity and Tolerance. <i>Progress in Molecular Biology and Translational Science</i> , 2010, 92, 207-248.	0.9	43
531	PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1. <i>International Immunology</i> , 2010, 22, 651-660.	1.8	189
532	<i>Cryptococcus neoformans</i> Variants Generated by Phenotypic Switching Differ in Virulence through Effects on Macrophage Activation. <i>Infection and Immunity</i> , 2010, 78, 1049-1057.	1.0	32

#	ARTICLE	IF	CITATIONS
533	Distribution of PD-1+ Lymphocytes in Reactive Lymphadenopathies. <i>Pathobiology</i> , 2010, 77, 24-27.	1.9	15
534	Pegylated interferon $\hat{\pm}$ -2b up-regulates specific CD8+ T cells in patients with chronic hepatitis B. <i>World Journal of Gastroenterology</i> , 2010, 16, 6145.	1.4	16
535	PD-1 on Immature and PD-1 Ligands on Migratory Human Langerhans Cells Regulate Antigen-Presenting Cell Activity. <i>Journal of Investigative Dermatology</i> , 2010, 130, 2222-2230.	0.3	28
536	PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions. <i>Mucosal Immunology</i> , 2010, 3, 81-91.	2.7	157
537	Renal tubular PD-L1 (CD274) suppresses alloreactive human T-cell responses. <i>Kidney International</i> , 2010, 78, 38-47.	2.6	72
538	Role of PD-1 in Regulating T-Cell Immunity. <i>Current Topics in Microbiology and Immunology</i> , 2010, 350, 17-37.	0.7	244
539	Induction of pathogenic cytotoxic T lymphocyte tolerance by dendritic cells: a novel therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 797-824.	1.5	8
540	Hepatitis B Immunology for Clinicians. <i>Clinics in Liver Disease</i> , 2010, 14, 409-424.	1.0	15
542	Lipid Rafts, Pseudotyping, and Virus-Like Particles: Relevance of a Novel, Configurable, and Modular Antigen-Presenting Platform. <i>International Archives of Allergy and Immunology</i> , 2011, 154, 89-110.	0.9	16
543	Co-stimulatory molecules in and beyond co-stimulation " tipping the balance in atherosclerosis?. <i>Thrombosis and Haemostasis</i> , 2011, 106, 804-813.	1.8	46
546	Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines. <i>Cytokine</i> , 2011, 56, 231-238.	1.4	216
547	Molecular and cellular characterization of expanded and cryopreserved human limbal epithelial stem cells reveal unique immunological properties. <i>Experimental Eye Research</i> , 2011, 92, 47-56.	1.2	17
548	B7-H1 and B7-DC receptors of oral squamous carcinoma cells are upregulated by <i>Porphyromonas gingivalis</i> . <i>Immunobiology</i> , 2011, 216, 1302-1310.	0.8	95
549	T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics. <i>Trends in Molecular Medicine</i> , 2011, 17, 47-55.	3.5	44
550	Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. <i>Critical Care</i> , 2011, 15, R99.	2.5	263
551	Cinnamon extract suppresses experimental colitis through modulation of antigen-presenting cells. <i>World Journal of Gastroenterology</i> , 2011, 17, 976.	1.4	34
552	Cytotoxic T Lymphocytes and Vaccine Development 2011. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-1.	3.0	1
553	Improved Immunological Tolerance Following Combination Therapy with CTLA-4/Ig and AAV-Mediated PD-L1/2 Muscle Gene Transfer. <i>Frontiers in Microbiology</i> , 2011, 2, 199.	1.5	18

#	ARTICLE	IF	CITATIONS
554	WSX1 Expression in Tumors Induces Immune Tolerance via Suppression of Effector Immune Cells. PLoS ONE, 2011, 6, e19072.	1.1	8
555	SÅzary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-Î² on the cell surface. Blood, 2011, 117, 3382-3390.	0.6	33
556	Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood, 2011, 118, 965-974.	0.6	158
557	Role of PD-L1 and PD-L2 in allergic diseases and asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 155-162.	2.7	103
558	Modulation of CD4+ T cell responses following splenectomy in hepatitis C virus-related liver cirrhosis. Clinical and Experimental Immunology, 2011, 165, 243-250.	1.1	34
559	CD8+â€fCD28â€” and CD8+â€fCD57+ T cells and their role in health and disease. Immunology, 2011, 134, 17-32. 2.0		378
560	Intrinsic and extrinsic control of peripheral Tâ€cell tolerance by costimulatory molecules of the CD28/â€B7 family. Immunological Reviews, 2011, 241, 180-205.	2.8	330
561	Timeline: a decade of advances in immunotherapy. Nature Medicine, 2011, 17, 296-296.	15.2	4
562	The role of the PDâ€1 pathway in autoimmunity and peripheral tolerance. Annals of the New York Academy of Sciences, 2011, 1217, 45-59.	1.8	290
563	PD-L2 induction on dendritic cells exposed to Mycobacterium avium downregulates BCG-specific T cell response. Tuberculosis, 2011, 91, 36-46.	0.8	19
564	Altered TNF-Î± and IFN-Î³ levels associated with PD1 but not TNFA polymorphisms in patients with chronic HBV infection. Infection, Genetics and Evolution, 2011, 11, 1624-1630.	1.0	26
565	L2pB1: A new player in autoimmunity. Molecular Immunology, 2011, 48, 1292-1300.	1.0	12
566	PD-L2 is expressed on activated human T cells and regulates their function. Molecular Immunology, 2011, 48, 2214-2219.	1.0	100
567	A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood, 2011, 118, 2254-2265.	0.6	328
568	PD-1 polymorphisms are associated with sporadic breast cancer in Chinese Han population of Northeast China. Breast Cancer Research and Treatment, 2011, 129, 195-201.	1.1	69
569	Program death 1 (PD1) haplotyping in patients with breast carcinoma. Molecular Biology Reports, 2011, 38, 4205-4210.	1.0	39
570	Involvement of ERK and JNK pathways in IFN-Î³-induced B7-DC expression on tumor cells. Journal of Cancer Research and Clinical Oncology, 2011, 137, 243-250.	1.2	10
571	Inverse correlation of programmed death 1 (PD-1) expression in T cells to the spinal radiologic changes in Taiwanese patients with ankylosing spondylitis. Clinical Rheumatology, 2011, 30, 1181-1187.	1.0	20



#	ARTICLE	IF	CITATIONS
572	The effects of PDL-Ig on collagen-induced arthritis. <i>Rheumatology International</i> , 2011, 31, 513-519.	1.5	54
573	Intrahepatic levels of PD-1/PD-L correlate with liver inflammation in chronic hepatitis B. <i>Inflammation Research</i> , 2011, 60, 47-53.	1.6	57
574	T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract. <i>Immunologic Research</i> , 2011, 50, 269-275.	1.3	64
575	Phenotype, effector function, and tissue localization of PD-1-expressing human follicular helper T cell subsets. <i>BMC Immunology</i> , 2011, 12, 53.	0.9	42
576	Expression and function of PD-1 in human CD4 <sup>+</sup> T cells that recognize phosphoantigens. <i>European Journal of Immunology</i> , 2011, 41, 345-355.	1.6	138
577	Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. <i>European Journal of Immunology</i> , 2011, 41, 2977-2986.	1.6	131
578	Cancer immunotherapy: Progress and challenges in the clinical setting. <i>European Journal of Immunology</i> , 2011, 41, 1510-1515.	1.6	24
579	Overall survival and PD-1 expression in metastasized malignant melanoma. <i>Cancer</i> , 2011, 117, 2192-2201.	2.0	204
580	Essential Role of B7-H1 in Double-Stranded RNA-Induced Augmentation of an Asthma Phenotype in Mice. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011, 45, 31-39.	1.4	11
581	Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics. <i>Therapeutic Delivery</i> , 2011, 2, 873-889.	1.2	20
582	HIV-Mediated Phosphatidylinositol 3-Kinase/Serine/Threonine Kinase Activation in APCs Leads to Programmed Death-1 Ligand Upregulation and Suppression of HIV-Specific CD8 T Cells. <i>Journal of Immunology</i> , 2011, 187, 2932-2943.	0.4	33
583	Using monoclonal antibodies to stimulate antitumor cellular immunity. <i>Expert Review of Vaccines</i> , 2011, 10, 1093-1106.	2.0	14
584	PD-1 Signaling in HIV and Chronic Viral Infection – Potential for Therapeutic Intervention?. <i>Current Medicinal Chemistry</i> , 2011, 18, 3971-3980.	1.2	15
585	Effects of genetic polymorphisms of programmed cell death 1 and its ligands on the development of ankylosing spondylitis. <i>Rheumatology</i> , 2011, 50, 1809-1813.	0.9	35
586	The PDL1-PD1 Axis Converts Human T <sub>H</sub> 1 Cells into Regulatory T Cells. <i>Science Translational Medicine</i> , 2011, 3, 111ra120.	5.8	370
587	Blockade of B7-H1 (Programmed Death Ligand 1) Enhances Humoral Immunity by Positively Regulating the Generation of T Follicular Helper Cells. <i>Journal of Immunology</i> , 2011, 186, 5648-5655.	0.4	118
588	The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo. <i>Journal of Immunology</i> , 2011, 187, 1097-1105.	0.4	159
589	B Cells and TCR Avidity Determine Distinct Functions of CD4 <sup>+</sup> T Cells in Retroviral Infection. <i>Journal of Immunology</i> , 2011, 187, 3321-3330.	0.4	34

#	ARTICLE	IF	CITATIONS
590	Identification of PD-1 as a Unique Marker for Failing Immune Reconstitution in HIV-1-Infected Patients on Treatment. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, 118-124.	0.9	85
591	CD4 T Cells Promote Rather than Control Tuberculosis in the Absence of PD-1-Mediated Inhibition. <i>Journal of Immunology</i> , 2011, 186, 1598-1607.	0.4	269
592	The Novel Costimulatory Programmed Death Ligand 1/B7.1 Pathway Is Functional in Inhibiting Alloimmune Responses In Vivo. <i>Journal of Immunology</i> , 2011, 187, 1113-1119.	0.4	115
593	Human PD-L1-overexpressing porcine vascular endothelial cells induce functionally suppressive human CD4+CD25hiFoxp3+ Treg cells. <i>Journal of Leukocyte Biology</i> , 2011, 90, 77-86.	1.5	21
594	IFN- $\gamma$ Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity. <i>Journal of Immunology</i> , 2011, 186, 2772-2779.	0.4	278
595	Regulation of Trypanosoma cruzi-Induced Myocarditis by Programmed Death Cell Receptor 1. <i>Infection and Immunity</i> , 2011, 79, 1873-1881.	1.0	48
596	A Functional Polymorphism in B and T Lymphocyte Attenuator Is Associated with Susceptibility to Rheumatoid Arthritis. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-8.	3.3	34
597	The PD-1/PD-L1 (B7-H1) Pathway in Chronic Infection-Induced Cytotoxic T Lymphocyte Exhaustion. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-9.	3.0	118
598	Herpesvirus Exploitation of Host Immune Inhibitory Pathways. <i>Viruses</i> , 2012, 4, 1182-1201.	1.5	20
599	Novel Anti-Melanoma Immunotherapies: Disarming Tumor Escape Mechanisms. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-9.	3.3	24
600	PD-L1-Expressing Dendritic Cells Contribute to Viral Resistance during Acute HSV-1 Infection. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-9.	3.3	17
601	Programmed Death Ligand 2 in Cancer-Induced Immune Suppression. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-8.	3.3	282
602	Coinhibitory Molecules in Autoimmune Diseases. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-7.	3.3	39
603	Novel Strategies for Immunotherapy in Multiple Myeloma: Previous Experience and Future Directions. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-28.	3.3	28
604	Targeting Costimulatory Molecules to Improve Antitumor Immunity. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-17.	3.0	71
605	<i>Immunology of Liver</i> , 2012, , 233-275.		0
606	PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A. <i>Cell Cycle</i> , 2012, 11, 4305-4309.	1.3	103
607	T-cell Inhibitors. <i>Dermatitis</i> , 2012, 23, 195-202.	0.8	6

#	ARTICLE	IF	CITATIONS
608	Selective Activation of Intracellular Signalling Pathways in Dendritic Cells for Cancer Immunotherapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2012, 12, 29-39.	0.9	23
609	The PD-1/PD-L1 Pathway in Human Pathology. <i>Current Molecular Medicine</i> , 2012, 12, 259-267.	0.6	58
610	Antibodies Against B7-DC with Differential Binding Properties Exert Opposite Effects. <i>Hybridoma</i> , 2012, 31, 40-47.	0.5	6
611	Positive and Negative Regulation of Cellular Immune Responses in Physiologic Conditions and Diseases. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-11.	3.3	78
612	Therapeutic Intervention in Cancer and Chronic Viral Infections: Antibody Mediated Manipulation of PD-1/PD-L1 Interaction. <i>Reviews on Recent Clinical Trials</i> , 2012, 7, 10-23.	0.4	31
613	Pancreatic Ductal Adenocarcinoma. <i>Journal of Investigative Medicine</i> , 2012, 60, 643-663.	0.7	65
614	Genome-wide identification and evolutionary analysis of B7-H3. <i>International Journal of Data Mining and Bioinformatics</i> , 2012, 6, 292.	0.1	8
615	Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma. <i>Blood</i> , 2012, 119, 161-169.	0.6	103
616	Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1. <i>Clinical Cancer Research</i> , 2012, 18, 6580-6587.	3.2	543
617	Role of the PD-1 Pathway in the Immune Response. <i>American Journal of Transplantation</i> , 2012, 12, 2575-2587.	2.6	348
618	Immunology beats cancer: a blueprint for successful translation. <i>Nature Immunology</i> , 2012, 13, 1129-1132.	7.0	148
619	Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 10468-10473.	3.3	112
620	The expression, function, and clinical relevance of B7 family members in cancer. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1327-1341.	2.0	72
621	Znaczenie receptora programowanej śmierci 1 oraz jego ligandów w układzie immunologicznym oraz nowotworach. <i>Acta Haematologica Polonica</i> , 2012, 43, 132-145.	0.1	11
622	Immunotherapy earns its spot in the ranks of cancer therapy. <i>Journal of Experimental Medicine</i> , 2012, 209, 201-209.	4.2	118
623	Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. <i>Journal of Experimental Medicine</i> , 2012, 209, 1201-1217.	4.2	864
625	A potential role for the PD1/PD-L1 pathway in the neuroinflammation of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 624.e11-624.e22.	1.5	36
626	T-cell activation and transplantation tolerance. <i>Transplantation Reviews</i> , 2012, 26, 212-222.	1.2	25

#	ARTICLE	IF	CITATIONS
627	Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation. <i>Science Signaling</i> , 2012, 5, ra46.	1.6	411
628	Role of PD-L1/PD-1 in the immune response to respiratory viral infections. <i>Microbes and Infection</i> , 2012, 14, 495-499.	1.0	14
629	Expression of prohibitins on the surface of activated T cells. <i>Biochemical and Biophysical Research Communications</i> , 2012, 420, 275-280.	1.0	26
630	Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. <i>Current Opinion in Immunology</i> , 2012, 24, 207-212.	2.4	1,186
631	Intact $\beta$ - $\text{H}^3$ signaling promotes allograft prolongation through preferential suppression of $\text{T}_\text{H}1$ effector responses. <i>European Journal of Immunology</i> , 2012, 42, 2343-2353.	1.6	33
632	Molecular characterization of immunoinhibitory factors PD-1/PD-L1 in chickens infected with Marek's disease virus. <i>Virology Journal</i> , 2012, 9, 94.	1.4	18
633	The Intrahepatic Expression and Distribution of BTLA and its Ligand HVEM in patients with HBV-related acute-on-chronic liver failure. <i>Diagnostic Pathology</i> , 2012, 7, 142.	0.9	21
634	Immune Tolerance and Transplantation. <i>Seminars in Oncology</i> , 2012, 39, 629-642.	0.8	68
635	Exposure of a Distinct PDCA-1+ (CD317) B Cell Population to Agonistic Anti-4-1BB (CD137) Inhibits T and B Cell Responses Both In Vitro and In Vivo. <i>PLoS ONE</i> , 2012, 7, e50272.	1.1	12
636	Lack of an association of programmed cell death-1 PD1.3 polymorphism with risk of hepatocellular carcinoma susceptibility in Turkish population: A case-control study. <i>Gene</i> , 2012, 511, 308-313.	1.0	23
637	Cross-reactivity of anti-programmed death ligand 2 polyclonal antibody in mouse tissues. <i>Science China Life Sciences</i> , 2012, 55, 940-947.	2.3	3
638	Control of Innate and Adaptive Immune Responses during Infectious Diseases. , 2012, , .		4
641	Multiple Mechanisms of Immune Suppression by B Lymphocytes. <i>Molecular Medicine</i> , 2012, 18, 123-137.	1.9	109
642	CO-INHIBITORY MOLECULE PROGRAMMED DEATH-1 AND ITS LIGANDS: A NEW ALTERNATIVE THERAPY FOR HUMAN IMMUNODEFICIENCY VIRUS INFECTION?. <i>American Journal of Infectious Diseases</i> , 2012, 8, 149-162.	0.1	0
643	B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma. <i>World Journal of Gastroenterology</i> , 2012, 18, 971.	1.4	46
644	The blockade of immune checkpoints in cancer immunotherapy. <i>Nature Reviews Cancer</i> , 2012, 12, 252-264.	12.8	10,874
645	Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. <i>New England Journal of Medicine</i> , 2012, 366, 2455-2465.	13.9	6,820
646	Study of CD4+CD8+ Double positive T lymphocyte phenotype and function in Indian patients infected with HIV-1. <i>Journal of Medical Virology</i> , 2012, 84, 845-856.	2.5	22

#	ARTICLE	IF	CITATIONS
647	Reduced tumor antigen density leads to PD-1/PD-L1-mediated impairment of partially exhausted CD8 <sup>+</sup> T cells. <i>European Journal of Immunology</i> , 2012, 42, 662-671.	1.6	17
648	PD-1 expression on Melanoma-reactive T cells increases during progression to metastatic disease. <i>International Journal of Cancer</i> , 2012, 130, 2327-2336.	2.3	34
649	Involvement of Inducible Costimulator Ligand (ICOSL) Expression in Thyroid Tissue in Hyperthyroidism of Graves' Disease Patients. <i>Journal of Clinical Immunology</i> , 2012, 32, 1253-1261.	2.0	12
650	Characterization of Effector Memory CD8 <sup>+</sup> T Cells in the Synovial Fluid of Rheumatoid Arthritis. <i>Journal of Clinical Immunology</i> , 2012, 32, 709-720.	2.0	67
651	Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 453-468.	2.0	22
652	Aging-associated B7-1 <sup>+</sup> B cells enhance anti-tumor immunity via Th1 and Th17 induction. <i>Aging Cell</i> , 2012, 11, 128-138.	3.0	18
653	Sublingual administration of <i>Lactobacillus paracasei</i> KW3110 inhibits Th2-dependent allergic responses via upregulation of PD-L2 on dendritic cells. <i>Clinical Immunology</i> , 2012, 143, 170-179.	1.4	16
654	Role of Lentivirus-Mediated Overexpression of Programmed Death-Ligand 1 on Corneal Allograft Survival. <i>American Journal of Transplantation</i> , 2012, 12, 1313-1322.	2.6	33
655	Antigen-specific blocking of CD4 <sup>+</sup> specific immunological synapse formation using BPI and current therapies for autoimmune diseases. <i>Medicinal Research Reviews</i> , 2012, 32, 727-764.	5.0	28
656	Expression and biological function of programmed death ligands in human placenta mesenchymal stem cells. <i>Cell Biology International</i> , 2013, 37, 137-148.	1.4	32
657	Programmed Death 1 Pathway inhibition in Metastatic Renal Cell Cancer and Prostate Cancer. <i>Current Oncology Reports</i> , 2013, 15, 98-104.	1.8	41
658	Metastatic Melanoma to the Brain: Surgery and Radiation Is Still the Standard of Care. <i>Current Treatment Options in Oncology</i> , 2013, 14, 264-279.	1.3	19
659	Increased PD-1 on CD4 <sup>+</sup> CD28 <sup>+</sup> T cell and soluble PD-1 ligand-1 in patients with T2DM: Association with atherosclerotic macrovascular diseases. <i>Metabolism: Clinical and Experimental</i> , 2013, 62, 778-785.	1.5	67
661	Enhanced anti-cancer activity of human dendritic cells sensitized with gamma-irradiation-induced apoptotic colon cancer cells. <i>Cancer Letters</i> , 2013, 335, 278-288.	3.2	16
662	Programmed cell death 1 inhibits inflammatory helper T-cell development through controlling the innate immune response. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 16073-16078.	3.3	44
663	BTNL8, a butyrophilin-like molecule that costimulates the primary immune response. <i>Molecular Immunology</i> , 2013, 56, 819-828.	1.0	34
664	Immunotherapy for advanced melanoma: Fulfilling the promise. <i>Cancer Treatment Reviews</i> , 2013, 39, 879-885.	3.4	44
666	A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. <i>Nature Immunology</i> , 2013, 14, 1212-1218.	7.0	783

#	ARTICLE	IF	CITATIONS
667	Programmed Death Receptor-1/Programmed Death Receptor Ligand-1 Blockade after Transient Lymphodepletion To Treat Myeloma. <i>Journal of Immunology</i> , 2013, 190, 5620-5628.	0.4	91
668	Human T Cells Engineered To Express a Programmed Death 1/28 Costimulatory Retargeting Molecule Display Enhanced Antitumor Activity. <i>Journal of Immunology</i> , 2013, 191, 4121-4129.	0.4	87
669	Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity. <i>Autoimmunity Reviews</i> , 2013, 12, 1091-1100.	2.5	213
670	Mesenchymal stem cells control alloreactive CD8+CD28 <sup>hi</sup> T cells. <i>Clinical and Experimental Immunology</i> , 2013, 174, 449-458.	1.1	41
671	Gene Therapy Approaches to Prevent Corneal Graft Rejection: Where Do We Stand?. <i>Ophthalmic Research</i> , 2013, 50, 135-140.	1.0	9
672	Immune Escape. , 2013, , 149-164.		1
673	Immune Co-signaling to Treat Cancer. , 2013, , 211-280.		1
674	Intrahepatic Expression of Programmed Death-1 and its Ligands in Patients with HBV-Related Acute-on-Chronic Liver Failure. <i>Inflammation</i> , 2013, 36, 110-120.	1.7	31
675	Immunotherapy of melanoma. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 97-105.	2.2	53
676	Tumor-infiltrating PD1-Positive Lymphocytes and FoxP3-Positive Regulatory T Cells Predict Distant Metastatic Relapse and Survival of Clear Cell Renal Cell Carcinoma. <i>Translational Oncology</i> , 2013, 6, 282-289.	1.7	112
677	Strategies to reverse melanoma-induced T-cell dysfunction. <i>Clinics in Dermatology</i> , 2013, 31, 251-256.	0.8	8
678	Notch signaling regulates PD-1 expression during CD8 <sup>+</sup> T cell activation. <i>Immunology and Cell Biology</i> , 2013, 91, 82-88.	1.0	105
679	Current advances in immunotherapy for pancreatic cancer. <i>Current Problems in Cancer</i> , 2013, 37, 273-279.	1.0	13
680	Advances in targeting cell surface signalling molecules for immune modulation. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 130-146.	21.5	229
681	Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 847-861.	1.4	110
682	Immunotherapy for Renal Cell Carcinoma. , 2013, , 279-301.		0
683	PD-1 coinhibitory signals: The link between pathogenesis and protection. <i>Seminars in Immunology</i> , 2013, 25, 219-227.	2.7	58
684	At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. <i>Journal of Leukocyte Biology</i> , 2013, 94, 25-39.	1.5	317

#	ARTICLE	IF	CITATIONS
685	The antihistamines clemastine and desloratadine inhibit $\text{STAT3}$ and $\text{c-Myc}$ activities and induce apoptosis in cutaneous T-cell lymphoma cell lines. <i>Experimental Dermatology</i> , 2013, 22, 119-124.	1.4	16
686	The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 667-676.	1.1	290
687	Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. <i>European Journal of Cancer</i> , 2013, 49, 2233-2242.	1.3	384
688	Silencing of the glucocorticoid-induced leucine zipper improves the immunogenicity of clinical-grade dendritic cells. <i>Cytotherapy</i> , 2013, 15, 740-749.	0.3	15
689	Potentiating Functional Antigen-specific CD8+ T Cell Immunity by a Novel PD1 Isoform-based Fusion DNA Vaccine. <i>Molecular Therapy</i> , 2013, 21, 1445-1455.	3.7	19
690	Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination. <i>Clinical Cancer Research</i> , 2013, 19, 997-1008.	3.2	161
691	Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer. <i>Cancer Immunology Research</i> , 2013, 1, 85-91.	1.6	161
692	Plasmacytoid Dendritic Cells in Patients With Autoimmune Thyroid Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 2822-2833.	1.8	34
693	PD-L2 modulates asthma severity by directly decreasing dendritic cell IL-12 production. <i>Mucosal Immunology</i> , 2013, 6, 728-739.	2.7	40
694	PD-1 and CTLA-4 Mediated Inhibitory Signaling for T cell Exhaustion during Chronic Viral Infections. <i>Journal of Clinical &amp; Cellular Immunology</i> , 2013, 01, .	1.5	3
695	Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells. <i>Frontiers in Immunology</i> , 2013, 4, 481.	2.2	67
696	Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?. <i>Journal of Carcinogenesis</i> , 2013, 12, 7.	2.5	10
697	Self-Organized Criticality Theory and the Expansion of PD-1-Positive Effector CD4 T Cells: Search for Autoantibody-Inducing CD4 T Cells. <i>Frontiers in Immunology</i> , 2013, 4, 87.	2.2	1
698	Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 1021-1034.	3.2	458
699	Macrophage PD-L1 strikes back: PD-1/PD-L1 interaction drives macrophages toward regulatory subsets. <i>Advances in Bioscience and Biotechnology (Print)</i> , 2013, 04, 19-29.	0.3	14
700	PD-1 is a novel regulator of human B-cell activation. <i>International Immunology</i> , 2013, 25, 129-137.	1.8	261
701	ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. <i>European Journal of Endocrinology</i> , 2013, 169, R153-R164.	1.9	102
702	Batf3-Dependent Dendritic Cells in the Renal Lymph Node Induce Tolerance against Circulating Antigens. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 543-549.	3.0	36

#	ARTICLE	IF	CITATIONS
703	Emerging treatments in management of prostate cancer: biomarker validation and endpoints for immunotherapy clinical trial design. <i>ImmunoTargets and Therapy</i> , 2013, 3, 1.	2.7	4
704	Modulation of Tumor Immunity by Soluble and Membrane-Bound Molecules at the Immunological Synapse. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-19.	3.3	12
705	Differentiation and activation of equine monocyte-derived dendritic cells are not correlated with CD206 or CD83 expression. <i>Immunology</i> , 2013, 139, 472-483.	2.0	19
706	ITIM-dependent negative signaling pathways for the control of cell-mediated xenogeneic immune responses. <i>Xenotransplantation</i> , 2013, 20, 397-406.	1.6	14
707	Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 15001-15006.	3.3	154
708	Periodontal Ligament Stem Cells Regulate B Lymphocyte Function via Programmed Cell Death Protein 1. <i>Stem Cells</i> , 2013, 31, 1371-1382.	1.4	77
709	Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer. <i>Journal of Surgical Oncology</i> , 2013, 107, 517-522.	0.8	75
710	PD-1 as a potential target in cancer therapy. <i>Cancer Medicine</i> , 2013, 2, 662-673.	1.3	369
711	Apolipoprotein A1 as a potential biomarker in the ascitic fluid for the differentiation of advanced ovarian cancers. <i>Biomarkers</i> , 2013, 18, 532-541.	0.9	16
712	Structure and Interactions of the Human Programmed Cell Death 1 Receptor. <i>Journal of Biological Chemistry</i> , 2013, 288, 11771-11785.	1.6	256
713	Butyrophilin Btn2a2 Inhibits TCR Activation and Phosphatidylinositol 3-Kinase/Akt Pathway Signaling and Induces Foxp3 Expression in T Lymphocytes. <i>Journal of Immunology</i> , 2013, 190, 5030-5036.	0.4	38
714	HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 9879-9884.	3.3	160
715	The role of B7 family molecules in hematologic malignancy. <i>Blood</i> , 2013, 121, 734-744.	0.6	159
716	Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. <i>Blood</i> , 2013, 122, 3062-3073.	0.6	156
717	The Influence of Macrophages and the Tumor Microenvironment on Natural Killer Cells. <i>Current Molecular Medicine</i> , 2013, 13, 68-79.	0.6	20
718	A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients with Chronic Hepatitis C Virus Infection. <i>PLoS ONE</i> , 2013, 8, e63818.	1.1	204
719	Secreted and Transmembrane 1A Is a Novel Co-Stimulatory Ligand. <i>PLoS ONE</i> , 2013, 8, e73610.	1.1	21
720	In Vivo T Cell Activation Induces the Formation of CD209+ PDL-2+ Dendritic Cells. <i>PLoS ONE</i> , 2013, 8, e76258.	1.1	6



#	ARTICLE	IF	CITATIONS
721	Characterization of a Soluble B7-H3 (sB7-H3) Spliced from the Intron and Analysis of sB7-H3 in the Sera of Patients with Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2013, 8, e76965.	1.1	36
722	TLR2 Directing PD-L2 Expression Inhibit T Cells Response in <i>Schistosoma japonicum</i> Infection. <i>PLoS ONE</i> , 2013, 8, e82480.	1.1	23
723	The nature of activatory and tolerogenic dendritic cell-derived signal II. <i>Frontiers in Immunology</i> , 2013, 4, 53.	2.2	91
724	Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go. <i>Frontiers in Immunology</i> , 2013, 4, 417.	2.2	62
725	Findings in Murine Viral Myocarditis. , 2013, , .		0
726	Genetic Deletion of Mst1 Alters T Cell Function and Protects against Autoimmunity. <i>PLoS ONE</i> , 2014, 9, e98151.	1.1	41
727	Helminth Induced Suppression of Macrophage Activation Is Correlated with Inhibition of Calcium Channel Activity. <i>PLoS ONE</i> , 2014, 9, e101023.	1.1	25
728	Regulation of Neuroinflammation through Programed Death-1/Programed Death Ligand Signaling in Neurological Disorders. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 271.	1.8	38
729	Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke. <i>Frontiers in Cellular Neuroscience</i> , 2014, 8, 228.	1.8	11
730	PD-1 and PD-L1 antibodies for melanoma. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3111-3116.	1.4	54
731	Trial Watch. <i>Oncolmmunology</i> , 2014, 3, e27297.	2.1	99
732	Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 663-686.	1.4	17
733	Synovial T cell hyporesponsiveness to myeloid dendritic cells is reversed by preventing PD-1/PD-L1 interactions. <i>Arthritis Research and Therapy</i> , 2014, 16, 497.	1.6	28
734	Programmed Death-1 Pathway in Host Tissues Ameliorates Th17/Th1-Mediated Experimental Chronic Craft-versus-Host Disease. <i>Journal of Immunology</i> , 2014, 193, 2565-2573.	0.4	67
735	Malaria drives T cells to exhaustion. <i>Frontiers in Microbiology</i> , 2014, 5, 249.	1.5	70
736	Immunotherapeutic and oncolytic viral therapeutic strategies in pancreatic cancer. <i>Future Oncology</i> , 2014, 10, 1255-1275.	1.1	5
737	Recent advances of immunotherapy in lung cancer: anti-programmed cell death-1/programmed death ligand-1 antibodies. <i>Lung Cancer Management</i> , 2014, 3, 175-190.	1.5	1
738	The role of cytotoxic T cells in IgG4-related dacryoadenitis and sialadenitis, the so-called Mikulicz's disease. <i>Modern Rheumatology</i> , 2014, 24, 953-960.	0.9	10

#	ARTICLE	IF	CITATIONS
739	Identification and characterization of bovine programmed death ligand 2. <i>Microbiology and Immunology</i> , 2014, 58, 388-397.	0.7	1
740	Immunological in vivo effects of B7-H1 deficiency. <i>Immunology Letters</i> , 2014, 162, 273-286.	1.1	5
741	The Immunological Synapse. <i>Cancer Immunology Research</i> , 2014, 2, 1023-1033.	1.6	330
742	Evolving role of tumor antigens for future melanoma therapies. <i>Future Oncology</i> , 2014, 10, 1457-1468.	1.1	15
743	Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2014, 10, 79-90.	1.1	23
744	Local tumour ablative therapies: Opportunities for maximising immune engagement and activation. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 510-523.	3.3	21
745	Biochemical Signaling of PD-1 on T Cells and Its Functional Implications. <i>Cancer Journal (Sudbury, Mass)</i> , 2014, 20, 262-264.	1.0	146
746	The perspective of immunotherapy. <i>Current Opinion in Oncology</i> , 2014, 26, 204-214.	1.1	64
747	Fusion Protein of Mutant B7-DC and Fc Enhances the Antitumor Immune Effect of GM-CSF-secreting Whole-cell Vaccine. <i>Journal of Immunotherapy</i> , 2014, 37, 147-154.	1.2	2
748	PD-1 as an Immune Modulatory Receptor. <i>Cancer Journal (Sudbury, Mass)</i> , 2014, 20, 262-264.	1.0	62
749	Expression of Programmed Cell Death 1 Ligand 2 (PD-L2) Is a Distinguishing Feature of Primary Mediastinal (Thymic) Large B-cell Lymphoma and Associated With PDCD1LG2 Copy Gain. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1715-1723.	2.1	138
750	Dendritic Cell Cancer Vaccines: From the Bench to the Bedside. <i>Rambam Maimonides Medical Journal</i> , 2014, 5, e0024.	0.4	11
751	Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1. <i>Frontiers in Immunology</i> , 2014, 5, 206.	2.2	108
752	Host bone marrow-derived IL-12 enhances donor T cell engraftment in a mouse model of bone marrow transplantation. <i>Journal of Hematology and Oncology</i> , 2014, 7, 16.	6.9	6
753	Sarcoma Immunotherapy: Past Approaches and Future Directions. <i>Sarcoma</i> , 2014, 2014, 1-13.	0.7	43
754	Expression of Programmed Death-1 (PD-1) on CD4+ and CD8+ T cells in Rheumatoid Arthritis. <i>Inflammation</i> , 2014, 37, 116-121.	1.7	58
755	Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokine stimulations. <i>Cytokine</i> , 2014, 65, 33-41.	1.4	50
756	FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. <i>Nature Medicine</i> , 2014, 20, 272-282.	15.2	141

#	ARTICLE	IF	CITATIONS
757	Comparison of dynamic expressions of Tim-3 and PD-1 in the brains between toxoplasmic encephalitis-resistant BALB/c and -susceptible C57BL/6 mice. <i>Parasitology Research</i> , 2014, 113, 1261-1267.	0.6	9
758	Targeting the PD1/PD-L1 axis in melanoma: Biological rationale, clinical challenges and opportunities. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 89, 140-165.	2.0	148
759	Orchestrating immune check-point blockade for cancer immunotherapy in combinations. <i>Current Opinion in Immunology</i> , 2014, 27, 89-97.	2.4	111
761	The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2014, 18, 1-14.	1.5	38
762	Increased percentages of PD-1 on CD4 <sup>+</sup> T cells is associated with higher INF- $\gamma$ production and altered IL-17 production in patients with systemic lupus erythematosus. <i>Scandinavian Journal of Rheumatology</i> , 2014, 43, 307-313.	0.6	31
763	Interferon $\alpha$ -induced programmed death ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment. <i>European Journal of Haematology</i> , 2014, 92, 195-203.	1.1	92
764	Bioinformatics for cancer immunotherapy target discovery. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 1235-1249.	2.0	25
765	Programmed death 1 and B and T lymphocyte attenuator immunoreceptors and their association with malignant T lymphoproliferative disorders: brief review. <i>Hematological Oncology</i> , 2014, 32, 113-119.	0.8	21
766	The Path to Reactivation of Antitumor Immunity and Checkpoint Immunotherapy. <i>Cancer Immunology Research</i> , 2014, 2, 926-936.	1.6	23
767	No longer an untreatable disease: How targeted and immunotherapies have changed the management of melanoma patients. <i>Molecular Oncology</i> , 2014, 8, 1140-1158.	2.1	47
768	Synergistic effects of IL-4 and TNF $\alpha$ on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation. <i>Journal of Translational Medicine</i> , 2014, 12, 151.	1.8	52
769	The development of endometrial hyperplasia in aged PD-1-deficient female mice. <i>Diagnostic Pathology</i> , 2014, 9, 97.	0.9	4
770	Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 977-983.	2.0	31
771	Expression analysis of programmed death ligand 2 in tumors caused by the avian oncovirus Marek's disease virus. <i>Archives of Virology</i> , 2014, 159, 2123-2126.	0.9	3
772	Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. <i>Breast Cancer Research and Treatment</i> , 2014, 146, 15-24.	1.1	472
773	PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection. <i>Cancer Immunology Research</i> , 2014, 2, 320-331.	1.6	138
774	Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 5064-5074.	3.2	2,050
775	Role of the Programmed Death-1 (PD-1) pathway in regulation of Theiler's murine encephalomyelitis virus-induced demyelinating disease. <i>Journal of Neuroimmunology</i> , 2014, 274, 78-85.	1.1	12

#	ARTICLE	IF	CITATIONS
776	Targeting Apoptosis in Autoimmune Hepatitis. <i>Digestive Diseases and Sciences</i> , 2014, 59, 2890-2904.	1.1	42
777	RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. <i>Journal of Experimental Medicine</i> , 2014, 211, 943-959.	4.2	249
778	PD-1/PD-Ls pathways between CD4+ T cells and pleural mesothelial cells in human tuberculous pleurisy. <i>Tuberculosis</i> , 2014, 94, 131-139.	0.8	11
779	Immune checkpoint blockade in hepatocellular carcinoma: Current progress and future directions. <i>Hepatology</i> , 2014, 60, 1776-1782.	3.6	210
780	The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 19-30.	1.3	48
781	CD80 and PD-L2 define functionally distinct memory B cell subsets that are independent of antibody isotype. <i>Nature Immunology</i> , 2014, 15, 631-637.	7.0	348
782	The PD-1/PD-Ls pathway and autoimmune diseases. <i>Cellular Immunology</i> , 2014, 290, 72-79.	1.4	298
783	Vaccination with <i>Leishmania mexicana</i> LPG induces PD-1 in CD8+ and PD-L2 in macrophages thereby suppressing the immune response: A model to assess vaccine efficacy. <i>Vaccine</i> , 2014, 32, 1259-1265.	1.7	26
784	B7-H3 and B7-H1 expression in cerebral spinal fluid and tumor tissue correlates with the malignancy grade of glioma patients. <i>Oncology Letters</i> , 2014, 8, 1195-1201.	0.8	51
785	PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy. <i>Cancer Control</i> , 2014, 21, 231-237.	0.7	127
786	Increased expression of herpesvirus entry mediator in 1,25-dihydroxyvitamin D3-treated mouse bone marrow-derived dendritic cells promotes the generation of CD4+CD25+Foxp3+ regulatory T cells. <i>Molecular Medicine Reports</i> , 2014, 9, 813-818.	1.1	18
788	Targeting immune checkpoints in melanoma: an update. <i>Melanoma Management</i> , 2015, 2, 339-352.	0.1	2
789	Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1726-1735.	0.5	208
792	Human Cancer Immunotherapy with PD-1/PD-L1 Blockade. <i>Biomarkers in Cancer</i> , 2015, 7s2, BIC.S29325.	3.6	51
793	<sc>DNA</sc> vaccines encoding <sc>DEC</sc>205â€targeted antigens: immunity or tolerance?. <i>Immunology</i> , 2015, 145, 519-533.	2.0	25
794	Fluorescence tagging and inducible depletion of PDâ€L2â€expressing Bâ€1 B cells <i>in vivo</i>. <i>Annals of the New York Academy of Sciences</i> , 2015, 1362, 77-85.	1.8	7
795	PD-L1 Gene Polymorphism and High Level of Plasma Soluble Pd-L1 Protein may be aSsociated with Non-Small Cell Lung Cancer. <i>International Journal of Biological Markers</i> , 2015, 30, 364-368.	0.7	56
796	Genomic alterations underlying immune privilege in malignant lymphomas. <i>Current Opinion in Hematology</i> , 2015, 22, 343-354.	1.2	18

#	ARTICLE	IF	CITATIONS
797	Pembrolizumab in the management of metastatic melanoma. <i>Melanoma Management</i> , 2015, 2, 315-325.	0.1	4
798	Pancreatitis Secondary to Anti-Programmed Death Receptor 1 Immunotherapy Diagnosed by FDG PET/CT. <i>Clinical Nuclear Medicine</i> , 2015, 40, e528-e529.	0.7	62
799	Emerging Role for Novel Immunotherapy Agents in Metastatic Renal Cell Carcinoma: From Bench to Bedside. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e291-e297.	1.8	4
800	Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. <i>Journal of Clinical Investigation</i> , 2015, 125, 3384-3391.	3.9	1,112
801	Possible therapeutic implication of PD-L1/PD-1 axis in endometrial cancer. <i>Journal of Solid Tumors</i> , 2015, 5, .	0.1	1
802	Zielgerichtete Therapien gegen PD-1 bei malignen Erkrankungen des Lymphsystems: Biologischer Hintergrund, klinische Herausforderungen und Chancen. <i>Karger Kompass Onkologie</i> , 2015, 2, 8-14.	0.0	0
803	Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. <i>Viruses</i> , 2015, 7, 5889-5901.	1.5	19
804	Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway. <i>Forum on Immunopathological Diseases and Therapeutics</i> , 2015, 6, 7-17.	0.1	82
805	Positive expression of programmed death ligand-1 correlates with superior outcomes and might be a therapeutic target in primary pulmonary lymphoepithelioma-like carcinoma. <i>OncoTargets and Therapy</i> , 2015, 8, 1451.	1.0	37
806	Immunotherapy for Bone and Soft Tissue Sarcomas. <i>BioMed Research International</i> , 2015, 2015, 1-11.	0.9	16
807	Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme. <i>BioMed Research International</i> , 2015, 2015, 1-12.	0.9	29
808	Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?. , 2015, 34, 313-321.		31
809	LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. <i>Oncotarget</i> , 2015, 6, 27359-27377.	0.8	242
810	Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?. <i>Annals of Oncology</i> , 2015, 26, 1813-1823.	0.6	219
811	Monoclonal antibodies specific to human $\beta$ 2PD1: A novel immunoregulator potentially involved in HIV-1 and tumor pathogenesis. <i>MABs</i> , 2015, 7, 620-629.	2.6	6
812	Targeting the PD-1/PD-L1 Immune Evasion Axis With DNA Aptamers as a Novel Therapeutic Strategy for the Treatment of Disseminated Cancers. <i>Molecular Therapy - Nucleic Acids</i> , 2015, 4, e237.	2.3	106
813	Programmed death-1 checkpoint blockade in acute myeloid leukemia. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1191-1203.	1.4	75
814	Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2015, 7, 107-121.	1.4	8

#	ARTICLE	IF	CITATIONS
815	Differential control of CD4 <sup>+</sup> T <sub>H</sub> cell subsets by the PD-1/PD-L1 axis in a mouse model of allergic asthma. <i>European Journal of Immunology</i> , 2015, 45, 1019-1029.	1.6	62
816	Introduction to Costimulation and Costimulatory Molecules. , 2015, , 1-43.		15
817	Costimulation Immunotherapy in Infectious Diseases. , 2015, , 83-129.		10
818	Costimulation in Lymphomas and Cancers. , 2015, , 185-254.		7
819	Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma. <i>Annals of Hematology</i> , 2015, 94, 1545-1552.	0.8	73
820	The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. <i>Clinical Therapeutics</i> , 2015, 37, 764-782.	1.1	469
821	Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the E $\mu$ -TCL1 CLL mouse model. <i>Blood</i> , 2015, 126, 212-221.	0.6	111
822	Cancer and the Immune System: Basic Concepts and Targets for Intervention. <i>Seminars in Oncology</i> , 2015, 42, 523-538.	0.8	220
823	New Strategies in Melanoma: Entering the Era of Combinatorial Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 2424-2435.	3.2	29
824	PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. <i>Cancer Immunology Research</i> , 2015, 3, 1308-1315.	1.6	114
826	Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 4286-4293.	3.2	627
827	Current status of checkpoint inhibitors in lymphoma. <i>International Journal of Hematologic Oncology</i> , 2015, 4, 167-174.	0.7	0
828	The Pekin duck programmed death-ligand 1: cDNA cloning, genomic structure, molecular characterization and mRNA expression analysis. <i>International Journal of Immunogenetics</i> , 2015, 42, 111-120.	0.8	7
829	Association between co-inhibitory molecule gene tagging single nucleotide polymorphisms and the risk of colorectal cancer in Chinese. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 1533-1544.	1.2	37
830	Re: 5-Year Longitudinal Followup after Retropubic and Transobturator Mid Urethral Slings. <i>European Urology</i> , 2015, 67, 817-818.	0.9	0
831	Re: Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. <i>European Urology</i> , 2015, 67, 816-817.	0.9	37
832	Immune Checkpoint Blockade and Interferon- $\gamma$ in Melanoma. <i>Seminars in Oncology</i> , 2015, 42, 436-447.	0.8	34
833	Overexpression of Programmed Death Ligands in Naturally Occurring Postweaning Multisystemic Wasting Syndrome. <i>Viral Immunology</i> , 2015, 28, 101-106.	0.6	9

#	ARTICLE	IF	CITATIONS
834	Mechanisms of tumor-induced T cell immune suppression and therapeutics to counter those effects. Archives of Pharmacal Research, 2015, 38, 1415-1433.	2.7	14
835	Immunology of Pregnancy. , 2015, , 1835-1874.		23
836	Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential. Therapeutic Advances in Medical Oncology, 2015, 7, 12-21.	1.4	22
838	Relationship between <i>programmed cell deathâ€1</i> polymorphisms and clearance of hepatitis B virus. International Journal of Immunogenetics, 2015, 42, 133-139.	0.8	7
839	Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer. Clinical Cancer Research, 2015, 21, 3031-3040.	3.2	355
840	PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Molecular Cancer Therapeutics, 2015, 14, 847-856.	1.9	1,787
841	PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation. Journal of Translational Medicine, 2015, 13, 5.	1.8	73
842	Molecular mechanisms of hormonal and hormonal-cytokine control of immune tolerance in pregnancy. Biochemistry (Moscow) Supplement Series A: Membrane and Cell Biology, 2015, 9, 21-39.	0.3	1
843	Numbers of CD8+PD-1+ and CD4+PD-1+ Cells in Peripheral Blood of Patients with Chronic Lymphocytic Leukemia Are Independent of Binet Stage and Are Significantly Higher Compared to Healthy Volunteers. Acta Haematologica, 2015, 134, 208-214.	0.7	18
844	Combination cancer immunotherapy and new immunomodulatory targets. Nature Reviews Drug Discovery, 2015, 14, 561-584.	21.5	1,058
845	PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nature Communications, 2015, 6, 6692.	5.8	834
846	Immune Checkpoint Inhibition in Renal Cell Carcinoma. , 2015, , 259-279.		0
847	Immune outcomes in the liver: Is CD8 T cell fate determined by the environment?. Journal of Hepatology, 2015, 63, 1005-1014.	1.8	45
848	New immunotherapies targeting the PD-1 pathway. Trends in Pharmacological Sciences, 2015, 36, 587-595.	4.0	158
849	Inflammation and Lung Cancer. , 2015, , .		2
850	The evolving locally-advanced non-small cell lung cancer landscape: Building on past evidence and experience. Critical Reviews in Oncology/Hematology, 2015, 96, 319-327.	2.0	25
851	Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some. Frontiers in Immunology, 2015, 6, 127.	2.2	51
852	Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies. Drug Discovery Today, 2015, 20, 1127-1134.	3.2	27

#	ARTICLE	IF	CITATIONS
853	IL-10 producing B cells partially restore E2-mediated protection against EAE in PD-L1 deficient mice. <i>Journal of Neuroimmunology</i> , 2015, 285, 129-136.	1.1	26
854	Feto-maternal immune regulation by TIM-3/galectin-9 pathway and PD-1 molecule in mice at day 14.5 of pregnancy. <i>Placenta</i> , 2015, 36, 1153-1160.	0.7	32
855	Cancer Immunotherapy with Vaccines and Checkpoint Blockade. , 2015, , 709-738.e8.		0
856	Nivolumab in the treatment of advanced melanoma. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 945-956.	0.5	0
857	Nivolumab in renal cell carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1049-1060.	1.4	4
858	Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma. <i>Cancer Immunology Research</i> , 2015, 3, 1123-1129.	1.6	127
859	OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. <i>Frontiers in Oncology</i> , 2015, 5, 34.	1.3	193
860	Syndecan-1 Modulates the Motility and Resolution Responses of Macrophages. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 332-340.	1.1	42
861	Anti-PD-1-Targeted Therapies Focusing on Lymphatic Malignancies: Biological Rationale, Clinical Challenges and Opportunities. <i>Acta Haematologica</i> , 2015, 133, 129-135.	0.7	8
862	PD-L1 Inhibition With MPDL3280A for Solid Tumors. <i>Seminars in Oncology</i> , 2015, 42, 484-487.	0.8	46
863	Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. <i>Human Pathology</i> , 2015, 46, 357-365.	1.1	252
864	Programmed cell death-1 inhibition in lymphoma. <i>Lancet Oncology</i> , The, 2015, 16, e234-e245.	5.1	56
865	PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitorâ€Treated Melanoma Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3140-3148.	3.2	120
866	Immunotherapy in Prostate Cancer. <i>Current Urology Reports</i> , 2015, 16, 34.	1.0	8
867	Immunotherapy for lung cancer: for whom the bell tolls?. <i>Tumor Biology</i> , 2015, 36, 1411-1422.	0.8	17
868	The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date. <i>Drugs</i> , 2015, 75, 563-575.	4.9	18
870	Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Nonâ€Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 976-984.	3.2	196
871	Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy. <i>Molecular Immunology</i> , 2015, 67, 4-17.	1.0	180



#	ARTICLE	IF	CITATIONS
872	Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 6682-6687.	3.3	266
873	Safety of pembrolizumab for the treatment of melanoma. Expert Opinion on Drug Safety, 2015, 14, 957-964.	1.0	27
874	Immune checkpoint inhibition in lymphoid disease. British Journal of Haematology, 2015, 170, 291-304.	1.2	20
875	Immunologic Checkpoints Blockade in Renal Cell, Prostate, and Urothelial Malignancies. Seminars in Oncology, 2015, 42, 495-505.	0.8	44
876	Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. Cancer Cell, 2015, 27, 450-461.	7.7	3,266
877	Complement protein C1q bound to apoptotic cells suppresses human macrophage and dendritic cell-mediated Th17 and Th1 T cell subset proliferation. Journal of Leukocyte Biology, 2015, 97, 147-160.	1.5	92
878	Cognate interaction with iNKT cells expands IL-10-producing B regulatory cells. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 12474-12479.	3.3	28
879	Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Modern Pathology, 2015, 28, 1535-1544.	2.9	76
880	Predictive biomarkers in precision medicine and drug development against lung cancer. Chinese Journal of Cancer, 2015, 34, 295-309.	4.9	34
881	Checkpoint blockade in combination with cancer vaccines. Vaccine, 2015, 33, 7377-7385.	1.7	33
882	Programmed death-1 & its ligands: promising targets for cancer immunotherapy. Immunotherapy, 2015, 7, 777-792.	1.0	18
883	Anti-PD-1 and PD-L1 therapy for bladder cancer: what is on the horizon?. Future Oncology, 2015, 11, 2299-2306.	1.1	20
884	Immunological landscape and immunotherapy of hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 681-700.	8.2	478
885	PD-1 expression on CD4+ T cells and myeloid DCs correlates with the immune pathogenesis of atrial fibrillation. Journal of Cellular and Molecular Medicine, 2015, 19, 1223-1233.	1.6	23
886	Targeting immune checkpoints: New opportunity for mesothelioma treatment?. Cancer Treatment Reviews, 2015, 41, 914-924.	3.4	41
887	HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade. Cancer Immunology Research, 2015, 3, 1375-1385.	1.6	342
888	Salmonella induces PD-L1 expression in B cells. Immunology Letters, 2015, 167, 131-140.	1.1	19
889	PD-1 Blockers. Cell, 2015, 162, 937.	13.5	126

#	ARTICLE	IF	CITATIONS
890	Immune Checkpoint Inhibitors. Progress in Tumor Research, 2015, 42, 55-66.	0.1	151
891	Multiplying therapies and reducing toxicity in metastatic melanoma. Cancer Biology and Therapy, 2015, 16, 1014-1018.	1.5	9
892	Epigenetic Modulation of Microglial Inflammatory Gene Loci in Helminth-Induced Immune Suppression. ASN Neuro, 2015, 7, 175909141559212.	1.5	20
893	PDL-1/PDL-2 blockade in mice dendritic cells by RNAi techniques to induce antitumor immunity. Immunotherapy, 2015, 7, 1145-1158.	1.0	9
894	Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 2015, 16, 385-390.	1.1	115
895	Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. Immunotherapy, 2015, 7, 1169-1186.	1.0	45
896	Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma. Therapeutic Advances in Urology, 2015, 7, 365-377.	0.9	103
897	Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. Molecular Oncology, 2015, 9, 1936-1965.	2.1	64
898	The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy. Expert Opinion on Therapeutic Targets, 2015, 19, 201-211.	1.5	85
899	The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer. Pediatric Blood and Cancer, 2015, 62, 190-197.	0.8	24
900	Clinical blockade of PD1 and LAG3 – potential mechanisms of action. Nature Reviews Immunology, 2015, 15, 45-56.	10.6	524
901	The development of immunomodulatory monoclonal antibodies as a new therapeutic modality for cancer: The Bristol-Myers Squibb experience. , 2015, 148, 132-153.		50
902	Alteration in regulatory T cells and programmed cell death 1-expressing regulatory T cells in active generalized vitiligo and their clinical correlation. British Journal of Dermatology, 2015, 172, 940-950.	1.4	52
903	Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends in Molecular Medicine, 2015, 21, 24-33.	3.5	628
904	Structural genomic alterations in primary mediastinal large B-cell lymphoma. Leukemia and Lymphoma, 2015, 56, 2239-2250.	0.6	18
905	Human Chorionic Villous Mesenchymal Stem Cells Modify the Functions of Human Dendritic Cells, and Induce an Anti-Inflammatory Phenotype in CD1+ Dendritic Cells. Stem Cell Reviews and Reports, 2015, 11, 423-441.	5.6	63
906	Immunotherapy Targeting the PD-1 Signaling Pathway. Japanese Journal of Lung Cancer, 2016, 56, 61-65.	0.0	0
907	Immune Checkpoint Blockade Therapy: Merits and Demerits. Journal of Clinical & Experimental Dermatology Research, 2016, 7, .	0.1	0

#	ARTICLE	IF	CITATIONS
908	Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer. <i>Oncotarget</i> , 2016, 7, 32113-32128.	0.8	100
909	Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 5855-5866.	1.0	11
910	Generation of Tolerogenic Dendritic Cells and Their Therapeutic Applications. <i>Immune Network</i> , 2016, 16, 52.	1.6	52
911	Enhanced Anti-tumor Reactivity of Cytotoxic T Lymphocytes Expressing PD-1 Decoy. <i>Immune Network</i> , 2016, 16, 134.	1.6	8
912	Association of the programmed cell death-1 PD1.5 C>T polymorphism with cervical cancer risk in a Chinese population. <i>Genetics and Molecular Research</i> , 2016, 15, .	0.3	13
913	A personalized Approach for Targeting the Melanoma: Inhibition of Oncogenic Signaling in Combination with Small Molecules. <i>General Medicine (Los Angeles, Calif )</i> , 2016, 04, .	0.2	1
914	The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 771-788.	0.6	84
915	Basic Overview of Current Immunotherapy Approaches in Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 298-308.	1.8	115
916	Manipulating the Immune System With Checkpoint Inhibitors for Patients With Metastatic Sarcoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e558-e564.	1.8	8
917	Obesity accelerates T cell senescence in murine visceral adipose tissue. <i>Journal of Clinical Investigation</i> , 2016, 126, 4626-4639.	3.9	207
918	Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium. <i>Journal of Immunology Research</i> , 2016, 2016, 1-14.	0.9	36
919	Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors. <i>Vaccines</i> , 2016, 4, 37.	2.1	63
920	IL-1 $\beta$ , But Not Programed Death-1 and Programed Death Ligand Pathway, Is Critical for the Human Th17 Response to <i>Mycobacterium tuberculosis</i> . <i>Frontiers in Immunology</i> , 2016, 7, 465.	2.2	16
921	The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. <i>Frontiers in Immunology</i> , 2016, 7, 550.	2.2	409
922	Adjunct Strategies for Tuberculosis Vaccines: Modulating Key Immune Cell Regulatory Mechanisms to Potentiate Vaccination. <i>Frontiers in Immunology</i> , 2016, 7, 577.	2.2	18
923	Recent Advances in Immunotherapy in Metastatic NSCLC. <i>Frontiers in Oncology</i> , 2016, 6, 239.	1.3	29
924	A Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune Checkpoints. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1151.	1.8	134
925	Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1169.	1.8	53

#	ARTICLE	IF	CITATIONS
926	Immunoregulation in Fungal Diseases. <i>Microorganisms</i> , 2016, 4, 47.	1.6	14
927	Programmed Cell Death-1 Polymorphisms Decrease the Cancer Risk: A Meta-Analysis Involving Twelve Case-Control Studies. <i>PLoS ONE</i> , 2016, 11, e0152448.	1.1	35
928	Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4805-4813.	1.0	42
929	Regulation of Th2 Cell Immunity by Dendritic Cells. <i>Immune Network</i> , 2016, 16, 1.	1.6	73
930	Pembrolizumab (Keytruda). <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2777-2789.	1.4	237
931	Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders. <i>American Journal of Surgical Pathology</i> , 2016, 40, 443-453.	2.1	51
932	Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1). <i>American Journal of Surgical Pathology</i> , 2016, 40, 1133-1142.	2.1	85
933	Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2016, 34, 596-603.	1.2	43
934	Immune-mediated respiratory adverse events of checkpoint inhibitors. <i>Current Opinion in Oncology</i> , 2016, 28, 269-277.	1.1	39
935	Reversing T Cell Dysfunction for Tumor Immunotherapy. , 2016, , 109-128.		0
936	Programmed death ligand-1 expression is associated with poor disease free survival in salivary gland carcinomas. <i>Journal of Surgical Oncology</i> , 2016, 114, 36-43.	0.8	87
937	<sc>OMIP</sc>: Immunologic checkpoint expression on murine effector and memory <sc>T</sc> cell subsets. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2016, 89, 427-429.	1.1	16
938	Pan-cancer analysis of copy number changes in programmed death ligand 1 (PD-L1, CD274) associations with gene expression, mutational load, and survival. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 626-639.	1.5	80
939	The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches. <i>ESMO Open</i> , 2016, 1, e000122.	2.0	55
941	Survival of Lung Adenocarcinoma Patients Predicted from Expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on Tumor Cells and Tumor-Infiltrating T Cells. <i>Cancer Immunology Research</i> , 2016, 4, 1049-1060.	1.6	34
942	Immune checkpoint inhibitors for hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2016, 3, 201-211.	4.2	5
943	Merkel Cell Carcinoma: Characteristics, Management, and What's on the Horizon. <i>Clinical Skin Cancer</i> , 2016, 1, 66-74.	0.1	1
944	Cutaneous Metastatic Melanoma Resembling a Halo Nevus, in the Setting of PD-1 Inhibition. <i>American Journal of Dermatopathology</i> , 2016, 38, e159-e162.	0.3	7

#	ARTICLE	IF	CITATIONS
945	Immune-related endocrine disorders in novel immune checkpoint inhibition therapy. <i>Genes and Diseases</i> , 2016, 3, 252-256.	1.5	17
946	GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade. <i>Molecular Therapy</i> , 2016, 24, 1135-1149.	3.7	281
947	Myeloid PTEN deficiency impairs tumor-immune surveillance via immune-checkpoint inhibition. <i>Oncolmmunology</i> , 2016, 5, e1164918.	2.1	13
948	High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. <i>European Journal of Cancer</i> , 2016, 59, 152-159.	1.3	174
949	Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. <i>Lancet Oncology</i> , The, 2016, 17, 956-965.	5.1	1,369
950	Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies. <i>Annals of Medicine</i> , 2016, 48, 428-439.	1.5	32
951	Novel immunotherapies for the treatment of melanoma. <i>Immunotherapy</i> , 2016, 8, 613-632.	1.0	5
952	PD-L1 Expression in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 964-975.	0.5	329
953	Combinatorial Cancer Immunotherapies. <i>Advances in Immunology</i> , 2016, 130, 251-277.	1.1	107
954	Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). <i>Annals of Oncology</i> , 2016, 27, 1492-1504.	0.6	460
955	Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8+ T cells. <i>Oncology Reports</i> , 2016, 35, 699-708.	1.2	62
956	The clinical impact of ICOS signal in colorectal cancer patients. <i>Oncolmmunology</i> , 2016, 5, e1141857.	2.1	66
957	Enhanced cytotoxic T cell function and inhibition of tumor progression by Mst1 deficiency. <i>FEBS Letters</i> , 2016, 590, 68-75.	1.3	17
958	Emerging Opportunities and Challenges in Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 1845-1855.	3.2	242
959	Programmed Death Ligand-1 Immunohistochemistry – A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 341-344.	1.2	107
960	Cancer immunotherapy: the beginning of the end of cancer?. <i>BMC Medicine</i> , 2016, 14, 73.	2.3	908
961	Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 473-486.	12.5	831
962	Recent developments in the use of immunotherapy in non-small cell lung cancer. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 781-798.	1.0	29

#	ARTICLE	IF	CITATIONS
963	Perspectives for immunotherapy in endocrine cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, R469-R484.	1.6	12
964	Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant. <i>Structure</i> , 2016, 24, 1719-1728.	1.6	86
965	Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. <i>European Journal of Cancer</i> , 2016, 67, 46-54.	1.3	77
966	Progress and opportunities for immune therapeutics in osteosarcoma. <i>Immunotherapy</i> , 2016, 8, 1233-1244.	1.0	54
967	Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. <i>Journal of Clinical Oncology</i> , 2016, 34, 3838-3845.	0.8	715
968	PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome. <i>Oncolmmunology</i> , 2016, 5, e1235107.	2.1	104
969	Anti-PD-1 inhibits Foxp3+ Treg cell conversion and unleashes intratumoural effector T cells thereby enhancing the efficacy of a cancer vaccine in a mouse model. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1491-1498.	2.0	61
970	Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?. <i>Haematologica</i> , 2016, 101, 1144-1158.	1.7	6
971	PD-1/PD-L1, Only a Piece of the Puzzle. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 1187-1188.	1.2	9
972	Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer. <i>Current Oncology Reports</i> , 2016, 18, 59.	1.8	35
973	The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment. <i>Oral Oncology</i> , 2016, 61, 152-158.	0.8	48
974	The immune system and cancer evasion strategies: therapeutic concepts. <i>Journal of Internal Medicine</i> , 2016, 279, 541-562.	2.7	212
975	Immunotherapy for lung cancer. <i>Respirology</i> , 2016, 21, 821-833.	1.3	268
976	Negative influence of programmed death-1 ligands on the survival of esophageal cancer patients treated with chemotherapy. <i>Cancer Science</i> , 2016, 107, 726-733.	1.7	43
977	Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. <i>Molecular Cancer</i> , 2016, 15, 55.	7.9	212
978	An update on the pharmacodynamics, pharmacokinetics, safety and clinical efficacy of nivolumab in the treatment of solid cancers. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1255-1261.	1.5	12
979	Clinical significance of T cell metabolic reprogramming in cancer. <i>Clinical and Translational Medicine</i> , 2016, 5, 29.	1.7	69
980	Association of programmed death-1 polymorphisms with the risk and prognosis of esophageal squamous cell carcinoma. <i>Cancer Genetics</i> , 2016, 209, 365-375.	0.2	29

#	ARTICLE	IF	CITATIONS
981	PD-L1 expression in penile cancer: a new frontier for immune checkpoint inhibitors?. <i>Annals of Oncology</i> , 2016, 27, 1658-1659.	0.6	3
982	Programmed Death-1 Ligand 2-Mediated Regulation of the PD-L1 to PD-1 Axis Is Essential for Establishing CD4 + T Cell Immunity. <i>Immunity</i> , 2016, 45, 333-345.	6.6	92
983	PD-L2 Elbows out PD-L1 to Rescue T Cell Immunity to Malaria. <i>Immunity</i> , 2016, 45, 231-233.	6.6	7
984	Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications. <i>Radiotherapy and Oncology</i> , 2016, 120, 185-194.	0.3	99
985	Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy. <i>Signal Transduction and Targeted Therapy</i> , 2016, 1, 16029.	7.1	53
986	Varicella-Zoster Virus Downregulates Programmed Death Ligand 1 and Major Histocompatibility Complex Class I in Human Brain Vascular Adventitial Fibroblasts, Perineurial Cells, and Lung Fibroblasts. <i>Journal of Virology</i> , 2016, 90, 10527-10534.	1.5	21
987	PD-1/PD-L and autoimmunity: A growing relationship. <i>Cellular Immunology</i> , 2016, 310, 27-41.	1.4	211
988	PD-L1 expression is associated with advanced non-small cell lung cancer. <i>Oncology Letters</i> , 2016, 12, 921-927.	0.8	18
989	Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer. <i>Oncology Letters</i> , 2016, 12, 944-950.	0.8	75
990	Novel targets for paclitaxel nano formulations: Hopes and hypes in triple negative breast cancer. <i>Pharmacological Research</i> , 2016, 111, 577-591.	3.1	46
991	Expression of PD-L1 and HLA Class I in Esophageal Squamous Cell Carcinoma: Prognostic Factors for Patient Outcome. <i>Annals of Surgical Oncology</i> , 2016, 23, 508-515.	0.7	49
993	Intraperitoneal immunotherapy: historical perspectives and modern therapy. <i>Cancer Gene Therapy</i> , 2016, 23, 373-381.	2.2	33
994	Nivolumab in melanoma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1247-1261.	1.1	20
995	Programmed Death Ligand 1 Plays a Neuroprotective Role in Experimental Autoimmune Neuritis by Controlling Peripheral Nervous System Inflammation in Rats. <i>Journal of Immunology</i> , 2016, 197, 3831-3840.	0.4	26
996	Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies. <i>Protein and Cell</i> , 2016, 7, 866-877.	4.8	44
997	Induction of IL-25 secretion from tumour-associated fibroblasts suppresses mammary tumour metastasis. <i>Nature Communications</i> , 2016, 7, 11311.	5.8	32
998	Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy. <i>Nature Communications</i> , 2016, 7, 13354.	5.8	224
999	Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway. <i>New England Journal of Medicine</i> , 2016, 375, 1767-1778.	13.9	1,025

#	ARTICLE	IF	CITATIONS
1000	Preparation and application of a novel monoclonal antibody specific for human B7-H3. <i>Molecular Medicine Reports</i> , 2016, 14, 943-948.	1.1	7
1001	The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma. <i>International Immunopharmacology</i> , 2016, 38, 81-89.	1.7	44
1002	Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. <i>Cancer Immunology Research</i> , 2016, 4, 679-687.	1.6	81
1003	Expression of PD-L1 Identifies a Subgroup of More Aggressive Non-Small Cell Carcinomas of the Lung. <i>Pathobiology</i> , 2016, 83, 267-275.	1.9	21
1004	Checkpoint Inhibitors and Their Application in Breast Cancer. <i>Breast Care</i> , 2016, 11, 108-115.	0.8	45
1006	Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy. <i>Lung Cancer</i> , 2016, 99, 4-10.	0.9	81
1007	PD-1 rs2227982 Polymorphism Is Associated With the Decreased Risk of Breast Cancer in Northwest Chinese Women. <i>Medicine (United States)</i> , 2016, 95, e3760.	0.4	42
1008	Novel technologies and emerging biomarkers for personalized cancer immunotherapy. , 2016, 4, 3.		183
1009	BIP induces mice CD19 hi regulatory B cells producing IL-10 and highly expressing PD-L1, FasL. <i>Molecular Immunology</i> , 2016, 69, 44-51.	1.0	34
1010	Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 389-396.	1.4	35
1011	Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. <i>Pathology</i> , 2016, 48, 177-187.	0.3	210
1012	Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 4057-4066.	3.2	433
1013	Evaluation of innate and adaptive immunity contributing to the antitumor effects of PD1 blockade in an orthotopic murine model of pancreatic cancer. <i>Onc Immunology</i> , 2016, 5, e1160184.	2.1	13
1014	PD-1 function in apoptosis of T lymphocytes in canine visceral leishmaniasis. <i>Immunobiology</i> , 2016, 221, 879-888.	0.8	39
1015	Immune checkpoint blockade in lymphoid malignancies. <i>FEBS Journal</i> , 2016, 283, 2233-2244.	2.2	18
1016	The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. <i>Advances in Immunology</i> , 2016, 130, 25-74.	1.1	181
1017	A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage. <i>Onc Immunology</i> , 2016, 5, e1091146.	2.1	66
1018	Basics of PD-1 in self-tolerance, infection, and cancer immunity. <i>International Journal of Clinical Oncology</i> , 2016, 21, 448-455.	1.0	74



#	ARTICLE	IF	CITATIONS
1019	Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 655-674.	1.4	21
1020	Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8+ Cytolytic T Cell Responses. <i>Immunity</i> , 2016, 44, 274-286.	6.6	144
1021	PD-1/PD-L1 blockage in cancer treatment—from basic research to clinical application. <i>International Journal of Clinical Oncology</i> , 2016, 21, 447-447.	1.0	10
1022	Anti-Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis. <i>Translational Oncology</i> , 2016, 9, 32-40.	1.7	17
1023	Coinhibitory Pathways in Immunotherapy for Cancer. <i>Annual Review of Immunology</i> , 2016, 34, 539-573.	9.5	718
1024	An increased number of PD-1+ and Tim-3+ CD8+ T cells is involved in immune evasion in gastric cancer. <i>Surgery Today</i> , 2016, 46, 1341-1347.	0.7	34
1025	Immunotherapy of Cancer. , 2016, , .		3
1026	Anti-PD-1 and Anti-PD-L1 mAbs. , 2016, , 283-294.		1
1027	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , 2016, 387, 1909-1920.	6.3	3,077
1028	Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. <i>Lancet, The</i> , 2016, 387, 1837-1846.	6.3	2,390
1029	Expression and prognostic roles of PIK3CA, JAK2, PD-L1, and PD-L2 in Epstein-Barr virus-associated gastric carcinoma. <i>Human Pathology</i> , 2016, 53, 25-34.	1.1	57
1030	Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists. <i>Pathology</i> , 2016, 48, 194-202.	0.3	19
1031	Regulation of PD-L1: a novel role of pro-survival signalling in cancer. <i>Annals of Oncology</i> , 2016, 27, 409-416.	0.6	597
1032	PD-1 expression on dendritic cells suppresses CD8 <sup>+</sup> T cell function and antitumor immunity. <i>Oncolmmunology</i> , 2016, 5, e1085146.	2.1	131
1033	Process of hepatic metastasis from pancreatic cancer: biology with clinical significance. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 1137-1161.	1.2	24
1034	The associations between PD-1, CTLA-4 gene polymorphisms and susceptibility to ankylosing spondylitis: a meta-analysis and systemic review. <i>Rheumatology International</i> , 2016, 36, 33-44.	1.5	17
1035	Biomarkers for immunotherapy in genitourinary malignancies. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 205-213.	0.8	14
1036	PDCD1 PD-1.3 polymorphism and allergic bronchial asthma in Russian and Buryat patients. <i>Journal of Asthma</i> , 2017, 54, 46-52.	0.9	6

#	ARTICLE	IF	CITATIONS
1037	Cancer immunotherapy â€” immune checkpoint blockade and associated endocrinopathies. <i>Nature Reviews Endocrinology</i> , 2017, 13, 195-207.	4.3	515
1038	Adaptive Immunity to Plasmodium Blood Stages. , 2017, , 47-66.		3
1039	Aptamers for CD Antigens: From Cell Profiling to Activity Modulation. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 6, 29-44.	2.3	33
1040	A current perspective on cancer immune therapy: stepâ€”step approach to constructing the magic bullet. <i>Clinical and Translational Medicine</i> , 2017, 6, 3.	1.7	58
1041	Noncoding <sc>RNA</sc>s and immune checkpointsâ€”clinical implications as cancer therapeutics. <i>FEBS Journal</i> , 2017, 284, 1952-1966.	2.2	99
1042	Novel immune check point inhibiting antibodies in cancer therapyâ€”Opportunities and challenges. <i>Drug Resistance Updates</i> , 2017, 30, 39-47.	6.5	98
1043	Circulating T lymphocyte subsets, cytokines, and immune checkpoint inhibitors in patients with bipolar II or major depression: a preliminary study. <i>Scientific Reports</i> , 2017, 7, 40530.	1.6	32
1044	Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. <i>Cancer Immunology Research</i> , 2017, 5, 106-117.	1.6	236
1045	Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review. <i>World Journal of Urology</i> , 2017, 35, 1401-1407.	1.2	29
1046	Tumoral PD-L1 expression in desmoplastic melanoma is associated with depth of invasion, tumor-infiltrating CD8 cytotoxic lymphocytes and the mixed cytomorphological variant. <i>Modern Pathology</i> , 2017, 30, 357-369.	2.9	25
1047	Programmed cell deathâ€”1 expression correlates with disease severity and ILâ€”5 in chronic rhinosinusitis with nasal polyps. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 985-993.	2.7	23
1048	PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective. <i>Journal of Hematology and Oncology</i> , 2017, 10, 34.	6.9	82
1050	Chemotherapy induces tumor immune evasion by upregulation of programmed cell death ligandâ€”1 expression in bone marrow stromal cells. <i>Molecular Oncology</i> , 2017, 11, 358-372.	2.1	43
1051	Emerging role of checkpoint blockade therapy in lymphoma. <i>Therapeutic Advances in Hematology</i> , 2017, 8, 81-90.	1.1	32
1052	Virosome-bound antigen enhances DC-dependent specific CD4+ T cell stimulation, inducing a Th1 and Treg profile in vitro. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 1725-1737.	1.7	10
1053	In situ and in silico kinetic analyses of programmed cell death-1 (PD-1) receptor, programmed cell death ligands, and B7-1 protein interaction network. <i>Journal of Biological Chemistry</i> , 2017, 292, 6799-6809.	1.6	16
1054	Characterization of the Antiâ€”PD-1 Antibody REGN2810 and Its Antitumor Activity in Human <i>PD-1</i> Knock-In Mice. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 861-870.	1.9	92
1055	Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. <i>Cell Discovery</i> , 2017, 3, 17004.	3.1	147

#	ARTICLE	IF	CITATIONS
1056	Structure-guided development of a high-affinity human Programmed Cell Death-1: Implications for tumor immunotherapy. <i>EBioMedicine</i> , 2017, 17, 30-44.	2.7	52
1057	New monoclonal antibodies on the horizon in multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2017, 8, 41-53.	1.1	15
1058	Inflammatory cytokines compromise programmed cell death-1 (PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1. <i>Clinical and Experimental Immunology</i> , 2017, 188, 455-466.	1.1	55
1059	Targeting the programmed death-1 pathway in lymphoid neoplasms. <i>Cancer Treatment Reviews</i> , 2017, 54, 99-109.	3.4	27
1060	PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy. <i>Oncolmunology</i> , 2017, 6, e1294299.	2.1	114
1061	An unexpected N-terminal loop in PD-1 dominates binding by nivolumab. <i>Nature Communications</i> , 2017, 8, 14369.	5.8	192
1062	PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. <i>Blood</i> , 2017, 129, 2186-2197.	0.6	156
1063	Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials. <i>Oncology</i> , 2017, 92, 50-62.	0.9	180
1064	The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors. <i>Neurotherapeutics</i> , 2017, 14, 1049-1065.	2.1	20
1065	Oral administration of the lactic acid bacterium <i>Pediococcus acidilactici</i> attenuates atherosclerosis in mice by inducing tolerogenic dendritic cells. <i>Heart and Vessels</i> , 2017, 32, 768-776.	0.5	24
1066	Immune checkpoints and their inhibition in cancer and infectious diseases. <i>European Journal of Immunology</i> , 2017, 47, 765-779.	1.6	418
1067	Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy. <i>Annals of Oncology</i> , 2017, 28, 1658-1666.	0.6	26
1069	Metastatic melanoma in a 95 years old patient responding to treatment with talimogene laherparepvec followed by nivolumab. <i>Acta Oncologica</i> , 2017, 56, 1327-1330.	0.8	2
1070	Immune Characterization of the Programmed Death Receptor Pathway in High Risk Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 577-581.	0.9	33
1071	PD-1 regulates KLRG1+ group 2 innate lymphoid cells. <i>Journal of Experimental Medicine</i> , 2017, 214, 1663-1678.	4.2	163
1072	Checkpoint inhibitors in hematological malignancies. <i>Journal of Hematology and Oncology</i> , 2017, 10, 103.	6.9	106
1073	Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress. <i>Journal of Hematology and Oncology</i> , 2017, 10, 86.	6.9	64
1074	The use of immunotherapy in the treatment of melanoma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 88.	6.9	89

#	ARTICLE	IF	CITATIONS
1075	PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 3158-3167.	3.2	426
1076	Transcriptional and epigenetic regulation of T cell hyporesponsiveness. <i>Journal of Leukocyte Biology</i> , 2017, 102, 601-615.	1.5	39
1077	TCR + CD3 + CD4 $\alpha^+$ CD8 $\alpha^+$ effector T cells in psoriasis. <i>Clinical Immunology</i> , 2017, 181, 51-59.	1.4	39
1078	Immunogenomics: using genomics to personalize cancer immunotherapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 209-219.	1.4	7
1079	Signals that drive T follicular helper cell formation. <i>Immunology</i> , 2017, 152, 185-194.	2.0	41
1080	Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. <i>Cancer Treatment Reviews</i> , 2017, 58, 22-33.	3.4	76
1081	Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2017, 70, 34-42.	0.8	38
1082	Association of PD-1.5 C/T, but Not PD-1.3 G/A, with Malignant and Benign Brain Tumors in Iranian Patients. <i>Immunological Investigations</i> , 2017, 46, 469-480.	1.0	10
1083	Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study. <i>Thyroid</i> , 2017, 27, 894-901.	2.4	123
1084	Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma. <i>Molecular and Cellular Proteomics</i> , 2017, 16, 1705-1717.	2.5	56
1085	Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 153-164.	0.4	59
1086	Contribution of Soluble Forms of Programmed Death 1 and Programmed Death Ligand 2 to Disease Severity and Progression in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1879-1890.	2.9	47
1087	Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis. <i>British Journal of Pharmacology</i> , 2017, 174, 3940-3955.	2.7	48
1088	Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies. <i>Drugs</i> , 2017, 77, 843-857.	4.9	40
1089	Pembrolizumab use for the treatment of advanced melanoma. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 765-780.	1.4	10
1090	CD8 T cell regulation by T regulatory cells and the programmed cell death protein 1 pathway. <i>Immunology</i> , 2017, 151, 146-153.	2.0	12
1091	Cancer immunotherapies targeting the PD-1 signaling pathway. <i>Journal of Biomedical Science</i> , 2017, 24, 26.	2.6	501
1092	PD-1/PD-L1 Pathway in Breast Cancer. <i>Oncology Research and Treatment</i> , 2017, 40, 294-297.	0.8	124

#	ARTICLE	IF	CITATIONS
1093	PD-L2: A prognostic marker in chromophobe renal cell carcinoma?. <i>Medical Oncology</i> , 2017, 34, 71.	1.2	17
1094	Cancer Immunotherapy: Whence and Whither. <i>Molecular Cancer Research</i> , 2017, 15, 635-650.	1.5	30
1095	Induction of T-Cell Infiltration and Programmed Death Ligand 2 Expression by Adeno-Associated Virus in Rhesus Macaque Skeletal Muscle and Modulation by Prednisone. <i>Human Gene Therapy</i> , 2017, 28, 493-509.	1.4	17
1096	Short review of potential synergies of immune checkpoint inhibition and radiotherapy with a focus on Hodgkin lymphoma: radio-immunotherapy opens new doors. <i>Immunotherapy</i> , 2017, 9, 423-433.	1.0	9
1097	Immune checkpoint inhibition and its relationship with hypermutation phenotype as a potential treatment for Glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 132, 359-372.	1.4	8
1098	PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. <i>Journal of Experimental Medicine</i> , 2017, 214, 895-904.	4.2	614
1099	The Role of Targeted Therapy in the Management of Sinonasal Malignancies. <i>Otolaryngologic Clinics of North America</i> , 2017, 50, 443-455.	0.5	12
1100	Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma. <i>European Journal of Cancer</i> , 2017, 76, 152-166.	1.3	82
1101	Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?. <i>Blood</i> , 2017, 129, 275-279.	0.6	85
1102	Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update. <i>Liver Cancer</i> , 2017, 6, 1-12.	4.2	60
1103	Programmed death-1 ligand-1 gene rs2890658 polymorphism associated with the risk of esophageal squamous cell carcinoma in smokers. <i>Cancer Biomarkers</i> , 2017, 21, 65-71.	0.8	11
1104	Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer. <i>British Journal of Cancer</i> , 2017, 117, 1753-1760.	2.9	40
1105	Trapping Cancers as They Adapt to Survive. <i>Cancer Discovery</i> , 2017, 7, 1216-1217.	7.7	3
1106	Immune checkpoint inhibitors in renal cell carcinoma. <i>Clinical Science</i> , 2017, 131, 2627-2642.	1.8	62
1107	Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 119, 30-39.	2.0	40
1108	Endocrine side effects of cancer immunotherapy. <i>Endocrine-Related Cancer</i> , 2017, 24, T331-T347.	1.6	131
1109	Kaposi's Sarcoma-Associated Herpesvirus Increases PD-L1 and Proinflammatory Cytokine Expression in Human Monocytes. <i>MBio</i> , 2017, 8, .	1.8	57
1110	Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer. <i>Cancer Immunology Research</i> , 2017, 5, 1046-1055.	1.6	42

#	ARTICLE	IF	CITATIONS
1111	Immune Dysfunction in Non-Hodgkin Lymphoma: Avenues for New Immunotherapy-Based Strategies. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 484-494.	1.2	4
1112	Radiotherapy in combination with immune checkpoint inhibitors. <i>Current Opinion in Oncology</i> , 2017, 29, 105-111.	1.1	14
1113	Dendritic Cell-Based Cancer Therapies: Current Status and Future Directions. <i>Molecular and Translational Medicine</i> , 2017, , 99-120.	0.4	1
1114	Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma. <i>Oncology</i> , 2017, 93, 387-394.	0.9	31
1115	Second-line systemic therapy in metastatic renal-cell carcinoma: A review. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 640-646.	0.8	14
1116	The Prognostic Significance of Soluble Programmed Death Ligand 1 Expression in Cancers: A Systematic Review and Meta-analysis. <i>Scandinavian Journal of Immunology</i> , 2017, 86, 361-367.	1.3	45
1117	Role of PD-1 in Immunity and Diseases. <i>Current Topics in Microbiology and Immunology</i> , 2017, 410, 75-97.	0.7	136
1118	PD-1 Blockade Promotes Epitope Spreading in Anticancer CD8+ T Cell Responses by Preventing Fratricidal Death of Subdominant Clones To Relieve Immunodomination. <i>Journal of Immunology</i> , 2017, 199, 3348-3359.	0.4	54
1119	Mining the Complex Family of Protein Tyrosine Phosphatases for Checkpoint Regulators in Immunity. <i>Current Topics in Microbiology and Immunology</i> , 2017, 410, 191-214.	0.7	8
1120	Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma. <i>Oncolmmunology</i> , 2017, 6, e1338237.	2.1	47
1121	Differential regulation of PD-1 and its ligands in allergic asthma. <i>Clinical and Experimental Allergy</i> , 2017, 47, 1417-1425.	1.4	20
1122	Enhancing the antitumour-specific immunity of a lung DNA vaccine in vivo by fusion expression of MAGE-A3 and soluble PD-1. <i>Biotechnology and Biotechnological Equipment</i> , 2017, 31, 1064-1069.	0.5	2
1123	Atezolizumab for the treatment of non-small cell lung cancer. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 935-945.	1.3	34
1124	Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1. <i>Hepatology</i> , 2017, 66, 1920-1933.	3.6	142
1125	Characterization of poly(L-glutamic acid)-grafted hyaluronan as a novel candidate medicine and biomedical device for intra-articular injection. <i>Journal of Biomedical Materials Research - Part A</i> , 2017, 105, 3006-3016.	2.1	4
1126	A novel bifunctional anti-PD-L1/TGF- $\beta$ 2 Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells. <i>Oncolmmunology</i> , 2017, 6, e1349589.	2.1	137
1127	Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase III study. <i>Cancer Science</i> , 2017, 108, 1223-1230.	1.7	66
1128	ILC2s regulate adaptive Th2 cell functions via PD-L1 checkpoint control. <i>Journal of Experimental Medicine</i> , 2017, 214, 2507-2521.	4.2	109

#	ARTICLE	IF	CITATIONS
1129	Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. <i>Scientific Reports</i> , 2017, 7, 5532.	1.6	166
1130	Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2. <i>Structure</i> , 2017, 25, 1163-1174.	1.6	253
1131	Programmed death 1 is highly expressed on CD <sup>8</sup> T cells in patients with stable multiple sclerosis and inhibits their cytotoxic response to Epstein-Barr virus. <i>Immunology</i> , 2017, 152, 660-676.	2.0	37
1132	PD-L2 Regulates B-1 Cell Antibody Production against Phosphorylcholine through an IL-5-Dependent Mechanism. <i>Journal of Immunology</i> , 2017, 199, 2020-2029.	0.4	31
1133	Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. <i>Cell</i> , 2017, 170, 1120-1133.e17.	13.5	960
1134	The Expression and Clinical Signification of PD-1 in Lymph Nodes of Patients with Non-small Cell Lung Cancer. <i>Immunological Investigations</i> , 2017, 46, 639-646.	1.0	10
1135	Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma. <i>Current Treatment Options in Oncology</i> , 2017, 18, 51.	1.3	69
1136	Recent advances in cancer immunology and immunology-based anticancer therapies. <i>Biomedicine and Pharmacotherapy</i> , 2017, 96, 1491-1500.	2.5	17
1137	Emerging Concepts Targeting Immune Checkpoints in Cancer and Autoimmunity. <i>Current Topics in Microbiology and Immunology</i> , 2017, , .	0.7	1
1138	Histopathological and genotypic characterization of metastatic colorectal carcinoma with PD-L1 (CD274) expression: Possible roles of tumour micro environmental factors for CD274 expression. <i>Journal of Pathology: Clinical Research</i> , 2017, 3, 268-278.	1.3	18
1139	Cardiotoxicity of immune checkpoint inhibitors. <i>ESMO Open</i> , 2017, 2, e000247.	2.0	186
1140	Construction of high level prokaryotic expression and purification system of PD-L1 extracellular domain by using <i>Escherichia coli</i> host cell machinery. <i>Immunology Letters</i> , 2017, 190, 34-41.	1.1	9
1141	PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies. <i>Human Pathology</i> , 2017, 66, 13-33.	1.1	46
1142	Immunogenicity and immunomodulatory effects of the human chondrocytes, hChonJ. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 199.	0.8	14
1143	The future of immune checkpoint cancer therapy after PD-1 and CTLA-4. <i>Immunotherapy</i> , 2017, 9, 681-692.	1.0	94
1144	T-cell exhaustion in tuberculosis: pitfalls and prospects. <i>Critical Reviews in Microbiology</i> , 2017, 43, 133-141.	2.7	75
1145	Off-the-shelf™ immunotherapy with iPSC-derived rejuvenated cytotoxic T lymphocytes. <i>Experimental Hematology</i> , 2017, 47, 2-12.	0.2	22
1146	Phenotypic and Functional Analysis of Antigen-Specific T Cell Exhaustion. <i>Methods in Molecular Biology</i> , 2017, 1514, 83-92.	0.4	1

#	ARTICLE	IF	CITATIONS
1147	Clinicopathologic profile, immunophenotype, and genotype of CD274 (PD-L1)-positive colorectal carcinomas. <i>Modern Pathology</i> , 2017, 30, 278-285.	2.9	77
1148	Radiotherapy combination opportunities leveraging immunity for the next oncology practice. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 65-85.	157.7	344
1149	Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 93-99.	0.6	40
1150	OMIPâ€³7: 16â€³color panel to measure inhibitory receptor signatures from multiple human immune cell subsets. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2017, 91, 175-179.	1.1	21
1151	PD-1/PD-L1 binding studies using microscale thermophoresis. <i>Scientific Reports</i> , 2017, 7, 17623.	1.6	56
1152	Monocyte programmed death ligand-1 expression is an early marker for predicting infectious complications in acute pancreatitis. <i>Critical Care</i> , 2017, 21, 186.	2.5	31
1153	PD-L1 expression as poor prognostic factor in patients with non-squamous non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 58457-58468.	0.8	42
1154	Introduction to Translational Immunotherapy for Brain Tumors. , 2017, , xiii-xxix.		0
1155	Systemic Therapy Options for Patients With Unresectable Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 661-672.	1.8	8
1156	Immune Regulation in Breast Cancer Metastasis and Immunotherapy. , 2017, , .		0
1157	Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy. <i>Cancers</i> , 2017, 9, 13.	1.7	40
1158	Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2537-2549.	2.0	6
1159	Targeting Immune Cell Checkpoints during Sepsis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2413.	1.8	125
1160	Programmed Cell Death 1 (PD-1) and Cytotoxic T Lymphocyte-Associated Antigen 4 (CTLA-4) in Viral Hepatitis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1517.	1.8	69
1161	PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. <i>Frontiers in Immunology</i> , 2017, 8, 1597.	2.2	225
1162	Immune-Mediated Therapies for Liver Cancer. <i>Genes</i> , 2017, 8, 76.	1.0	20
1163	Nasal Polyp-Derived Mesenchymal Stromal Cells Exhibit Lack of Immune-Associated Molecules and High Levels of Stem/Progenitor Cells Markers. <i>Frontiers in Immunology</i> , 2017, 8, 39.	2.2	15
1164	Cbl-b Deficiency Mediates Resistance to Programed Death-Ligand 1/Programed Death-1 Regulation. <i>Frontiers in Immunology</i> , 2017, 8, 42.	2.2	26



#	ARTICLE	IF	CITATIONS
1165	Macrophages Polarized by Expression of ToxoGRA15II Inhibit Growth of Hepatic Carcinoma. <i>Frontiers in Immunology</i> , 2017, 8, 137.	2.2	18
1166	Immunometabolic Regulations Mediated by Coinhibitory Receptors and Their Impact on T Cell Immune Responses. <i>Frontiers in Immunology</i> , 2017, 8, 330.	2.2	44
1167	Pulmonary Delivery of Virosome-Bound Antigen Enhances Antigen-Specific CD4+ T Cell Proliferation Compared to Liposome-Bound or Soluble Antigen. <i>Frontiers in Immunology</i> , 2017, 8, 359.	2.2	19
1168	CD28 Blockade Ex Vivo Induces Alloantigen-Specific Immune Tolerance but Preserves T-Cell Pathogen Reactivity. <i>Frontiers in Immunology</i> , 2017, 8, 1152.	2.2	11
1169	Glycogen Synthase Kinase 3 Inactivation Compensates for the Lack of CD28 in the Priming of CD8+ Cytotoxic T-Cells: Implications for anti-PD-1 Immunotherapy. <i>Frontiers in Immunology</i> , 2017, 8, 1653.	2.2	42
1170	Differential Impact of miR-21 on Pain and Associated Affective and Cognitive Behavior after Spared Nerve Injury in B7-H1 ko Mouse. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 219.	1.4	19
1171	Dynamics of Immune Checkpoints, Immune System, and BCG in the Treatment of Superficial Bladder Cancer. <i>Computational and Mathematical Methods in Medicine</i> , 2017, 2017, 1-9.	0.7	12
1172	Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses. <i>PLoS ONE</i> , 2017, 12, e0179201.	1.1	28
1173	Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types. <i>BMC Medical Genomics</i> , 2017, 10, 74.	0.7	35
1174	PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1331.	1.8	60
1175	Clinical Significance and Therapeutic Potential of the Programmed Death Ligand-1 (PD-L1) and PD-L2 Expression in Human Colorectal Cancer. <i>Journal of Cancer Science &amp; Therapy</i> , 2017, 09, .	1.7	2
1176	Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade. <i>Oncotarget</i> , 2017, 8, 110693-110707.	0.8	115
1177	Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors. <i>Oncotarget</i> , 2017, 8, 41641-41669.	0.8	15
1178	PD-1/PD-Ls: A New Target for Regulating Immunopathogenesis in Central Nervous System Disorders. <i>Current Drug Delivery</i> , 2017, 14, 791-796.	0.8	0
1179	Regulation of the maturation of human monocytes into immunosuppressive macrophages. <i>Blood Advances</i> , 2017, 1, 2510-2519.	2.5	29
1180	Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent. <i>Oncotarget</i> , 2017, 8, 71371-71384.	0.8	85
1181	Tumor PD-L1 status and CD8+ tumor-infiltrating T cells: markers of improved prognosis in oropharyngeal cancer. <i>Oncotarget</i> , 2017, 8, 80443-80452.	0.8	78
1182	Emerging treatment options for the management of Hodgkin&#39;s lymphoma: clinical utility of Nivolumab. <i>Journal of Blood Medicine</i> , 2017, Volume 8, 41-54.	0.7	5

#	ARTICLE	IF	CITATIONS
1183	Elevated expression of PD-1 on T cells correlates with disease activity in rheumatoid arthritis. <i>Molecular Medicine Reports</i> , 2018, 17, 3297-3305.	1.1	11
1184	The future of immune checkpoint blockade immunotherapy: towards personalized therapy or towards combination therapy. <i>Journal of Thoracic Disease</i> , 2017, 9, 4226-4229.	0.6	10
1185	High-affinity human PD-L1 variants attenuate the suppression of T cell activation. <i>Oncotarget</i> , 2017, 8, 88360-88375.	0.8	30
1186	Genotypic and phenotypic signatures to predict immune checkpoint blockade therapy response in patients with colorectal cancer. <i>Translational Research</i> , 2018, 196, 62-70.	2.2	9
1187	The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma. <i>Esophagus</i> , 2018, 15, 103-108.	1.0	14
1188	Oncogenic JAK2 <sup>V617F</sup> causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	166
1189	Immune Checkpoint Inhibition in Hodgkin Lymphoma. <i>HemaSphere</i> , 2018, 2, e20.	1.2	15
1190	Cyclosporin A inhibits adipogenic differentiation and regulates immunomodulatory functions of murine mesenchymal stem cells. <i>Biochemical and Biophysical Research Communications</i> , 2018, 498, 516-522.	1.0	6
1191	Is it possible to rechallenge with PD-1/PD-L1 inhibitors after progression?. <i>Immunotherapy</i> , 2018, 10, 345-347.	1.0	9
1192	PD-1 is required to maintain stem cell properties in human dental pulp stem cells. <i>Cell Death and Differentiation</i> , 2018, 25, 1350-1360.	5.0	31
1193	Bacterially activated B-cells drive T cell differentiation towards Tr1 through PD-1/PD-L1 expression. <i>Molecular Immunology</i> , 2018, 96, 48-60.	1.0	13
1194	Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians. <i>Cancer Treatment Reviews</i> , 2018, 65, 54-64.	3.4	51
1195	Under-Evaluated or Unassessed Pathogenic Pathways in Autoimmune Hepatitis and Implications for Future Management. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1706-1725.	1.1	13
1196	<sup>HOXC</sup> 10 promotes proliferation and invasion and induces immunosuppressive gene expression in glioma. <i>FEBS Journal</i> , 2018, 285, 2278-2291.	2.2	35
1197	Towards predictive biomarkers for immunotherapy response in breast cancer patients. <i>Breast Cancer Management</i> , 2018, 7, BMT05.	0.2	4
1198	In Vivo Antitumor Effects of MK615 Led by PD-L1 Downregulation. <i>Integrative Cancer Therapies</i> , 2018, 17, 646-653.	0.8	12
1199	Shp-2 Is Dispensable for Establishing T Cell Exhaustion and for PD-1 Signaling In Vivo. <i>Cell Reports</i> , 2018, 23, 39-49.	2.9	114
1200	Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer. <i>Immunology Letters</i> , 2018, 196, 155-160.	1.1	55

#	ARTICLE	IF	CITATIONS
1201	Chemokines beyond chemo-attraction: CXCL10 and its significant role in cancer and autoimmunity. <i>Cytokine</i> , 2018, 109, 24-28.	1.4	153
1202	Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer. <i>Cancer Cell</i> , 2018, 33, 463-479.e10.	7.7	1,074
1203	A Correlative Analysis of PD-L1, PD-1, PD-L2, EGFR, HER2, and HER3 Expression in Oropharyngeal Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 710-716.	1.9	25
1204	Cell death-based treatments of melanoma:conventional treatments and new therapeutic strategies. <i>Cell Death and Disease</i> , 2018, 9, 112.	2.7	94
1205	PD-L1 reverses depigmentation in Pmel-1 vitiligo mice by increasing the abundance of Tregs in the skin. <i>Scientific Reports</i> , 2018, 8, 1605.	1.6	41
1206	A novel role for coinhibitory receptors/checkpoint proteins in the immunopathology of sepsis. <i>Journal of Leukocyte Biology</i> , 2018, 103, 1151-1164.	1.5	25
1207	Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 1617-1628.	3.2	44
1208	PD-L1 expression is regulated by both DNA methylation and NF- $\kappa$ B during EMT signaling in non-small cell lung carcinoma. <i>OncImmunology</i> , 2018, 7, e1423170.	2.1	150
1209	Established, emerging and elusive molecular targets in the treatment of lung cancer. <i>Journal of Pathology</i> , 2018, 244, 565-577.	2.1	15
1211	Preclinical Data Supporting Antitumor Activity of PD-1 Blockade. <i>Cancer Journal (Sudbury, Mass )</i> , 2018, 24, 2-6.	1.0	5
1212	PD-1/PD-L1 in disease. <i>Immunotherapy</i> , 2018, 10, 149-160.	1.0	90
1213	Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E468-E477.	3.3	72
1214	Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects. <i>Medicinal Research Reviews</i> , 2018, 38, 1447-1468.	5.0	27
1215	Triple-Negative Breast Cancer. , 2018, , .		0
1216	Molecular Profiling and Targeted Therapy for Triple-Negative Breast Cancer. , 2018, , 117-140.		0
1217	Inhibitors of the PD-1 Pathway in Tumor Therapy. <i>Journal of Immunology</i> , 2018, 200, 375-383.	0.4	112
1218	Exploring immune checkpoints as potential therapeutic targets in atherosclerosis. <i>Cardiovascular Research</i> , 2018, 114, 368-377.	1.8	64
1219	Pathogenic roles of B lymphocytes in systemic sclerosis. <i>Immunology Letters</i> , 2018, 195, 76-82.	1.1	56

#	ARTICLE	IF	CITATIONS
1220	Monocyte Programmed Death Ligand-1, A Predicator for 28-Day Mortality in Septic Patients. <i>American Journal of the Medical Sciences</i> , 2018, 355, 362-367.	0.4	14
1221	IFN- $\gamma$ decreased the suppressive function of CD33+HLA-DR <sup>low</sup> myeloid cells through down-regulation of PD-1/PD-L2 signaling pathway. <i>Molecular Immunology</i> , 2018, 94, 107-120.	1.0	17
1222	The Basics of Cancer Immunotherapy. , 2018, , .		5
1223	The Basic Concepts in Cancer Immunology and Immunotherapy. , 2018, , 1-19.		3
1224	Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences. <i>Targeted Oncology</i> , 2018, 13, 125-140.	1.7	19
1225	Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. <i>Oncolmmunology</i> , 2018, 7, e1356144.	2.1	113
1226	Immune checkpoint blockade therapy. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1403-1414.	1.5	79
1227	The Pekin duck programmed death ligand-2: cDNA cloning, genomic structure, molecular characterization and expression analysis. <i>Biochemistry and Biophysics Reports</i> , 2018, 13, 116-122.	0.7	1
1228	Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-“Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 926-937.	0.5	27
1229	Nivolumab in squamous cell carcinoma of the head and neck. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 409-420.	1.1	9
1230	Chemokines and cancer: new immune checkpoints for cancer therapy. <i>Current Opinion in Immunology</i> , 2018, 51, 140-145.	2.4	109
1231	Emerging therapeutic biomarkers of autoimmune hepatitis and their impact on current and future management. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 547-564.	1.4	18
1232	Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody L1Mab-4. <i>Biochemistry and Biophysics Reports</i> , 2018, 13, 123-128.	0.7	4
1233	B7-DC (PD-L2) costimulation of CD4+ T-helper 1 response via RGMb. <i>Cellular and Molecular Immunology</i> , 2018, 15, 888-897.	4.8	32
1234	CD103+ lung dendritic cells (LDCs) induce stronger Th1/Th17 immunity to a bacterial lung infection than CD11b <sup>hi</sup> LDCs. <i>Cellular and Molecular Immunology</i> , 2018, 15, 377-387.	4.8	33
1235	PD-1 and cancer: molecular mechanisms and polymorphisms. <i>Immunogenetics</i> , 2018, 70, 73-86.	1.2	100
1236	Small-Molecule Inhibition of PD-1 Transcription Is an Effective Alternative to Antibody Blockade in Cancer Therapy. <i>Cancer Research</i> , 2018, 78, 706-717.	0.4	86
1237	Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. <i>Annals of Oncology</i> , 2018, 29, 71-83.	0.6	253

#	ARTICLE	IF	CITATIONS
1238	Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy. <i>Journal of Internal Medicine</i> , 2018, 283, 110-120.	2.7	162
1239	PD-1 pathway and its clinical application: A 20 year journey after discovery of the complete human PD - 1 gene. <i>Gene</i> , 2018, 638, 20-25.	1.0	87
1240	The diverse functions of the PD1 inhibitory pathway. <i>Nature Reviews Immunology</i> , 2018, 18, 153-167.	10.6	1,210
1241	Immune checkpoint blockade in infectious diseases. <i>Nature Reviews Immunology</i> , 2018, 18, 91-104.	10.6	407
1242	The application and mechanism of PD pathway blockade for cancer therapy. <i>Postgraduate Medical Journal</i> , 2018, 94, 53-60.	0.9	10
1243	Immunotherapy of Lymphoma and Myeloma: Facts and Hopes. <i>Clinical Cancer Research</i> , 2018, 24, 1002-1010.	3.2	30
1244	Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 55-70.	1.9	5
1245	Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients. <i>Clinical Cancer Research</i> , 2018, 24, 896-905.	3.2	464
1246	CD8+ T Cells in Immunotherapy, Radiotherapy, and Chemotherapy. , 2018, , 23-39.		7
1247	PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective. <i>Seminars in Cancer Biology</i> , 2018, 52, 53-65.	4.3	58
1248	Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition. <i>Nature Reviews Urology</i> , 2018, 15, 112-124.	1.9	73
1249	Evaluating antidisease immunity to malaria and implications for vaccine design. <i>Immunology</i> , 2018, 153, 423-434.	2.0	24
1250	Immunotherapeutic Biomarkers and Selection Strategies. <i>Current Cancer Research</i> , 2018, , 69-114.	0.2	0
1251	The Significance of the PD-L1 Expression in Non-“Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers. <i>Clinical Lung Cancer</i> , 2018, 19, 120-129.	1.1	61
1252	Recent advances in melanoma research via “omics” platforms. <i>Journal of Proteomics</i> , 2018, 188, 152-166.	1.2	13
1253	Immune checkpoint inhibitors: new strategies to checkmate cancer. <i>Clinical and Experimental Immunology</i> , 2018, 191, 133-148.	1.1	57
1254	Humanized mice in studying efficacy and mechanisms of PD-1-“targeted cancer immunotherapy. <i>FASEB Journal</i> , 2018, 32, 1537-1549.	0.2	260
1255	Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes. <i>Human Pathology</i> , 2018, 71, 91-99.	1.1	102

#	ARTICLE	IF	CITATIONS
1256	PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. <i>Blood</i> , 2018, 131, 68-83.	0.6	311
1257	Immunomodulatory Bonds of the Partnership between Dendritic Cells and T Cells. <i>Critical Reviews in Immunology</i> , 2018, 38, 379-401.	1.0	58
1258	<i>PD-L1</i> (<i>CD274</i>) and <i>PD-L2</i> (<i>PDCD1LG2</i>) promoter methylation is associated with HPV infection and transcriptional repression in head and neck squamous cell carcinomas. <i>Oncotarget</i> , 2018, 9, 641-650.	0.8	50
1259	Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1428-1439.	0.8	551
1260	Safety and Antitumor Activity of the Anti“Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 61-67.	0.8	259
1261	Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC. <i>Translational Lung Cancer Research</i> , 2018, 7, 691-702.	1.3	8
1262	Immunotherapy in previously treated non-small cell lung cancer (NSCLC). <i>Journal of Thoracic Disease</i> , 2018, 10, S422-S432.	0.6	9
1264	Clinical relevance of PD-L1 and PD-L2 overexpression in patients with esophageal squamous cell carcinoma. <i>Journal of Thoracic Disease</i> , 2018, 10, 4433-4444.	0.6	24
1266	Programmed death ligand-1 inhibitors potentially carry a lower risk of pneumonitis compared with programmed death-1 inhibitors in patients with non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, S4082-S4084.	0.6	1
1267	The Contribution of Co-signaling Pathways to Anti-malarial T Cell Immunity. <i>Frontiers in Immunology</i> , 2018, 9, 2926.	2.2	7
1269	Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2018, 30, 157-172.	0.7	40
1270	Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80. <i>Frontiers in Immunology</i> , 2018, 9, 3061.	2.2	28
1271	Immune Checkpoint Inhibitors in Pediatric Solid Tumors: Status in 2018. <i>Ochsner Journal</i> , 2018, 18, 370-376.	0.5	33
1272	Lungen- und Urothelkarzinom. PD-L1-Blockade mit Atezolizumab: Äœberzeugend wirksam bei jedem PD-L1-Status. <i>Oncology Research and Treatment</i> , 2018, 41, 64-65.	0.8	2
1273	First person: Arlene Sharpe, MD, PhD. <i>Cancer</i> , 2018, 124, 3795-3796.	2.0	0
1274	Putting the Immunologic Brakes on Cancer. <i>Cell</i> , 2018, 175, 1452-1454.	13.5	75
1275	Clinicopathological analysis of PD-L2 expression in colorectal cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7635-7642.	1.0	18
1276	Preliminary report: one of the PD-1 gene variants may be a valuable marker for colorectal cancer. <i>Archives of Medical Science - Civilization Diseases</i> , 2018, 3, 34-40.	0.1	1

#	ARTICLE	IF	CITATIONS
1277	Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases. <i>Frontiers in Microbiology</i> , 2018, 9, 3158.	1.5	66
1278	Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy. , 2018, 6, 149.		35
1279	Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors. <i>Scientific Reports</i> , 2018, 8, 17812.	1.6	39
1280	Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma. <i>Cancer Management and Research</i> , 2018, Volume 10, 6457-6468.	0.9	23
1281	Adipose Tissue T Cells in HIV/SIV Infection. <i>Frontiers in Immunology</i> , 2018, 9, 2730.	2.2	9
1282	Immune-Related Adverse Events: Pneumonitis. <i>Advances in Experimental Medicine and Biology</i> , 2018, 995, 131-149.	0.8	19
1283	Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma. <i>Frontiers in Immunology</i> , 2018, 9, 2749.	2.2	41
1284	Immune checkpoint inhibitors in cancer therapy. <i>Journal of Biomedical Research</i> , 2018, 32, 317.	0.7	101
1286	A CD300c-Fc Fusion Protein Inhibits T Cell Immunity. <i>Frontiers in Immunology</i> , 2018, 9, 2657.	2.2	9
1287	Cancer Vaccine Immunotherapy with RNA-Loaded Liposomes. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2890.	1.8	44
1288	Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy. <i>Trends in Biochemical Sciences</i> , 2018, 43, 1014-1032.	3.7	151
1289	EF Hand Domain Family Member D2 Is Required for T Cell Cytotoxicity. <i>Journal of Immunology</i> , 2018, 201, 2824-2831.	0.4	13
1290	The PD-1 rs36084323 A&gt;G polymorphism decrease cancer risk in Asian: A meta-analysis. <i>Pathology Research and Practice</i> , 2018, 214, 1758-1764.	1.0	14
1291	On the Road to Immunotherapyâ€”Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies. <i>Frontiers in Immunology</i> , 2018, 9, 2182.	2.2	15
1292	Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again. <i>Genome Medicine</i> , 2018, 10, 79.	3.6	36
1293	Predictive biomarkers for tumor immune checkpoint blockade. <i>Cancer Management and Research</i> , 2018, Volume 10, 4501-4507.	0.9	18
1294	Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study. <i>In Vivo</i> , 2018, 32, 1541-1550.	0.6	4
1295	Nivolumab for the treatment of hepatocellular carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 1169-1175.	1.1	99

#	ARTICLE	IF	CITATIONS
1296	Pomalidomide Inhibits PD-L1 Induction to Promote Antitumor Immunity. <i>Cancer Research</i> , 2018, 78, 6655-6665.	0.4	20
1297	Antigen in the Absence of DAMPs Promotes Immune Tolerance: The Role of Dendritic Cells and Regulatory T Cells. , 2018, , 791-827.		1
1298	Immune Protection of SIV Challenge by PD-1 Blockade During Vaccination in Rhesus Monkeys. <i>Frontiers in Immunology</i> , 2018, 9, 2415.	2.2	19
1299	Nobel committee honors tumor immunologists. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 262.	3.5	43
1300	Nobel goes to immune checkpoint – Innovative cancer treatment by immunotherapy. <i>Science China Life Sciences</i> , 2018, 61, 1445-1450.	2.3	3
1301	An update: emerging drugs to treat squamous cell carcinomas of the head and neck. <i>Expert Opinion on Emerging Drugs</i> , 2018, 23, 283-299.	1.0	44
1302	Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 543-554.	1.2	31
1303	Characterization of the Neuroendocrine Tumor Immune Microenvironment. <i>Pancreas</i> , 2018, 47, 1123-1129.	0.5	63
1304	High expression of programmed cell death protein 1 on peripheral blood T cell subsets is associated with poor prognosis in metastatic gastric cancer. <i>Oncology Letters</i> , 2018, 16, 4448-4454.	0.8	4
1305	Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer. <i>Antibody Therapeutics</i> , 2018, 1, 65-73.	1.2	25
1306	Combinations of Bevacizumab With Cancer Immunotherapy. <i>Cancer Journal (Sudbury, Mass )</i> , 2018, 24, 193-204.	1.0	144
1307	Stromal Cell PD-L1 Inhibits CD8+ T-cell Antitumor Immune Responses and Promotes Colon Cancer. <i>Cancer Immunology Research</i> , 2018, 6, 1426-1441.	1.6	66
1308	New developments in immunotherapy for lymphoma. <i>Cancer Biology and Medicine</i> , 2018, 15, 189.	1.4	24
1309	Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. <i>Frontiers in Immunology</i> , 2018, 9, 1878.	2.2	127
1310	Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer. <i>Cancer Research</i> , 2018, 78, 4270-4281.	0.4	117
1311	Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. <i>Trends in Immunology</i> , 2018, 39, 624-631.	2.9	153
1312	Receptors That Inhibit Macrophage Activation: Mechanisms and Signals of Regulation and Tolerance. <i>Journal of Immunology Research</i> , 2018, 2018, 1-14.	0.9	21
1313	Immunotherapies: Exploiting the Immune System for Cancer Treatment. <i>Journal of Immunology Research</i> , 2018, 2018, 1-16.	0.9	89



#	ARTICLE	IF	CITATIONS
1314	Similarities and differences between helminth parasites and cancer cell lines in shaping human monocytes: Insights into parallel mechanisms of immune evasion. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006404.	1.3	18
1315	Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. <i>British Journal of Cancer</i> , 2018, 119, 153-159.	2.9	329
1316	Clinicopathological value of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) expression in synovium of patients with rheumatoid arthritis. <i>Clinical and Experimental Medicine</i> , 2018, 18, 487-494.	1.9	15
1317	Classification of gallbladder cancer by assessment of CD8+ TIL and PD-L1 expression. <i>BMC Cancer</i> , 2018, 18, 766.	1.1	42
1318	<i>Quis Custodiet Ipsos Custodes</i>? Regulation of Cell-Mediated Immune Responses Following Viral Lung Infections. <i>Annual Review of Virology</i> , 2018, 5, 363-383.	3.0	16
1319	Immunology, Immunotherapy, and Translating Basic Science into the Clinic for Bladder Cancer. <i>Bladder Cancer</i> , 2018, 4, 429-440.	0.2	5
1320	Combination immune checkpoint blockade as an effective therapy for mesothelioma. <i>Oncolmmunology</i> , 2018, 7, e1494111.	2.1	37
1321	Oncolytic virus and PD-1/PD-L1 blockade combination therapy. <i>Oncolytic Virotherapy</i> , 2018, Volume 7, 65-77.	6.0	57
1322	MicroRNAs as Immunotherapy Targets for Treating Gastroenterological Cancers. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2018, 2018, 1-20.	0.8	13
1323	Overexpression of low density lipoprotein receptor-related protein 1 (LRP1) is associated with worsened prognosis and decreased cancer immunity in clear-cell renal cell carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 1537-1543.	1.0	25
1324	Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. <i>European Journal of Cancer</i> , 2018, 101, 201-209.	1.3	41
1325	The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas. <i>Frontiers in Molecular Neuroscience</i> , 2018, 11, 82.	1.4	61
1326	Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. <i>Frontiers in Oncology</i> , 2018, 8, 86.	1.3	926
1327	Melanoma Immunotherapy: Next-Generation Biomarkers. <i>Frontiers in Oncology</i> , 2018, 8, 178.	1.3	53
1328	Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers. , 2018, 6, 65.		118
1329	Immune Monitoring of Cancer Patients Prior to and During CTLA-4 or PD-1/PD-L1 Inhibitor Treatment. <i>Biomedicines</i> , 2018, 6, 26.	1.4	16
1330	Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. <i>International Immunopharmacology</i> , 2018, 62, 29-39.	1.7	860
1331	Fetal Hepatic Response to Bovine Viral Diarrhea Virus Infection in Utero. <i>Pathogens</i> , 2018, 7, 54.	1.2	2

#	ARTICLE	IF	CITATIONS
1332	PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model. <i>BMC Cancer</i> , 2018, 18, 669.	1.1	20
1333	Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 1693-1698.	2.8	39
1334	Microbial biomarkers for immune checkpoint blockade therapy against cancer. <i>Journal of Gastroenterology</i> , 2018, 53, 999-1005.	2.3	15
1335	Immune checkpoint receptors: homeostatic regulators of immunity. <i>Hepatology International</i> , 2018, 12, 223-236.	1.9	43
1336	Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2018, 11, 15.	6.9	155
1337	PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. <i>Journal of Hematology and Oncology</i> , 2018, 11, 16.	6.9	96
1338	Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. , 2018, 6, 4.		118
1339	Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients. , 2018, 6, 18.		153
1340	Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism. <i>Endocrine Connections</i> , 2018, 7, R196-R211.	0.8	10
1341	Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. <i>Journal of Hematology and Oncology</i> , 2018, 11, 104.	6.9	303
1342	Antigen-Specific Signal Transduction. , 2018, , 282-305.		1
1343	Targeting the PD-1/PD-L1 Axis for the Treatment of Non-Small-Cell Lung Cancer. <i>Current Oncology</i> , 2018, 25, 324-334.	0.9	56
1344	Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients. <i>Clinical Cancer Research</i> , 2018, 24, 6345-6354.	3.2	43
1345	Risk of immune-related colitis with PD-1/PD-L1 inhibitors vs chemotherapy in solid tumors: systems assessment. <i>Journal of Cancer</i> , 2018, 9, 1614-1622.	1.2	17
1346	CMTM6 stabilizes PD-L1 expression and refines its prognostic value in tumors. <i>Annals of Translational Medicine</i> , 2018, 6, 54-54.	0.7	36
1347	Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. <i>Cancer Discovery</i> , 2018, 8, 1069-1086.	7.7	2,128
1348	Early Investigations and Recent Advances in Intraperitoneal Immunotherapy for Peritoneal Metastasis. <i>Vaccines</i> , 2018, 6, 54.	2.1	29
1349	Soluble B7-H3 (sB7-H3) is over-expressed in the serum of type 1 diabetes patients. <i>Diabetes Research and Clinical Practice</i> , 2018, 143, 332-336.	1.1	6

#	ARTICLE	IF	CITATIONS
1350	High-affinity PD-1 molecules deliver improved interaction with CTL1 and CTL2. <i>Cancer Science</i> , 2018, 109, 2435-2445.	1.7	21
1351	Comparative analysis of decidual and peripheral immune cells and immune-checkpoint molecules during pregnancy in wild-type and PACAP-deficient mice. <i>American Journal of Reproductive Immunology</i> , 2018, 80, e13035.	1.2	14
1352	Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 947-957.	1.4	46
1353	Neutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 1291-1299.	0.8	47
1354	Enterocolitis due to immune checkpoint inhibitors: a systematic review. <i>Gut</i> , 2018, 67, 2056-2067.	6.1	179
1355	PD-L1 Binds to B7-1 Only <i>In Cis</i> on the Same Cell Surface. <i>Cancer Immunology Research</i> , 2018, 6, 921-929.	1.6	133
1356	It is finally time for adjuvant therapy in melanoma. <i>Cancer Treatment Reviews</i> , 2018, 69, 101-111.	3.4	37
1357	New Treatment Modalities for the Management of Peritoneal Metastases. , 2018, , 469-506.		4
1358	Locoregional and Palliative Therapies for Patients with Unresectable Peritoneal Metastases. , 2018, , 527-559.		1
1359	Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue. <i>Current Medicinal Chemistry</i> , 2018, 25, 1327-1339.	1.2	99
1360	Principles of Protein Recognition by Small T-Cell Adhesion Proteins and Costimulatory Receptors. , 2018, , 39-80.		0
1361	Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy. <i>Cancer Treatment Reviews</i> , 2019, 74, 49-60.	3.4	38
1362	Immunotherapy and targeted therapies in older patients with advanced melanoma; Young International Society of Geriatric Oncology review paper. <i>Journal of Geriatric Oncology</i> , 2019, 10, 389-397.	0.5	20
1363	Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis. <i>Autoimmunity</i> , 2019, 52, 144-160.	1.2	10
1364	Side Effects of Systemic Therapy and Their Clinical Management. , 2019, , 773-789.		0
1365	PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity. , 2019, 7, 209.		73
1366	Chronic Implant-Related Bone Infections—Can Immune Modulation be a Therapeutic Strategy?. <i>Frontiers in Immunology</i> , 2019, 10, 1724.	2.2	124
1367	The Role of the Lymphocyte Functional Crosstalk and Regulation in the Context of Checkpoint Inhibitor Treatment—Review. <i>Frontiers in Immunology</i> , 2019, 10, 2043.	2.2	7

#	ARTICLE	IF	CITATIONS
1368	Understanding T cell signaling using membrane reconstitution. <i>Immunological Reviews</i> , 2019, 291, 44-56.	2.8	13
1369	Sex differences in the therapeutic effects of anti-PDL2 neutralizing antibody on stroke. <i>Metabolic Brain Disease</i> , 2019, 34, 1705-1712.	1.4	8
1370	Crohn's disease is facilitated by a disturbance of programmed death-1 ligand 2 on blood dendritic cells. <i>Clinical and Translational Immunology</i> , 2019, 8, e01071.	1.7	12
1371	Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease. <i>Physiological Reviews</i> , 2019, 99, 1765-1817.	13.1	550
1372	Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view. <i>Life Sciences</i> , 2019, 233, 116713.	2.0	42
1373	PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. <i>Nature Immunology</i> , 2019, 20, 1231-1243.	7.0	217
1374	Avelumab in gastric cancer. <i>Immunotherapy</i> , 2019, 11, 759-768.	1.0	17
1375	Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations. <i>Frontiers in Pharmacology</i> , 2019, 10, 726.	1.6	20
1376	Targeting PD-1 in cancer: Biological insights with a focus on breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 142, 35-43.	2.0	18
1377	T-Cell Engagers Based Bioassay for Evaluation of PD-1/PD-L1 Inhibitors Activity. <i>Biochemistry (Moscow)</i> , 2019, 84, 711-719.	0.7	3
1378	IL-22 production of effector CD4+ T-cells is altered in SLE patients. <i>European Journal of Medical Research</i> , 2019, 24, 24.	0.9	6
1379	Macrophage-Mediated Subversion of Anti-Tumour Immunity. <i>Cells</i> , 2019, 8, 747.	1.8	68
1380	Clinicopathological significance and prognostic implication of programmed death-1 ligand 2 expression in colorectal cancer. <i>International Journal of Biological Markers</i> , 2019, 34, 276-283.	0.7	4
1381	âššè,1/2è•ç%©âšç„è£...ä1/2“âœ”ç™CEç—†â...ç—«æ²»ç—ä,çš„âe”ç””. <i>Science China Materials</i> , 2019, 62, 1759-1781.5		19
1382	Peripheral T-Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 657-668.	0.9	7
1383	Myasthenia gravis induced by avelumab. <i>Immunotherapy</i> , 2019, 11, 1181-1185.	1.0	9
1384	Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 3021-3036.	1.2	20
1385	Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges. <i>Cancers</i> , 2019, 11, 1554.	1.7	73

#	ARTICLE	IF	CITATIONS
1386	SHP-2 in Lymphocytes' Cytokine and Inhibitory Receptor Signaling. <i>Frontiers in Immunology</i> , 2019, 10, 2468.	2.2	37
1387	The Role of Immune Checkpoint Receptors in Regulating Immune Reactivity in Lupus. <i>Cells</i> , 2019, 8, 1213.	1.8	14
1388	Glycogen synthase 3 (GSK-3) regulation of PD-1 expression and and its therapeutic implications. <i>Seminars in Immunology</i> , 2019, 42, 101295.	2.7	16
1389	Impact of clinicopathological features on the efficacy of immune checkpoint inhibitors plus conventional treatment in patients with advanced lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, 3794-3807.	0.6	3
1390	Identification of a monoclonal antibody that targets PD-1 in a manner requiring PD-1 Asn58 glycosylation. <i>Communications Biology</i> , 2019, 2, 392.	2.0	39
1391	Perinatal Mesenchymal Stromal Cells and Their Possible Contribution to Fetal-Maternal Tolerance. <i>Cells</i> , 2019, 8, 1401.	1.8	19
1392	Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma. <i>International Immunopharmacology</i> , 2019, 77, 105999.	1.7	43
1393	The role and therapeutic implications of T cells in cancer of the lung. <i>Clinical and Translational Immunology</i> , 2019, 8, e1076.	1.7	25
1394	Engineering of a novel subnanomolar affinity fibronectin III domain binder targeting human programmed death-ligand 1. <i>Protein Engineering, Design and Selection</i> , 2019, 32, 231-240.	1.0	6
1395	Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22246-22251.	3.3	142
1396	The Changing Therapeutic Landscape of Metastatic Renal Cancer. <i>Cancers</i> , 2019, 11, 1227.	1.7	49
1397	Radiation as an In Situ Auto-Vaccination: Current Perspectives and Challenges. <i>Vaccines</i> , 2019, 7, 100.	2.1	30
1398	Current status of clinical proteogenomics in lung cancer. <i>Expert Review of Proteomics</i> , 2019, 16, 761-772.	1.3	27
1399	Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies. , 2019, 7, 225.		16
1400	Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes. <i>Frontiers in Oncology</i> , 2019, 9, 883.	1.3	40
1401	Immune Checkpoints of the B7 Family. Part 1. General Characteristics and First Representatives: B7-1, B7-2, B7-H1, B7-H2, and B7-DC. <i>Russian Journal of Bioorganic Chemistry</i> , 2019, 45, 225-240.	0.3	6
1402	From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 396.	3.5	265
1403	The role of immune regulatory molecules in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2019, 337, 577061.	1.1	27

#	ARTICLE	IF	CITATIONS
1404	The Diverse Function of PD-1/PD-L Pathway Beyond Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 2298.	2.2	244
1405	High-Grade Neuroendocrine Carcinoma of the Head and Neck: Human Papillomavirus Status and PD-L1 Expression. <i>Orl</i> , 2019, 81, 309-316.	0.6	4
1406	The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy. <i>Journal of Clinical Medicine</i> , 2019, 8, 1534.	1.0	41
1407	Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?. <i>Journal of Clinical Medicine</i> , 2019, 8, 1547.	1.0	30
1409	Blockade of PD-L1 Enhances Cancer Immunotherapy by Regulating Dendritic Cell Maturation and Macrophage Polarization. <i>Cancers</i> , 2019, 11, 1400.	1.7	45
1410	CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity. <i>Nature Communications</i> , 2019, 10, 4355.	5.8	270
1411	Classical Hodgkinâ€™s Lymphoma in the Era of Immune Checkpoint Inhibition. <i>Journal of Clinical Medicine</i> , 2019, 8, 1596.	1.0	15
1412	Current concepts of non-coding RNA regulation of immune checkpoints in cancer. <i>Molecular Aspects of Medicine</i> , 2019, 70, 117-126.	2.7	41
1413	Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. <i>Journal of Clinical Medicine</i> , 2019, 8, 1566.	1.0	26
1414	PD-1 Blockade and TLR7 Activation Lack Therapeutic Benefit in Chronic Simian Immunodeficiency Virus-Infected Macaques on Antiretroviral Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	1.4	44
1415	Prognostic significance of PDâ€²2 expression in patients with oral squamous cell carcinomaâ€²A comparison to the PDâ€²1 expression profile. <i>Cancer Medicine</i> , 2019, 8, 1124-1134.	1.3	18
1416	PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program. <i>Modern Pathology</i> , 2019, 32, 741-754.	2.9	39
1417	Programmed cell death protein receptor and ligands in haematological malignancies â€œ Current status. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 135, 47-58.	2.0	4
1418	Impaired activation of lesional CD8+ T-cells is associated with enhanced expression of Programmed Death-1 in Indian Post Kala-azar Dermal Leishmaniasis. <i>Scientific Reports</i> , 2019, 9, 762.	1.6	15
1419	Involvement of the PD-1/PD-L1 Co-Inhibitory Pathway in the Pathogenesis of the Inflammatory Stage of Early-Onset Preeclampsia. <i>International Journal of Molecular Sciences</i> , 2019, 20, 583.	1.8	16
1420	Immune therapy of melanoma: Overview of therapeutic vaccines. <i>Journal of Cellular Physiology</i> , 2019, 234, 14612-14621.	2.0	25
1421	Inhibition of Heme Oxygenase-1 Activity Enhances Wilms Tumor-1-Specific T-Cell Responses in Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 482.	1.8	4
1422	Tacrolimus treatment for infertility related to maternalâ€²fetal immune interactions. <i>American Journal of Reproductive Immunology</i> , 2019, 81, e13097.	1.2	11

#	ARTICLE	IF	CITATIONS
1423	On the Other Side: Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy. <i>Frontiers in Oncology</i> , 2019, 9, 50.	1.3	11
1424	Human Dendritic Cells: Their Heterogeneity and Clinical Application Potential in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 3176.	2.2	261
1425	PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor. <i>Oncolmmunology</i> , 2019, 8, e1541535.	2.1	32
1426	TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma. <i>Cancer Immunology Research</i> , 2019, 7, 355-362.	1.6	82
1427	Interaction of CD99 and its ligand upregulates IL-6 and TNF- $\alpha$ upon T cell activation. <i>PLoS ONE</i> , 2019, 14, e0217393.	1.1	17
1428	Recent advances in the clinical development of immune checkpoint blockade therapy. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 609-626.	2.1	76
1429	Programmed Cell Death-1 Receptor (PD-1)-Mediated Regulation of Innate Lymphoid Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2836.	1.8	23
1430	Silencing of PD-L2/B7-DC by Topical Application of Small Interfering RNA Inhibits Elicitation of Contact Hypersensitivity. <i>Journal of Investigative Dermatology</i> , 2019, 139, 2164-2173.e1.	0.3	9
1431	Application of PD-1 Blockade in Cancer Immunotherapy. <i>Computational and Structural Biotechnology Journal</i> , 2019, 17, 661-674.	1.9	333
1432	PD-1 Dynamically Regulates Inflammation and Development of Brain-Resident Memory CD8 T Cells During Persistent Viral Encephalitis. <i>Frontiers in Immunology</i> , 2019, 10, 783.	2.2	33
1433	Association between peripheral blood markers and immune-related factors on tumor cells in patients with resected primary lung adenocarcinoma. <i>PLoS ONE</i> , 2019, 14, e0217991.	1.1	5
1434	Skint8, a Novel B7 Family-Related Molecule, Negatively Regulates T Cell Responses. <i>Journal of Immunology</i> , 2019, 203, 400-407.	0.4	6
1435	Combination of CTLA-4 and PD-1 blockers for treatment of cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 255.	3.5	577
1436	Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade. <i>Pharmacological Research</i> , 2019, 145, 104258.	3.1	115
1437	Development of immune checkpoint therapy for cancer. <i>Journal of Experimental Medicine</i> , 2019, 216, 1244-1254.	4.2	125
1438	PD1 pathway in immune-mediated myopathies. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e558.	3.1	42
1439	Immunotherapy in Nonmelanoma Skin Cancer. <i>Actas Dermo-sifiliogrÁficas</i> , 2019, 110, 353-359.	0.2	1
1440	Frontline Therapy for <i>BRAF</i>-Mutated Metastatic Melanoma: How Do You Choose, and Is There One Correct Answer?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 564-571.	1.8	42

#	ARTICLE	IF	CITATIONS
1441	CD55 Is Essential for CD103+ Dendritic Cell Tolerogenic Responses that Protect against Autoimmunity. <i>American Journal of Pathology</i> , 2019, 189, 1386-1401.	1.9	11
1442	PD-1/PD-L1 blockade in paediatric cancers: What does the future hold?. <i>Cancer Letters</i> , 2019, 457, 74-85.	3.2	15
1443	Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity. <i>Clinical Cancer Research</i> , 2019, 25, 4808-4819.	3.2	66
1444	Efficient development and expression of scFv recombinant proteins against PD-L1 surface domain and potency in cancer therapy. <i>Cytotechnology</i> , 2019, 71, 705-722.	0.7	7
1445	Siglec-9 Regulates an Effector Memory CD8+ T-cell Subset That Congregates in the Melanoma Tumor Microenvironment. <i>Cancer Immunology Research</i> , 2019, 7, 707-718.	1.6	94
1446	From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. <i>Advances in Cancer Research</i> , 2019, 143, 63-144.	1.9	52
1447	Regulation of programmed cell death ligand 1 expression by atypical protein kinase C lambda/iota in cutaneous angiosarcoma. <i>Cancer Science</i> , 2019, 110, 1780-1789.	1.7	18
1448	Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma. <i>Frontiers in Immunology</i> , 2019, 10, 453.	2.2	177
1449	Dynamic host immune response in virus-associated cancers. <i>Communications Biology</i> , 2019, 2, 109.	2.0	34
1450	Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 453-470.	1.3	28
1451	Osteosarcoma cell intrinsic PD-L2 signals promote invasion and metastasis via the RhoA-ROCK-LIMK2 and autophagy pathways. <i>Cell Death and Disease</i> , 2019, 10, 261.	2.7	52
1452	PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 1111-1122.	1.4	297
1453	Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis. <i>Frontiers in Oncology</i> , 2019, 9, 47.	1.3	52
1454	Immunological and clinical implications of immune checkpoint blockade in human cancer. <i>Archives of Pharmacal Research</i> , 2019, 42, 567-581.	2.7	17
1455	Prognostic Impact of Programmed Death-Ligand 2 Expression in Primary Lung Adenocarcinoma Patients. <i>Annals of Surgical Oncology</i> , 2019, 26, 1916-1924.	0.7	25
1456	A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 1925-1933.	0.7	23
1457	Clinicopathological, immune and molecular correlates of PD-L2 methylation in gastric adenocarcinomas. <i>Epigenomics</i> , 2019, 11, 639-653.	1.0	17
1458	Rethinking pulmonary toxicity in advanced non-small cell lung cancer in the era of combining anti-PD-1/PD-L1 therapy with thoracic radiotherapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 323-330.	3.3	18



#	ARTICLE	IF	CITATIONS
1459	Interferon- $\beta$ upregulates $\beta$ 2PD1 expression on human monocytes via the PI3K/AKT pathway. <i>Immunobiology</i> , 2019, 224, 388-396.	0.8	4
1460	Aberrant PD-1 ligand expression contributes to the myocardial inflammatory injury caused by Coxsackievirus B infection. <i>Antiviral Research</i> , 2019, 166, 1-10.	1.9	8
1461	Harnessing immune checkpoints in myeloid lineage cells for cancer immunotherapy. <i>Cancer Letters</i> , 2019, 452, 51-58.	3.2	16
1462	Molecular cloning, expression and characterization of Pekin duck programmed death-1. <i>Gene</i> , 2019, 702, 182-193.	1.0	0
1463	Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma. <i>Frontiers in Oncology</i> , 2019, 8, 656.	1.3	32
1464	Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy. <i>Immunotherapy</i> , 2019, 11, 515-529.	1.0	17
1465	BTNL2 $\alpha$ Ligand Protein Attenuates Type 1 Diabetes in Non-Obese Diabetic (NOD) Mice. <i>Advanced Healthcare Materials</i> , 2019, 8, 1800987.	3.9	5
1466	Current status of prognostic factors in patients with metastatic renal cell carcinoma. <i>International Journal of Urology</i> , 2019, 26, 608-617.	0.5	19
1467	The FG Loop of PD-1 Serves as a "Hotspot" for Therapeutic Monoclonal Antibodies in Tumor Immune Checkpoint Therapy. <i>IScience</i> , 2019, 14, 113-124.	1.9	34
1468	PD-1 Tumor Suppressor Signaling in T Cell Lymphomas. <i>Trends in Immunology</i> , 2019, 40, 403-414.	2.9	24
1469	Affective and cognitive behavior is not altered by chronic constriction injury in B7-H1 deficient and wildtype mice. <i>BMC Neuroscience</i> , 2019, 20, 16.	0.8	8
1470	Development of Cancer Immunotherapy Targeting the PD-1 Pathway. <i>Journal of Nippon Medical School</i> , 2019, 86, 10-14.	0.3	15
1471	Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology. <i>Molecules</i> , 2019, 24, 1190.	1.7	163
1472	Computational Redesign of PD-1 Interface for PD-L1 Ligand Selectivity. <i>Structure</i> , 2019, 27, 829-836.e3.	1.6	13
1473	Met inhibition revokes IFN $\gamma$ -induction of PD-1 ligands in MET-amplified tumours. <i>British Journal of Cancer</i> , 2019, 120, 527-536.	2.9	34
1474	T cell checkpoint regulators in the heart. <i>Cardiovascular Research</i> , 2019, 115, 869-877.	1.8	70
1475	Fc $\gamma$ R-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 292.	2.2	111
1476	Targeting Immune Signaling Checkpoints in Acute Myeloid Leukemia. <i>Journal of Clinical Medicine</i> , 2019, 8, 236.	1.0	49

#	ARTICLE	IF	CITATIONS
1477	Peptide-based targeted therapeutics and apoptosis imaging probes for cancer therapy. Archives of Pharmacal Research, 2019, 42, 150-158.	2.7	28
1478	Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL. Cancer Immunology Research, 2019, 7, 644-657.	1.6	106
1479	PD-1/PD-L Pathway Potentially Involved in ITP Immunopathogenesis. Thrombosis and Haemostasis, 2019, 119, 758-765.	1.8	21
1480	The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review. Technology in Cancer Research and Treatment, 2019, 18, 153303381983106.	0.8	116
1481	PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy. Journal of Cellular Physiology, 2019, 234, 16824-16837.	2.0	279
1482	Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis. Cancer Reports, 2019, 2, e1160.	0.6	26
1483	Orchestration between ILC2s and Th2 cells in shaping type 2 immune responses. Cellular and Molecular Immunology, 2019, 16, 225-235.	4.8	107
1484	Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 421-432.	1.4	45
1485	Biological therapies in lung cancer treatment: using our immune system as an ally to defeat the malignancy. Expert Opinion on Biological Therapy, 2019, 19, 457-467.	1.4	7
1486	PD-L1 expression levels on tumor cells affect their immunosuppressive activity. Oncology Letters, 2019, 18, 5399-5407.	0.8	54
1487	Managing Pulmonary Toxicities Associated with Immunotherapy: A Case Discussion. Oncologist, 2019, 24, 730-734.	1.9	9
1488	A high-affinity human PD-1/PD-L2 complex informs avenues for small-molecule immune checkpoint drug discovery. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 24500-24506.	3.3	43
1489	Immune Checkpoint PD-1/PD-L1 CTLA-4/CD80 are Blocked by Rhus verniciflua Stokes and its Active Compounds. Molecules, 2019, 24, 4062.	1.7	36
1490	Immunotherapy using anti-PD-1 and anti-PD-L1 in Leishmania amazonensis-infected BALB/c mice reduce parasite load. Scientific Reports, 2019, 9, 20275.	1.6	27
1491	miR29a and miR378b Influence CpG-Stimulated Dendritic Cells and Regulate cGAS/STING Pathway. Vaccines, 2019, 7, 197.	2.1	14
1492	Beyond the Cell Surface: Targeting Intracellular Negative Regulators to Enhance T cell Anti-Tumor Activity. International Journal of Molecular Sciences, 2019, 20, 5821.	1.8	23
1493	Co-signal Molecules in T Cell Activation. Advances in Experimental Medicine and Biology, 2019, , .	0.8	6
1494	Phosphorylation of PD-1-Y248 is a marker of PD-1-mediated inhibitory function in human T cells. Scientific Reports, 2019, 9, 17252.	1.6	20

#	ARTICLE	IF	CITATIONS
1495	Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway. <i>Journal of Biomedical Science</i> , 2019, 26, 96.	2.6	26
1496	PD-L1 Detection—Pearls and Pitfalls Associated With Current Methodologies Focusing on Entities Relevant to Dermatopathology. <i>American Journal of Dermatopathology</i> , 2019, 41, 539-565.	0.3	8
1497	Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies. <i>Liver Cancer</i> , 2019, 8, 413-426.	4.2	40
1498	Monoclonal Antibodies: Past, Present and Future. <i>Handbook of Experimental Pharmacology</i> , 2019, 260, 81-141.	0.9	41
1499	Basis of PD1/PD-L1 Therapies. <i>Journal of Clinical Medicine</i> , 2019, 8, 2168.	1.0	85
1500	Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue. <i>Oncologist</i> , 2019, 24, 394-401.	1.9	48
1501	Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction: From antibodies to small molecules. <i>Medicinal Research Reviews</i> , 2019, 39, 265-301.	5.0	128
1502	PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy. <i>Journal of Cellular Physiology</i> , 2019, 234, 1313-1325.	2.0	288
1503	Reversal of Triple-Negative Breast Cancer EMT by miR-200c Decreases Tryptophan Catabolism and a Program of Immunosuppression. <i>Molecular Cancer Research</i> , 2019, 17, 30-41.	1.5	49
1504	MicroRNA-497-5p down-regulation increases PD-L1 expression in clear cell renal cell carcinoma. <i>Journal of Drug Targeting</i> , 2019, 27, 67-74.	2.1	49
1505	A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 421-432.	2.0	93
1506	Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 199-224.	3.3	53
1507	PD-1 Expression on Circulating CD8+ T-Cells as a Prognostic Marker for Patients With Gastric Cancer. <i>Anticancer Research</i> , 2019, 39, 443-448.	0.5	18
1508	PD-1 and PD-L1 regulate cellular immunity in canine visceral leishmaniasis. <i>Comparative Immunology, Microbiology and Infectious Diseases</i> , 2019, 62, 76-87.	0.7	13
1509	Immunotherapy in advanced gastric cancer, is it the future?. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 25-32.	2.0	97
1510	Monocytes show immunoregulatory capacity on CD4+ T cells in a human in-vitro model of extracorporeal photopheresis. <i>Clinical and Experimental Immunology</i> , 2019, 195, 369-380.	1.1	8
1511	Epithelial-Stromal Interactions in Pancreatic Cancer. <i>Annual Review of Physiology</i> , 2019, 81, 211-233.	5.6	33
1512	Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 1564-1573.	3.2	33

#	ARTICLE	IF	CITATIONS
1513	A novel role for programmed cell death receptor ligand 2 in sepsis-induced hepatic dysfunction. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, G106-G114.	1.6	7
1514	Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer. <i>Drug Safety</i> , 2019, 42, 281-294.	1.4	69
1515	Analysis for Science Librarians of the 2018 Nobel Prize in Physiology or Medicine: The Life and Work of James P. Allison and Tasuku Honjo. <i>Science and Technology Libraries</i> , 2019, 38, 1-29.	0.8	0
1516	A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma. <i>Current Urology Reports</i> , 2019, 20, 1.	1.0	63
1517	Allogeneic hematopoietic stem cell transplantation in r/r Hodgkin lymphoma after treatment with checkpoint inhibitors: Feasibility and safety. <i>European Journal of Haematology</i> , 2019, 102, 150-156.	1.1	20
1518	Association of PD-L1, PD-L2, and Immune Response Markers in Matched Renal Clear Cell Carcinoma Primary and Metastatic Tissue Specimens. <i>American Journal of Clinical Pathology</i> , 2019, 151, 217-225.	0.4	25
1519	Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 201-211.	2.0	46
1520	FUT4 is involved in PD-1-related immunosuppression and leads to worse survival in patients with operable lung adenocarcinoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 65-76.	1.2	18
1521	A novel humanized anti-PD-1 monoclonal antibody potentiates therapy in oral squamous cell carcinoma. <i>Investigational New Drugs</i> , 2019, 37, 799-809.	1.2	4
1522	Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints. <i>Endocrine Reviews</i> , 2019, 40, 17-65.	8.9	349
1523	Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma. <i>Future Oncology</i> , 2019, 15, 349-358.	1.1	34
1524	Monoclonal Antibodies for the Treatment of Melanoma: Present and Future Strategies. <i>Methods in Molecular Biology</i> , 2019, 1904, 83-108.	0.4	47
1525	Academic Discovery of Anticancer Drugs: Historic and Future Perspectives. <i>Annual Review of Cancer Biology</i> , 2019, 3, 385-408.	2.3	17
1526	The role and clinical significance of programmed cell death- ligand 1 expressed on CD19+B-cells and subsets in systemic lupus erythematosus. <i>Clinical Immunology</i> , 2019, 198, 89-99.	1.4	12
1527	Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1715-1730.	2.9	92
1528	Identification of PD-L2, B7-H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningioma. <i>Oncimmunology</i> , 2019, 8, e1512943.	2.1	31
1529	EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions. <i>Gastric Cancer</i> , 2019, 22, 486-496.	2.7	72
1530	Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy. , 2019, 194, 84-106.		248

#	ARTICLE	IF	CITATIONS
1531	Molecular regulation of dendritic cell development and function in homeostasis, inflammation, and cancer. <i>Molecular Immunology</i> , 2019, 110, 24-39.	1.0	38
1532	Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019, 27, 92-100.	0.6	144
1533	Expression of immunoregulatory molecules PD-L1 and PD-1 in oral cancer and precancerous lesions: A cohort study of Japanese patients. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2019, 47, 33-40.	0.7	28
1534	<i>Cancer Immunology</i> , 2020, , 84-96.e5.		0
1535	Salmonella-mediated therapy targeting indoleamine 2, 3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growth. <i>Cancer Gene Therapy</i> , 2020, 27, 235-245.	2.2	42
1536	Combination therapy with PD-1 or PD-L1 inhibitors for cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 818-830.	1.0	86
1537	Role of cell surface proteoglycans in cancer immunotherapy. <i>Seminars in Cancer Biology</i> , 2020, 62, 48-67.	4.3	59
1538	Targeting B7-1 in immunotherapy. <i>Medicinal Research Reviews</i> , 2020, 40, 654-682.	5.0	44
1539	Genetic and Molecular Biology of Multiple Sclerosis Among Iranian Patients: An Overview. <i>Cellular and Molecular Neurobiology</i> , 2020, 40, 65-85.	1.7	3
1540	B7-H4, a promising target for immunotherapy. <i>Cellular Immunology</i> , 2020, 347, 104008.	1.4	56
1541	Maternal soluble PD-1 levels are significantly increased in women with preeclampsia. <i>American Journal of Reproductive Immunology</i> , 2020, 83, e13193.	1.2	14
1542	Are unsatisfactory outcomes after concurrent chemoradiotherapy for locally advanced non-small cell lung cancer due to treatment-related immunosuppression?. <i>Radiotherapy and Oncology</i> , 2020, 143, 51-57.	0.3	16
1543	PD-1 Imposes Qualitative Control of Cellular Transcriptomes in Response to T Cell Activation. <i>Molecular Cell</i> , 2020, 77, 937-950.e6.	4.5	35
1544	The structural features that distinguish PD-L2 from PD-L1 emerged in placental mammals. <i>Journal of Biological Chemistry</i> , 2020, 295, 4372-4380.	1.6	56
1545	LRP11 activates $\beta$ -catenin to induce PD-L1 expression in prostate cancer. <i>Journal of Drug Targeting</i> , 2020, 28, 508-515.	2.1	18
1546	PD-L2 + wound zone macrophage-like cells display M1/M2-mixed activation and restrain the effector Th1 responses. <i>Immunology and Cell Biology</i> , 2020, 98, 152-164.	1.0	7
1547	Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines. <i>Journal of Virology</i> , 2020, 94, .	1.5	54
1548	PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges. <i>Biomedicine and Pharmacotherapy</i> , 2020, 121, 109625.	2.5	92

#	ARTICLE	IF	CITATIONS
1549	Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules. <i>European Journal of Medicinal Chemistry</i> , 2020, 186, 111876.	2.6	98
1550	Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report. <i>Clinical Lung Cancer</i> , 2020, 21, e45-e48.	1.1	7
1551	PD-1 Expression on NK Cells in Malaria-Exposed Individuals Is Associated with Diminished Natural Cytotoxicity and Enhanced Antibody-Dependent Cellular Cytotoxicity. <i>Infection and Immunity</i> , 2020, 88, .	1.0	15
1552	Programmed death ligand 2 – A link between inflammation and bone loss in rheumatoid arthritis. <i>Journal of Translational Autoimmunity</i> , 2020, 3, 100028.	2.0	10
1553	Immunogenomics: steps toward personalized medicines. , 2020, , 73-90.		0
1554	Expressions of inhibitory checkpoint molecules in acute and chronic HBV and HCV infections: Implications for therapeutic monitoring and personalized therapy. <i>Reviews in Medical Virology</i> , 2020, 30, e2094.	3.9	10
1555	An Introduction to CAR Immunotherapy. , 2020, , 1-11.		1
1556	The Programmed Death Pathway in Ocular Adnexal Sebaceous Carcinoma. <i>Ophthalmic Plastic and Reconstructive Surgery</i> , 2020, 36, 74-79.	0.4	8
1557	New insight in endocrine-related adverse events associated to immune checkpoint blockade. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101370.	2.2	60
1558	Discovery of hPRDX5-based peptide inhibitors blocking PD-1/PD-L1 interaction through in silico proteolysis and rational design. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 185-193.	1.1	10
1559	Abscopal Effect Following Immunotherapy and Combined Stereotactic Body Radiation Therapy in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma: A Report of Two Cases and Literature Review. <i>Annals of Otology, Rhinology and Laryngology</i> , 2020, 129, 517-522.	0.6	22
1560	Advances of immune checkpoints in colorectal cancer treatment. <i>Biomedicine and Pharmacotherapy</i> , 2020, 123, 109745.	2.5	21
1561	Analyses of multi-omics differences between patients with high and low PD1/PDL1 expression in lung squamous cell carcinoma. <i>International Immunopharmacology</i> , 2020, 88, 106910.	1.7	6
1562	Immunotherapy With Radiotherapy and Chemoradiotherapy for Cervical Cancer. <i>Seminars in Radiation Oncology</i> , 2020, 30, 273-280.	1.0	39
1563	Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. <i>IScience</i> , 2020, 23, 101580.	1.9	22
1564	The Immunotherapy Revolution in Kidney Cancer Treatment. <i>Cancer Journal (Sudbury, Mass )</i> , 2020, 26, 419-431.	1.0	17
1565	The PD-1 Pathway Regulates Development and Function of Memory CD8+ T Cells following Respiratory Viral Infection. <i>Cell Reports</i> , 2020, 31, 107827.	2.9	72
1566	Colorectal Cancer Immunotherapy: Options and Strategies. <i>Frontiers in Immunology</i> , 2020, 11, 1624.	2.2	207

#	ARTICLE	IF	CITATIONS
1567	Using phage-assisted continuous evolution (PACE) to evolve human PD1. <i>Experimental Cell Research</i> , 2020, 396, 112244.	1.2	3
1568	The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 1721.	2.2	61
1569	Activation of CD8 T cells accelerates anti-PD-1 antibody-induced psoriasis-like dermatitis through IL-6. <i>Communications Biology</i> , 2020, 3, 571.	2.0	31
1570	PD-1 expression on uveal melanoma induces tumor proliferation and predicts poor patient survival. <i>International Journal of Biological Markers</i> , 2020, 35, 50-58.	0.7	11
1571	The Immune Profile of Pituitary Adenomas and a Novel Immune Classification for Predicting Immunotherapy Responsiveness. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3207-e3223.	1.8	30
1572	Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy. <i>Pharmaceutics</i> , 2020, 12, 663.	2.0	24
1573	Intracellular accumulation of PD-1 molecules in circulating T lymphocytes in advanced malignant melanoma: an implication for immune evasion mechanism. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1861-1869.	1.0	2
1574	A narrative review of synergistic drug administration in unresectable locally advanced non-small cell lung cancer: current landscape and future prospects in the era of immunotherapy. <i>Translational Lung Cancer Research</i> , 2020, 9, 2082-2096.	1.3	4
1575	Biotherapeutic Antibodies for the Treatment of Head and Neck Cancer: Current Approaches and Future Considerations of Photothermal Therapies. <i>Frontiers in Oncology</i> , 2020, 10, 559596.	1.3	9
1576	Overcoming Immune Evasion in Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8984.	1.8	88
1577	Pivotal role of PD-1/PD-L1 immune checkpoints in immune escape and cancer progression: Their interplay with platelets and FOXP3+Tregs related molecules, clinical implications and combinational potential with phytochemicals. <i>Seminars in Cancer Biology</i> , 2022, 86, 1033-1057.	4.3	14
1578	The Immune Checkpoint PD-1 in Natural Killer Cells: Expression, Function and Targeting in Tumour Immunotherapy. <i>Cancers</i> , 2020, 12, 3285.	1.7	85
1579	Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma. <i>Journal of Immunology Research</i> , 2020, 2020, 1-18.	0.9	12
1580	Distorted frequency of dendritic cells and their associated stimulatory and inhibitory markers augment the pathogenesis of pemphigus vulgaris. <i>Immunologic Research</i> , 2020, 68, 353-362.	1.3	5
1581	Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2020, 68, 36.	1.0	26
1582	Dynamic monitoring of serum soluble programmed cell death ligand 1 as a response predictor to chemotherapy in metastatic or recurrent gastrointestinal cancer. <i>Translational Cancer Research</i> , 2020, 9, 2434-2448.	0.4	2
1583	The relative and absolute benefit of programmed death receptor-1 vs programmed death ligand 1 therapy in advanced non-small-cell lung cancer: A systematic review and meta-analysis. <i>International Immunopharmacology</i> , 2020, 87, 106852.	1.7	3
1584	PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5228.	1.8	19

#	ARTICLE	IF	CITATIONS
1585	Differential Accumulation and Activation of Monocyte and Dendritic Cell Subsets in Inflamed Synovial Fluid Discriminates Between Juvenile Idiopathic Arthritis and Septic Arthritis. <i>Frontiers in Immunology</i> , 2020, 11, 1716.	2.2	13
1586	Targeting immune checkpoints in hematological malignancies. <i>Journal of Hematology and Oncology</i> , 2020, 13, 111.	6.9	66
1587	Liothyronine could block the programmed death-ligand 1 (PDL1) activity: an e-Pharmacophore modeling and virtual screening study. <i>Journal of Receptor and Signal Transduction Research</i> , 2020, , 1-9.	1.3	10
1588	Quantitative phosphoproteomic analysis reveals involvement of PD-1 in multiple T cell functions. <i>Journal of Biological Chemistry</i> , 2020, 295, 18036-18050.	1.6	16
1589	Pulmonary toxicity and RNA sequencing analyses of mouse in response to exposure to cellulose nanofibrils. <i>Inhalation Toxicology</i> , 2020, 32, 388-401.	0.8	3
1590	Prognostic and clinicopathological utility of PD-L2 expression in patients with digestive system cancers: A meta-analysis. <i>International Immunopharmacology</i> , 2020, 88, 106946.	1.7	4
1591	A pilot clinical study of the therapeutic antibody against canine PD-1 for advanced spontaneous cancers in dogs. <i>Scientific Reports</i> , 2020, 10, 18311.	1.6	61
1592	Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 1147-1158.	1.3	8
1593	Lack of myeloid cell infiltration as an acquired resistance strategy to immunotherapy. , 2020, 8, e001326.		16
1594	Abnormal membrane-bound and soluble programmed death ligand 2 (PD-L2) expression in systemic lupus erythematosus is associated with disease activity. <i>Immunology Letters</i> , 2020, 227, 96-101.	1.1	11
1595	Microbiota and Cancer: The Emerging Beneficial Role of Bifidobacteria in Cancer Immunotherapy. <i>Frontiers in Microbiology</i> , 2020, 11, 575072.	1.5	40
1596	Novel treatments using PD1 inhibitors for advanced and metastatic cutaneous squamous cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 819-822.	1.1	6
1597	Investigation of the PD-1 and PD-L1 Immune Checkpoint Molecules Throughout Healthy Human Pregnancy and in Nonpregnant Women. <i>Journal of Clinical Medicine</i> , 2020, 9, 2536.	1.0	15
1598	Cancer immunotherapyâ€‘related adverse events: causes and challenges. <i>Supportive Care in Cancer</i> , 2020, 28, 6111-6117.	1.0	22
1599	Voluntary wheel running can lead to modulation of immune checkpoint molecule expression. <i>Acta OncolÃ³gica</i> , 2020, 59, 1447-1454.	0.8	18
1600	Heat Shock Proteins and PD-1/PD-L1 as Potential Therapeutic Targets in Myeloproliferative Neoplasms. <i>Cancers</i> , 2020, 12, 2592.	1.7	8
1601	Revisiting the PD-1 pathway. <i>Science Advances</i> , 2020, 6, .	4.7	277
1602	A bilateral tumor model identifies transcriptional programs associated with patient response to immune checkpoint blockade. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 23684-23694.	3.3	32



#	ARTICLE	IF	CITATIONS
1603	<p><p>Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy</p></p>. Drug Design, Development and Therapy, 2020, Volume 14, 3625-3649.	2.0	80
1604	ICPis-Induced Autoimmune Polyendocrine Syndrome Type 2: A Review of the Literature and a Protocol for Optimal Management. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4208-e4218.	1.8	15
1605	<p><p>A Review About Pembrolizumab in First-Line Treatment of Advanced NSCLC: Focus on KEYNOTE Studies</p></p>. Cancer Management and Research, 2020, Volume 12, 6493-6509.	0.9	19
1606	The influence of programmed cell death ligand 2 (PD-L2) expression on survival outcome and tumor microenvironment in diffuse large B cell lymphoma. Leukemia and Lymphoma, 2020, 61, 3395-3403.	0.6	4
1607	Immunotherapy for advanced thyroid cancers â€” rationale, current advances and future strategies. Nature Reviews Endocrinology, 2020, 16, 629-641.	4.3	49
1608	Accelerator or Brake: Immune Regulators in Malaria. Frontiers in Cellular and Infection Microbiology, 2020, 10, 610121.	1.8	5
1609	Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges. Cancers, 2020, 12, 3173.	1.7	36
1610	Prognostic significance of PD-L1 in advanced non-small cell lung carcinoma. Medicine (United States), 2020, 99, e23172.	0.4	15
1611	Delicate Role of PD-L1/PD-1 Axis in Blood Vessel Inflammatory Diseases: Current Insight and Future Significance. International Journal of Molecular Sciences, 2020, 21, 8159.	1.8	23
1612	Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies. Frontiers in Cell and Developmental Biology, 2020, 8, 569219.	1.8	59
1613	Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation. OncoImmunology, 2020, 9, 1737385.	2.1	23
1614	Allosteric Inhibition of SHP2 Stimulates Antitumor Immunity by Transforming the Immunosuppressive Environment. Cancer Research, 2020, 80, 2889-2902.	0.4	61
1615	Immunomodulatory Strategies Targeting Dendritic Cells to Improve Corneal Graft Survival. Journal of Clinical Medicine, 2020, 9, 1280.	1.0	11
1616	New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. Drug Resistance Updates, 2020, 51, 100702.	6.5	53
1617	A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nature Reviews Immunology, 2020, 20, 651-668.	10.6	2,160
1618	Innate Functions of Dendritic Cell Subsets in Cardiac Allograft Tolerance. Frontiers in Immunology, 2020, 11, 869.	2.2	6
1619	Scientific based combination therapies with immunoâ€œoncology checkpoint inhibitors. British Journal of Clinical Pharmacology, 2020, 86, 1711-1725.	1.1	6
1620	PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas. Current Hematologic Malignancy Reports, 2020, 15, 372-381.	1.2	51

#	ARTICLE	IF	CITATIONS
1621	Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade. <i>Frontiers in Immunology</i> , 2020, 11, 1075.	2.2	36
1622	Soluble PD1 levels are increased with disease activity in paediatric onset autoimmune hepatitis and inflammatory bowel disease. <i>Autoimmunity</i> , 2020, 53, 253-260.	1.2	9
1623	Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy. <i>Biochemical and Biophysical Research Communications</i> , 2020, 527, 226-231.	1.0	21
1624	MERTK in cancer therapy: Targeting the receptor tyrosine kinase in tumor cells and the immune system. , 2020, 213, 107577.		43
1625	Molecular Biochemical Aspects of Cancer. , 2020, , .		3
1626	Combination rhIL-15 and Anti-PD-L1 (Avelumab) Enhances HIVGag-Specific CD8 T-Cell Function. <i>Journal of Infectious Diseases</i> , 2020, 222, 1540-1549.	1.9	7
1627	Importance of validating antibody panels: Anti-PD-L1 clone binds AF700 fluorophore. <i>Journal of Immunological Methods</i> , 2020, 483, 112795.	0.6	7
1628	Facing SARS-CoV-2 outbreak in immunotherapy era. <i>Future Oncology</i> , 2020, 16, 1475-1485.	1.1	9
1629	Biomarkers of Immune Checkpoint Inhibitor Efficacy in Cancer. <i>Current Oncology</i> , 2020, 27, 106-114.	0.9	17
1630	The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment. <i>Cells</i> , 2020, 9, 1427.	1.8	51
1631	Immune checkpoint inhibitors-induced autoimmunity: The impact of gender. <i>Autoimmunity Reviews</i> , 2020, 19, 102590.	2.5	37
1632	LAG3 (CD223) and autoimmunity: Emerging evidence. <i>Journal of Autoimmunity</i> , 2020, 112, 102504.	3.0	28
1633	Advances in immune neoadjuvant/adjuvant therapyâ€related adverse events of nonâ€small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, , .	0.7	5
1634	Risk of SARS-CoV-2 infection and disease in metastatic triple-negative breast cancer patients treated with immune checkpoint inhibitors. <i>Immunotherapy</i> , 2020, 12, 675-679.	1.0	3
1635	GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors. <i>Scientific Reports</i> , 2020, 10, 9027.	1.6	20
1636	Tumor-induced neurogenesis and immune evasion as targets of innovative anti-cancer therapies. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 99.	7.1	126
1637	Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 14331-14341.	3.3	55
1638	Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints. <i>Clinical and Translational Medicine</i> , 2020, 10, 374-411.	1.7	33

#	ARTICLE	IF	CITATIONS
1639	Regulation of Cancer Immune Checkpoints. <i>Advances in Experimental Medicine and Biology</i> , 2020, , .	0.8	7
1640	Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 364.	2.2	50
1641	Advances in targeted therapy for malignant lymphoma. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 15.	7.1	66
1642	CXCL-10: a new candidate for melanoma therapy?. <i>Cellular Oncology (Dordrecht)</i> , 2020, 43, 353-365.	2.1	37
1643	Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers. <i>British Journal of Cancer</i> , 2020, 122, 1535-1543.	2.9	37
1644	T cell costimulation, checkpoint inhibitors and anti-tumor therapy. <i>Journal of Biosciences</i> , 2020, 45, 1.	0.5	24
1645	Determinants of Resistance to Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1594.	1.8	39
1646	The Role of Neoadjuvant Therapy in Melanoma. <i>Current Oncology Reports</i> , 2020, 22, 80.	1.8	8
1647	The Role of Immunomodulatory Receptors in the Pathogenesis of HIV Infection: A Therapeutic Opportunity for HIV Cure?. <i>Frontiers in Immunology</i> , 2020, 11, 1223.	2.2	18
1648	Immunotherapy in Myeloproliferative Diseases. <i>Cells</i> , 2020, 9, 1559.	1.8	17
1649	Dual Roles of PU.1 in the Expression of PD-L2: Direct Transactivation with IRF4 and Indirect Epigenetic Regulation. <i>Journal of Immunology</i> , 2020, 205, 822-829.	0.4	11
1650	ERMAP is a B7 family-related molecule that negatively regulates T cell and macrophage responses. <i>Cellular and Molecular Immunology</i> , 2020, 18, 1920-1933.	4.8	8
1651	News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors. <i>Seminars in Cancer Biology</i> , 2022, 79, 18-43.	4.3	35
1652	Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment. <i>Advances in Cancer Research</i> , 2020, 147, 1-57.	1.9	32
1653	Fungal infection risks associated with the use of cytokine antagonists and immune checkpoint inhibitors. <i>Experimental Biology and Medicine</i> , 2020, 245, 1104-1114.	1.1	13
1654	Critical role of PD-L1 expression on non-tumor cells rather than on tumor cells for effective anti-PD-L1 immunotherapy in a transplantable mouse hematopoietic tumor model. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1001-1014.	2.0	7
1655	Cisplatin-induced programmed cell death ligand-2 expression is associated with metastasis ability in oral squamous cell carcinoma. <i>Cancer Science</i> , 2020, 111, 1113-1123.	1.7	20
1656	Prognostic impact of CD8+ T cell distribution and its association with the HLA class I expression in intrahepatic cholangiocarcinoma. <i>Surgery Today</i> , 2020, 50, 931-940.	0.7	34

#	ARTICLE	IF	CITATIONS
1658	PD-1/PD-L1-dependent immune response in colorectal cancer. <i>Journal of Cellular Physiology</i> , 2020, 235, 5461-5475.	2.0	86
1659	The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity. <i>Cell Research</i> , 2020, 30, 285-299.	5.7	129
1660	The importance of exosomal PDL1 in tumour immune evasion. <i>Nature Reviews Immunology</i> , 2020, 20, 209-215.	10.6	360
1661	Tumor Immunology and Tumor Evolution: Intertwined Histories. <i>Immunity</i> , 2020, 52, 55-81.	6.6	357
1662	mRNA Display Discovery of a Novel Programmed Death Ligand 1 (PD-L1) Binding Peptide (a Peptide Ligand) Tj ETQq0,0 0 rgBT/Overlock	1.6	10
1663	A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-“PD-1 antibody, in patients with advanced solid tumors. , 2020, 8, e000530.		54
1664	The Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 604.	2.2	51
1665	Natural Killer Cells: Tumor Surveillance and Signaling. <i>Cancers</i> , 2020, 12, 952.	1.7	56
1666	CD279 mediates the homeostasis and survival of regulatory T cells by enhancing T cell and macrophage interactions. <i>FEBS Open Bio</i> , 2020, 10, 1162-1170.	1.0	3
1667	Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2856.	1.8	31
1668	Early Hepatic Lesions Display Immature Tertiary Lymphoid Structures and Show Elevated Expression of Immune Inhibitory and Immunosuppressive Molecules. <i>Clinical Cancer Research</i> , 2020, 26, 4381-4389.	3.2	44
1669	Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?. <i>Frontiers in Pharmacology</i> , 2020, 11, 441.	1.6	48
1670	The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients. <i>Translational Andrology and Urology</i> , 2020, 9, 367-381.	0.6	8
1671	Tumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis Blockade. <i>Cells</i> , 2020, 9, 940.	1.8	8
1673	Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 343-354.	1.1	0
1674	Targeting PD-1 or PD-L1 in Metastatic Kidney Cancer: Combination Therapy in the First-Line Setting. <i>Clinical Cancer Research</i> , 2020, 26, 2087-2095.	3.2	35
1675	Serum levels of soluble programmed cell death protein 1 and soluble programmed cell death protein ligand 2 are increased in systemic lupus erythematosus and associated with the disease activity. <i>Lupus</i> , 2020, 29, 686-696.	0.8	8
1676	Circulating PD-1 mRNA in Peripheral Blood is a Potential Biomarker for Predicting Survival of Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2020, 27, 4035-4043.	0.7	7

#	ARTICLE	IF	CITATIONS
1677	<p>A New Immunological Prognostic Model Based on Immunohistochemistry for Extranodal Natural Killer/T-Cell Lymphoma Patients After Non-Anthracycline-Based Chemotherapy</p>. Cancer Management and Research, 2020, Volume 12, 1981-1990.	0.9	3
1678	The Role of B7 Family Molecules in Maternalâ€Fetal Immunity. Frontiers in Immunology, 2020, 11, 458.	2.2	33
1679	The Role of PD-1 in Acute and Chronic Infection. Frontiers in Immunology, 2020, 11, 487.	2.2	167
1680	The PD-1/PD-L pathway in rheumatic diseases. Journal of the Formosan Medical Association, 2021, 120, 48-59.	0.8	26
1681	Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy. Advanced Drug Delivery Reviews, 2021, 168, 158-180.	6.6	111
1682	Patients with systemic lupus erythematosus show increased proportions of CD19+CD20â~ B cells and secretion of related autoantibodies. Clinical Rheumatology, 2021, 40, 151-165.	1.0	7
1683	Advances in Small-Cell Lung Cancer (SCLC) Translational Research. Cold Spring Harbor Perspectives in Medicine, 2021, 11, a038240.	2.9	34
1684	Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure. Annual Review of Pharmacology and Toxicology, 2021, 61, 113-134.	4.2	40
1685	The Stone Guest: How Does pH Affect Binding Properties of PDâ€1/PDâ€L1 Inhibitors?. ChemMedChem, 2021, 16, 568-577.	1.6	9
1686	PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines. Journal of Advanced Research, 2021, 29, 45-54.	4.4	31
1687	Targeting <sc>CTLA</sc>â€4 in cancer: Is it the ideal companion for <sc>PD</sc>â€1 blockade immunotherapy combinations?. International Journal of Cancer, 2021, 149, 31-41.	2.3	23
1688	Tumorâ€derived exosomes in the PDâ€1/PDâ€L1 axis: Significant regulators as well as promising clinical targets. Journal of Cellular Physiology, 2021, 236, 4138-4151.	2.0	17
1689	Considerations for Use of Immune Checkpoint Inhibitors in Cancer Therapy for Patients with Co-Existing Thyroid Eye Disease. Ophthalmology and Therapy, 2021, 10, 5-12.	1.0	5
1690	Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annual Review of Pathology: Mechanisms of Disease, 2021, 16, 223-249.	9.6	956
1691	The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: Recent advances and opportunities. Critical Reviews in Oncology/Hematology, 2021, 157, 103160.	2.0	26
1692	A hyperacute immune map of ischaemic stroke patients reveals alterations to circulating innate and adaptive cells. Clinical and Experimental Immunology, 2021, 203, 458-471.	1.1	7
1693	Macrophageâ€Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention. Advanced Functional Materials, 2021, 31, 2006220.	7.8	63
1694	The role of B7 family members in the generation of Immunoglobulin. Journal of Leukocyte Biology, 2021, 109, 377-382.	1.5	0

#	ARTICLE	IF	CITATIONS
1696	A pilot radiogenomic study of DIPG reveals distinct subgroups with unique clinical trajectories and therapeutic targets. <i>Acta Neuropathologica Communications</i> , 2021, 9, 14.	2.4	11
1697	PD-1 and PD-L2 expression predict relapse risk and poor survival in patients with stage III colorectal cancer. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 423-432.	2.1	9
1698	Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series. <i>Endocrine Journal</i> , 2021, 68, 613-620.	0.7	8
1699	ANO9 regulates PD-L2 expression and binding ability to PD-1 in gastric cancer. <i>Cancer Science</i> , 2021, 112, 1026-1037.	1.7	12
1700	Serum soluble PD-1 plays a role in predicting infection complications in patients with acute pancreatitis. <i>Immunity, Inflammation and Disease</i> , 2021, 9, 310-318.	1.3	11
1701	A snapshot of the PD-1/PD-L1 pathway. <i>Journal of Cancer</i> , 2021, 12, 2735-2746.	1.2	105
1702	Programmed cell death-1 rs11568821 and interleukin-28B rs12979860 polymorphisms in autoimmune hepatitis. <i>Journal of Translational Autoimmunity</i> , 2021, 4, 100126.	2.0	2
1703	Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells. <i>Cancer Discovery</i> , 2021, 11, 1100-1117.	7.7	85
1704	T-cell-intrinsic and -extrinsic regulation of PD-1 function. <i>International Immunology</i> , 2021, 33, 693-698.	1.8	8
1705	YY1 expression and PD-1 regulation in CD8 T lymphocytes. , 2021, , 289-309.		1
1706	The Glycosylphosphatidylinositol Anchor Regulates T Cell Antigen Receptor Induced IL-2 Production. <i>Open Journal of Immunology</i> , 2021, 11, 1-24.	0.5	0
1707	Non-genetic cell-surface modification with a self-assembling molecular glue. <i>Chemical Communications</i> , 2021, 57, 1470-1473.	2.2	1
1708	Identification of MicroRNAs as Diagnostic Biomarkers for Breast Cancer Based on the Cancer Genome Atlas. <i>Diagnostics</i> , 2021, 11, 107.	1.3	15
1709	A narrative review of immune checkpoint mechanisms and current immune checkpoint therapy. <i>Annals of Blood</i> , 0, 7, 33-33.	0.4	3
1710	The inflammatory tumor microenvironment and tumor cell plasticity in the pathogenesis of colorectal cancer. <i>Onkologiya Zhurnal Imeni P A Gertsena</i> , 2021, 10, 66.	0.0	0
1711	Co-Inhibitors of Second Signal of Lymphocyte Response in Human Renal Transplants: PD-L2, GITR, and ILT-2/3/5 Positive Cells from Aspiration Biopsies Associate with Acute Rejection-Freedom. <i>Open Journal of Nephrology</i> , 2021, 11, 58-77.	0.0	0
1712	Immune Checkpoint Inhibitors: Cardiotoxicity in Pre-clinical Models and Clinical Studies. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 619650.	1.1	17
1713	Immunotherapy and radiation therapy sequencing: State of the data on timing, efficacy, and safety. <i>Cancer</i> , 2021, 127, 1553-1567.	2.0	33

#	ARTICLE	IF	CITATIONS
1714	Spatial Regulation of T-Cell Signaling by Programmed Death-Ligand 1 on Wireframe DNA Origami Flat Sheets. <i>ACS Nano</i> , 2021, 15, 3441-3452.	7.3	42
1715	Tislelizumab uniquely binds to the C2 loop of PD-1 with slow dissociated rate and complete PD-L1 blockage. <i>FEBS Open Bio</i> , 2021, 11, 782-792.	1.0	32
1716	<sc>Anti-PD1</sc> versus <sc>anti-PD-L1</sc> immunotherapy in first-line therapy for advanced non-small cell lung cancer: A systematic review and meta-analysis. <i>Thoracic Cancer</i> , 2021, 12, 1058-1066.	0.8	18
1717	Impact of cancer evolution on immune surveillance and checkpoint inhibitor response. <i>Seminars in Cancer Biology</i> , 2022, 84, 89-102.	4.3	21
1718	Gamma/Delta T Cells in the Course of Healthy Human Pregnancy: Cytotoxic Potential and the Tendency of CD8 Expression Make CD56+ $\gamma\delta$ T Cells a Unique Lymphocyte Subset. <i>Frontiers in Immunology</i> , 2020, 11, 596489.	2.2	13
1719	Functionally Competent, PD-1+ CD8+ Trm Cells Populate the Brain Following Local Antigen Encounter. <i>Frontiers in Immunology</i> , 2020, 11, 595707.	2.2	6
1720	The Potential Regulatory Roles of Circular RNAs in Tumor Immunology and Immunotherapy. <i>Frontiers in Immunology</i> , 2020, 11, 617583.	2.2	20
1721	The Tumor Microenvironment in SCC: Mechanisms and Therapeutic Opportunities. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 636544.	1.8	10
1722	Mouse Preclinical Cancer Immunotherapy Modeling Involving Anti-PD-1 Therapies Reveals the Need to Use Mouse Reagents to Mirror Clinical Paradigms. <i>Cancers</i> , 2021, 13, 729.	1.7	3
1723	Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 74.	3.5	19
1724	Programmed cell death-1/programmed cell death-ligand 1 inhibitors exert antiapoptosis and antiinflammatory activity in lipopolysaccharide stimulated murine alveolar macrophages. <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 400.	0.8	5
1725	Associations of PD-L1, PD-L2, and HLA class I expression with responses to immunotherapy in patients with advanced sarcoma: post hoc analysis of a phase 1/2 trial. <i>Clinical and Translational Oncology</i> , 2021, 23, 1620-1629.	1.2	2
1726	Immunotherapy for pancreatic ductal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 751-759.	0.8	18
1727	Prognostic and clinicopathological value of PD-L2 in lung cancer: A meta-analysis. <i>International Immunopharmacology</i> , 2021, 91, 107280.	1.7	4
1728	PD-L1 as a Potential Target in Cancer Therapy (Review). <i>Drug Development and Registration</i> , 2021, 10, 31-36.	0.2	3
1729	Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action. <i>European Journal of Immunology</i> , 2021, 51, 544-556.	1.6	71
1730	Atezolizumab and granzyme B as immunotoxin against PD-L1 antigen; an insilico study. <i>In Silico Pharmacology</i> , 2021, 9, 20.	1.8	5
1731	PD-L2 Is Constitutively Expressed in Normal and Malignant Urothelium. <i>Frontiers in Oncology</i> , 2021, 11, 626748.	1.3	6

#	ARTICLE	IF	CITATIONS
1732	High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients. <i>Genes</i> , 2021, 12, 273.	1.0	14
1733	Immune Checkpoints: Novel Therapeutic Targets to Attenuate Sepsis-Induced Immunosuppression. <i>Frontiers in Immunology</i> , 2020, 11, 624272.	2.2	43
1734	Mechanisms of immunogenic cell death and immune checkpoint blockade therapy. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 448-458.	0.8	15
1735	Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors. <i>Frontiers in Oncology</i> , 2021, 11, 650481.	1.3	23
1736	Advances in Drug Resistance of Esophageal Cancer: From the Perspective of Tumor Microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 664816.	1.8	17
1737	Checkpoint blockade toxicities: Insights into autoimmunity and treatment. <i>Seminars in Immunology</i> , 2021, 52, 101473.	2.7	11
1738	An in vivo method for diversifying the functions of therapeutic antibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	3
1739	T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs). <i>Anticancer Research</i> , 2021, 41, 1123-1141.	0.5	6
1740	Advanced Nanotechnology for Enhancing Immune Checkpoint Blockade Therapy. <i>Nanomaterials</i> , 2021, 11, 661.	1.9	23
1741	Insights into non-peptide small-molecule inhibitors of the PD-1/PD-L1 interaction: Development and perspective. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 33, 116038.	1.4	11
1742	Unraveling the Role of Immune Checkpoints in Leishmaniasis. <i>Frontiers in Immunology</i> , 2021, 12, 620144.	2.2	18
1743	Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	84
1744	Exosomal Non-Coding RNAs: Regulatory and Therapeutic Target of Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 653846.	1.3	2
1745	Toxicity Profile of Combining PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy in Non-Small Cell Lung Cancer: A Systematic Review. <i>Frontiers in Immunology</i> , 2021, 12, 627197.	2.2	12
1746	Immunosuppression Factors PD-1, PD-L1, and IDO1 and Colorectal Cancer. <i>Doklady Biochemistry and Biophysics</i> , 2021, 497, 66-70.	0.3	5
1747	Potential Impact of Human Cytomegalovirus Infection on Immunity to Ovarian Tumours and Cancer Progression. <i>Biomedicine</i> , 2021, 9, 351.	1.4	15
1748	Novel immune checkpoints beyond PD-1 in advanced melanoma. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 135-142.	0.3	5
1749	Therapeutic applications of the cancer immunoediting hypothesis. <i>Seminars in Cancer Biology</i> , 2022, 78, 63-77.	4.3	29



#	ARTICLE	IF	CITATIONS
1750	Identification of PD-1 ligands: PD-L1 and PD-L2 on macrophages in lung cancer milieu by flow cytometry. <i>Translational Lung Cancer Research</i> , 2021, 10, 1679-1689.	1.3	8
1751	Intersection of DNA Repair Pathways and the Immune Landscape Identifies PD-L2 as a Prognostic Marker in Epithelial Ovarian Cancer. <i>Cancers</i> , 2021, 13, 1972.	1.7	0
1752	PD-1/PD-L1 Expression Levels and Prognostic Significance in Chronic Lymphocytic Leukemia. <i>Acibadem Universitesi Saglik Bilimleri Dergisi</i> , 2021, 12, .	0.0	0
1753	Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review. <i>Cancer Cell International</i> , 2021, 21, 239.	1.8	35
1755	IFN $\gamma$ , and to a Lesser Extent TNF $\alpha$ , Provokes a Sustained Endothelial Costimulatory Phenotype. <i>Frontiers in Immunology</i> , 2021, 12, 648946.	2.2	12
1756	Immunity reloaded: Deconstruction of the PD-1 axis in B cell lymphomas. <i>Blood Reviews</i> , 2021, 50, 100832.	2.8	5
1757	Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions. <i>International Immunopharmacology</i> , 2021, 93, 107403.	1.7	30
1758	Advances in immunotherapy for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 525-543.	8.2	609
1759	Metabolic barriers to cancer immunotherapy. <i>Nature Reviews Immunology</i> , 2021, 21, 785-797.	10.6	245
1760	Protein-Based Nanomedicine for Therapeutic Benefits of Cancer. <i>ACS Nano</i> , 2021, 15, 8001-8038.	7.3	59
1761	A review of signaling and transcriptional control in T follicular helper cell differentiation. <i>Journal of Leukocyte Biology</i> , 2021, , .	1.5	8
1762	Immuno-Oncological Biomarkers for Squamous Cell Cancer of the Head and Neck: Current State of the Art and Future Perspectives. <i>Cancers</i> , 2021, 13, 1714.	1.7	14
1763	Human leukocyte antigen I is significantly downregulated in patients with myxoid liposarcomas. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3489-3499.	2.0	5
1764	Current and emerging therapies for primary central nervous system lymphoma. <i>Biomarker Research</i> , 2021, 9, 32.	2.8	20
1765	PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma. <i>Cells</i> , 2021, 10, 1152.	1.8	12
1766	Role of HOXC10 in Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 684021.	1.3	8
1767	Emerging concepts in PD-1 checkpoint biology. <i>Seminars in Immunology</i> , 2021, 52, 101480.	2.7	84
1768	The Role of Programmed Death-1 in Type 1 Diabetes. <i>Current Diabetes Reports</i> , 2021, 21, 20.	1.7	11

#	ARTICLE	IF	CITATIONS
1769	Immune checkpoints in targeted-immunotherapy of pancreatic cancer: New hope for clinical development. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 1083-1097.	5.7	23
1770	VRK2 inhibition synergizes with PD-1 blockade to improve T cell responses. <i>Immunology Letters</i> , 2021, 233, 42-47.	1.1	6
1771	Dynamic Collaborations for the Development of Immune Checkpoint Blockade Agents. <i>Journal of Personalized Medicine</i> , 2021, 11, 460.	1.1	5
1772	Assessment of Immune Status in Dynamics for Patients with Cancer Undergoing Immunotherapy. <i>Journal of Oncology</i> , 2021, 2021, 1-7.	0.6	2
1773	Identification of TAPBPL as a novel negative regulator of T cell function. <i>EMBO Molecular Medicine</i> , 2021, 13, e13404.	3.3	6
1774	Programmed cell death-1 single-nucleotide polymorphism rs10204525 is associated with human immunodeficiency virus type 1 RNA viral load in HIV-1-infected Moroccan subjects. <i>Medical Microbiology and Immunology</i> , 2021, 210, 187-196.	2.6	2
1775	Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies. <i>Frontiers in Oncology</i> , 2021, 11, 635007.	1.3	76
1776	The depths of PD-1 function within the tumor microenvironment beyond CD8+ T cells. <i>Seminars in Cancer Biology</i> , 2022, 86, 1045-1055.	4.3	17
1777	Programmed death ligand 2 expression plays a limited role in adenocarcinomas of the gastroesophageal junction after preoperative chemotherapy. <i>European Surgery - Acta Chirurgica Austriaca</i> , 2021, 53, 287-293.	0.3	3
1778	Up-Regulation of Immune Checkpoints in the Thymus of PRRSV-1-Infected Piglets in a Virulence-Dependent Fashion. <i>Frontiers in Immunology</i> , 2021, 12, 671743.	2.2	9
1779	Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1623-1634.	1.4	10
1780	Pembrolizumab-Associated Seronegative Myasthenia Gravis in a Patient With Metastatic Renal Cell Carcinoma. <i>Cureus</i> , 2021, 13, e15174.	0.2	2
1781	Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4435-4448.	3.2	35
1782	PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5123.	1.8	61
1783	A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 654463.	2.2	16
1784	Checkpoint blockade accelerates a novel switch from an NKT-driven TNF response toward a T cell driven IFN- $\gamma$ response within the tumor microenvironment. , 2021, 9, e002269.		2
1785	A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 3761-3771.	2.0	34
1786	Interaction of long non-coding RNAs and circular RNAs with microRNAs for the regulation of immunological responses in human cancers. <i>Seminars in Cell and Developmental Biology</i> , 2022, 124, 63-71.	2.3	15

#	ARTICLE	IF	CITATIONS
1787	Amlexanox enhances the antitumor effect of anti-PD-1 antibody. <i>Biochemical and Biophysical Research Communications</i> , 2021, 560, 1-6.	1.0	4
1788	Programmed Cell Death-1 Pathway Deficiency Enhances Autoimmunity Leading to Dacryoadenitis of Mice. <i>American Journal of Pathology</i> , 2021, 191, 1077-1093.	1.9	6
1789	Proteome Analysis in PAM Cells Reveals That African Swine Fever Virus Can Regulate the Level of Intracellular Polyamines to Facilitate Its Own Replication through ARG1. <i>Viruses</i> , 2021, 13, 1236.	1.5	15
1790	Human Adipose-Derived Stem/Stromal Cells Promote Proliferation and Migration in Head and Neck Cancer Cells. <i>Cancers</i> , 2021, 13, 2751.	1.7	9
1791	Expression and Prognostic Significance of PD-L2 in Diffuse Large B-Cell Lymphoma. <i>Frontiers in Oncology</i> , 2021, 11, 664032.	1.3	7
1793	T-cell Exhaustion in Organ Transplantation. <i>Transplantation</i> , 2022, 106, 489-499.	0.5	14
1794	PD-1/PD-L1 Axis as a Potential Therapeutic Target for Multiple Sclerosis: A T Cell Perspective. <i>Frontiers in Cellular Neuroscience</i> , 2021, 15, 716747.	1.8	11
1795	Multimarker profiling identifies protective and harmful immune processes in heart failure: findings from BIOSTAT-CHF. <i>Cardiovascular Research</i> , 2022, 118, 1964-1977.	1.8	10
1796	Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 495-508.	21.5	120
1797	Tumor-infiltrating FoxP3+ T cells are associated with poor prognosis in oral squamous cell carcinoma. <i>Clinical and Experimental Dental Research</i> , 2022, 8, 152-159.	0.8	6
1798	ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 645-660.	2.0	32
1799	Recent Advances on Immune Targeted Therapy of Colorectal Cancer Using bi-Specific Antibodies and Therapeutic Vaccines. <i>Biological Procedures Online</i> , 2021, 23, 13.	1.4	17
1800	Differential Involvement of Programmed Cell Death Ligands in Skin Immune Responses. <i>Journal of Investigative Dermatology</i> , 2022, 142, 145-154.e8.	0.3	12
1801	Evolving Dynamic Biomarkers for Prediction of Immune Responses to Checkpoint Inhibitors in Cancer. <i>Journal of Immunology</i> , 2022, 202, 1-10.	0.1	4
1802	Transcutaneous Carbon Dioxide Decreases Immunosuppressive Factors in Squamous Cell Carcinoma In Vivo. <i>BioMed Research International</i> , 2021, 2021, 1-9.	0.9	4
1803	Chimeric antigen receptor T cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges. <i>Voprosy Onkologii</i> , 2021, 67, 350-360.	0.1	2
1804	Narrative review of pembrolizumab for the treatment of esophageal cancer: evidence and outlook. <i>Annals of Translational Medicine</i> , 2021, 9, 1189-1189.	0.7	8
1805	PD-1-induced proliferating T cells exhibit a distinct transcriptional signature. <i>Immunology</i> , 2021, 164, 555-568.	2.0	5

#	ARTICLE	IF	CITATIONS
1806	Mifepristone inhibited the expression of B7-H2, B7-H3, B7-H4 and PD-L2 in adenomyosis. <i>Reproductive Biology and Endocrinology</i> , 2021, 19, 114.	1.4	7
1808	Immunotherapy against programmed death-1/programmed death ligand 1 in hepatocellular carcinoma: Importance of molecular variations, cellular heterogeneity, and cancer stem cells. <i>World Journal of Stem Cells</i> , 2021, 13, 795-824.	1.3	7
1809	Inhibitors of immune checkpointsâ€”PD-1, PD-L1, CTLA-4â€”new opportunities for cancer patients and a new challenge for internists and general practitioners. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 949-982.	2.7	72
1810	Tolerogenic Dendritic Cell-Based Approaches in Autoimmunity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8415.	1.8	30
1811	High Counts of CD68+ and CD163+ Macrophages in Mantle Cell Lymphoma Are Associated With Inferior Prognosis. <i>Frontiers in Oncology</i> , 2021, 11, 701492.	1.3	4
1812	Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 670900.	1.6	9
1814	The interplay of obesity, gut microbiome and diet in the immune check point inhibitors therapy era. <i>Seminars in Cancer Biology</i> , 2021, 73, 356-376.	4.3	32
1815	Faecal microbiota transplantation enhances efficacy of immune checkpoint inhibitors therapy against cancer. <i>World Journal of Gastroenterology</i> , 2021, 27, 5362-5375.	1.4	17
1816	Identification of a robust signature for clinical outcomes and immunotherapy response in gastric cancer: based on N6-methyladenosine related long noncoding RNAs. <i>Cancer Cell International</i> , 2021, 21, 432.	1.8	16
1817	Epitranscriptomic Approach: To Improve the Efficacy of ICB Therapy by Co-Targeting Intracellular Checkpoint CISH. <i>Cells</i> , 2021, 10, 2250.	1.8	6
1819	Immunogenomic pan-cancer landscape reveals immune escape mechanisms and immunoediting histories. <i>Scientific Reports</i> , 2021, 11, 15713.	1.6	10
1821	Perspectives on immune checkpoint ligands: expression, regulation, and clinical implications. <i>BMB Reports</i> , 2021, 54, 403-412.	1.1	7
1822	PD-1/PD-L1 Checkpoints and Resveratrol: A Controversial New Way for a Therapeutic Strategy. <i>Cancers</i> , 2021, 13, 4509.	1.7	10
1823	First line treatment of BRAF mutated advanced melanoma: Does one size fit all?. <i>Cancer Treatment Reviews</i> , 2021, 99, 102253.	3.4	26
1824	Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors. <i>JCI Insight</i> , 2021, 6, .	2.3	29
1825	Expression, prognostic significance and therapeutic implications of PDâ€L1 in gliomas. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	1.8	8
1826	Antigen and checkpoint receptor engagement recalibrates Tâ€cell receptor signal strength. <i>Immunity</i> , 2021, 54, 2481-2496.e6.	6.6	33
1827	L2pB1 Cells Contribute to Tumor Growth Inhibition. <i>Frontiers in Immunology</i> , 2021, 12, 722451.	2.2	2

#	ARTICLE	IF	CITATIONS
1828	Programmed Death Ligand 2 Gene Polymorphisms Are Associated With Lung Adenocarcinoma Risk in Female Never-Smokers. <i>Frontiers in Oncology</i> , 2021, 11, 753788.	1.3	4
1829	Recent insights into the pathogenesis of autoimmune hypophysitis. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 1175-1185.	1.3	7
1830	Immune PET Imaging. <i>Radiologic Clinics of North America</i> , 2021, 59, 875-886.	0.9	2
1831	The HIV-1 accessory protein Nef increases surface expression of the checkpoint receptor Tim-3 in infected CD4+ T cells. <i>Journal of Biological Chemistry</i> , 2021, 297, 101042.	1.6	11
1833	Role of the PD-1/PD-L1 Signaling in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Recent Insights and Future Directions. <i>Molecular Neurobiology</i> , 2021, 58, 6249-6271.	1.9	15
1835	The Role of Oncogenes and Redox Signaling in the Regulation of PD-L1 in Cancer. <i>Cancers</i> , 2021, 13, 4426.	1.7	15
1836	Cardiac Toxicity Associated with Cancer Immunotherapy and Biological Drugs. <i>Cancers</i> , 2021, 13, 4797.	1.7	12
1837	Motility Dynamics of T Cells in Tumor-Draining Lymph Nodes: A Rational Indicator of Antitumor Response and Immune Checkpoint Blockade. <i>Cancers</i> , 2021, 13, 4616.	1.7	13
1838	Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy. <i>World Journal of Surgical Oncology</i> , 2021, 19, 264.	0.8	21
1839	Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100214.	0.6	3
1840	Hepatocellular cancer therapy in patients with HIV infection: Disparities in cancer care, trials enrolment, and cancer-related research. <i>Translational Oncology</i> , 2021, 14, 101153.	1.7	5
1841	Immune Cycle-Based Strategies for Cancer Immunotherapy. <i>Advanced Functional Materials</i> , 2021, 31, 2107540.	7.8	24
1842	Strategic enhancement of immune checkpoint inhibition in refractory Colorectal Cancer: Trends and future prospective. <i>International Immunopharmacology</i> , 2021, 99, 108017.	1.7	5
1843	An update on immunotherapy with PD-1 and PD-L1 blockade. <i>Yeungnam University Journal of Medicine</i> , 2021, 38, 308-317.	0.7	1
1844	Peptide-based and small molecule PD-1 and PD-L1 pharmacological modulators in the treatment of cancer. , 2021, 227, 107870.		13
1845	Endocrinopathies Associated With Immune Checkpoint Inhibitors. , 2022, , 301-314.		0
1846	Improving the safety of iPSC-derived T cell therapy. , 2022, , 95-115.		3
1847	Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression. <i>Pituitary</i> , 2021, 24, 359-373.	1.6	12

#	ARTICLE	IF	CITATIONS
1848	Spatially Resolved and Quantitative Analysis of the Immunological Landscape in Human Meningiomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 150-159.	0.9	9
1849	Immune Tolerance of the Human Decidua. <i>Journal of Clinical Medicine</i> , 2021, 10, 351.	1.0	37
1850	Cancer Immunotherapy. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2021, , 1-41.	0.1	0
1851	PD-L2 based immune signature confers poor prognosis in HNSCC. <i>Oncolmunology</i> , 2021, 10, 1947569.	2.1	21
1852	Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1811-1820.	2.0	11
1853	Using CAR-NK cells to overcome the host resistance to antibody immunotherapy and immune checkpoint blockade therapy. , 2021, , 193-212.		1
1854	Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100405.	0.7	6
1855	Clinicopathological and Prognostic Analysis of PD-L1 and PD-L2 Expression in Surgically Resected Primary Tongue Squamous Cell Carcinoma. <i>Anticancer Research</i> , 2021, 41, 101-111.	0.5	7
1856	PD-L1 testing in advanced stage lung cancer using cytology samples: Suitability and reporting issues. Comparison between two tertiary referral centers. <i>Annals of Cytology and Pathology</i> , 2021, , 001-006.	0.3	0
1857	Pharmacologically Modified Dendritic Cells: A Route to Tolerance-associated Genes. , 0, , 619-647.		1
1858	Immune System, Inflammation, and Essential Fatty Acids and Their Metabolites in Cancer. , 2020, , 67-157.		1
1859	High-Dimensional Flow Cytometry Analysis of Regulatory Receptors on Human T Cells, NK Cells, and NKT Cells. <i>Methods in Molecular Biology</i> , 2021, 2194, 255-290.	0.4	2
1860	Modulation of T-Cell Mediated Immunity by Cytomegalovirus. , 2012, , 121-139.		3
1861	Immunological Targets for Immunotherapy: Inhibitory T Cell Receptors. <i>Methods in Molecular Biology</i> , 2020, 2055, 23-60.	0.4	12
1862	Inhibitory RNA Molecules in Immunotherapy for Cancer. <i>Methods in Molecular Biology</i> , 2010, 623, 325-339.	0.4	9
1863	Organ Transplantation: Modulation of T-Cell Activation Pathways Initiated by Cell Surface Receptors to Suppress Graft Rejection. <i>Methods in Molecular Biology</i> , 2010, 677, 419-430.	0.4	2
1864	Small Molecule Inhibition of Glycogen Synthase Kinase-3 in Cancer Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1164, 225-233.	0.8	9
1865	Immune-Related Adverse Events: Pneumonitis. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 255-269.	0.8	38

#	ARTICLE	IF	CITATIONS
1866	MicroRNAs in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1277, 1-31.	0.8	12
1867	Phosphorylation: A Fast Switch For Checkpoint Signaling. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 347-398.	0.8	2
1868	Checkpoints Under Traffic Control: From and to Organelles. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 431-453.	0.8	8
1869	Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 33-59.	0.8	232
1870	Spatiotemporal Changes in Checkpoint Molecule Expression. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 167-200.	0.8	5
1871	Co-signal Molecules in T-Cell Activation. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1189, 3-23.	0.8	45
1872	Cancer Immunotherapy Targeting Co-signal Molecules. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1189, 313-326.	0.8	4
1873	Signal Transduction Via Co-stimulatory and Co-inhibitory Receptors. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1189, 85-133.	0.8	14
1874	Control of Regulatory T Cells by Co-signal Molecules. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1189, 179-210.	0.8	25
1875	<i>Cancer Immunology</i> . , 2014, , 78-97.e5.		3
1876	Inmunoterapia en cncer cutneo no melanoma. <i>Actas Dermo-sifiliogrficas</i> , 2019, 110, 353-359.	0.2	4
1877	Epitope and Paratope Mapping of PD-1/Nivolumab by Mass Spectrometry-Based Hydrogen-Deuterium Exchange, Cross-linking, and Molecular Docking. <i>Analytical Chemistry</i> , 2020, 92, 9086-9094.	3.2	38
1878	Antigen-presenting cells and tolerance induction. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2002, 57, 2-8.	2.7	14
1879	Prognostic relevance of programmed cell death 1 ligand 2 (PDCD1LG2/PD-L2) in patients with advanced stage colon carcinoma treated with chemotherapy. <i>Scientific Reports</i> , 2020, 10, 22330.	1.6	13
1880	Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. <i>Microcirculation</i> , 2002, 9, 133-45.	1.0	146
1881	p110 PI3K as a therapeutic target of solid tumours. <i>Clinical Science</i> , 2020, 134, 1377-1397.	1.8	15
1882	PD-1 and BTLA regulate T cell signaling differentially and only partially through SHP1 and SHP2. <i>Journal of Cell Biology</i> , 2020, 219, .	2.3	65
1883	PD-1+ Monocytes Mediate Cerebral Vasospasm Following Subarachnoid Hemorrhage. <i>Neurosurgery</i> , 2021, 88, 855-863.	0.6	11

#	ARTICLE	IF	CITATIONS
1887	PD-L1 and calcitriol-dependent liposomal antigen-specific regulation of systemic inflammatory autoimmune disease. <i>JCI Insight</i> , 2019, 4, .	2.3	51
1888	Activation and inhibition of lymphocytes by costimulation. <i>Journal of Clinical Investigation</i> , 2002, 109, 295-299.	3.9	249
1889	Dendritic cell NLRC4 regulates influenza A virus-specific CD4+ T cell responses through FasL expression. <i>Journal of Clinical Investigation</i> , 2019, 129, 2888-2897.	3.9	18
1890	Immunotherapy transforms cancer treatment. <i>Journal of Clinical Investigation</i> , 2018, 129, 46-47.	3.9	34
1891	Time to dissect the autoimmune etiology of cancer antibody immunotherapy. <i>Journal of Clinical Investigation</i> , 2020, 130, 51-61.	3.9	66
1892	Activation and inhibition of lymphocytes by costimulation. <i>Journal of Clinical Investigation</i> , 2002, 109, 295-299.	3.9	140
1893	VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. <i>Journal of Clinical Investigation</i> , 2006, 116, 2817-2826.	3.9	218
1894	PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T cells in mice. <i>Journal of Clinical Investigation</i> , 2013, 123, 2629-2642.	3.9	57
1895	Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. <i>Journal of Clinical Investigation</i> , 2016, 126, 2642-2660.	3.9	81
1896	Analysis of PDL1 expression and T cells infiltration in 1014 gastric cancer patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, 50-50.	0.8	1
1897	Experimental Persistent Infection of BALB/c Mice with Small-Colony Variants of <i>Burkholderia pseudomallei</i> Leads to Concurrent Upregulation of PD-1 on T Cells and Skewed Th1 and Th17 Responses. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004503.	1.3	15
1898	T Cells from Programmed Death-1 Deficient Mice Respond Poorly to <i>Mycobacterium tuberculosis</i> Infection. <i>PLoS ONE</i> , 2011, 6, e19864.	1.1	74
1900	Cloning and Characterization of Porcine 4lg-B7-H3: A Potent Inhibitor of Porcine T-Cell Activation. <i>PLoS ONE</i> , 2011, 6, e21341.	1.1	6
1901	Programmed Death-1 and Its Ligand Are Novel Immunotolerant Molecules Expressed on Leukemic B Cells in Chronic Lymphocytic Leukemia. <i>PLoS ONE</i> , 2012, 7, e35178.	1.1	68
1902	Polymorphic Sites at the Immunoregulatory CTLA-4 Gene Are Associated with Chronic Chagas Disease and Its Clinical Manifestations. <i>PLoS ONE</i> , 2013, 8, e78367.	1.1	19
1903	A Quantitative Assessment of Costimulation and Phosphatase Activity on Microclusters in Early T Cell Signaling. <i>PLoS ONE</i> , 2013, 8, e79277.	1.1	4
1904	PD-L1 Expression on Circulating CD34 <sup>+</sup> Hematopoietic Stem Cells Closely Correlated with T-cell Apoptosis in Chronic Hepatitis C Infected Patients. <i>International Journal of Stem Cells</i> , 2018, 11, 78-86.	0.8	10
1905	Immune Checkpoint Inhibitors in the Treatment of Melanoma: From Basic Science to Clinical Application. , 0, , 121-142.		31



#	ARTICLE	IF	CITATIONS
1906	Costimulation Signals for Memory CD8+ T Cells During Viral Infections. <i>Critical Reviews in Immunology</i> , 2009, 29, 469-486.	1.0	57
1907	The Role of Novel T Cell Costimulatory Pathways in Autoimmunity and Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 559-575.	3.0	141
1908	Modern approaches to kidney cancer immunotherapy. <i>Onkourologiya</i> , 2018, 14, 54-67.	0.1	15
1909	Adaptive selection in the evolution of programmed cell death-1 and its ligands in vertebrates. <i>Aging</i> , 2020, 12, 3516-3557.	1.4	14
1910	Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor. <i>Oncotarget</i> , 2016, 7, 64967-64976.	0.8	42
1911	PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma. <i>Oncotarget</i> , 2016, 7, 72961-72977.	0.8	258
1912	Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic. <i>Oncotarget</i> , 2017, 8, 14416-14427.	0.8	70
1913	PD-1 mRNA expression in peripheral blood cells and its modulation characteristics in cancer patients. <i>Oncotarget</i> , 2017, 8, 50782-50791.	0.8	10
1914	Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody. <i>Oncotarget</i> , 2017, 8, 20558-20571.	0.8	49
1915	Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer. <i>Oncotarget</i> , 2017, 8, 97671-97682.	0.8	254
1916	PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer. <i>Oncotarget</i> , 2017, 8, 64066-64082.	0.8	62
1917	Prognostic value of PD-L1 expression in patients with primary solid tumors. <i>Oncotarget</i> , 2018, 9, 5058-5072.	0.8	47
1918	Prognostic values of the mRNA expression of natural killer receptor ligands and their association with clinicopathological features in breast cancer patients. <i>Oncotarget</i> , 2018, 9, 27171-27196.	0.8	7
1919	A structural model of the immune checkpoint CD160-HVEM complex derived from HDX-mass spectrometry and molecular modeling. <i>Oncotarget</i> , 2019, 10, 536-550.	0.8	6
1920	Preliminary observations on soluble programmed cell death protein-1 as a prognostic and predictive biomarker in patients with metastatic melanoma treated with patient-specific autologous vaccines. <i>Oncotarget</i> , 2019, 10, 5359-5371.	0.8	4
1921	The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients. <i>Oncotarget</i> , 2015, 6, 19393-19404.	0.8	61
1922	Differential Roles of Costimulatory Signaling Pathways in Type 1 Diabetes Mellitus. <i>Review of Diabetic Studies</i> , 2004, 1, 156-156.	0.5	7
1923	Costimulation and Pancreatic Autoimmunity: The PD-1/PD-L Conundrum. <i>Review of Diabetic Studies</i> , 2006, 3, 6-6.	0.5	10

#	ARTICLE	IF	CITATIONS
1924	HBV and HIV/HBV Infected Patients Have Distinct Immune Exhaustion and Apoptotic Serum Biomarker Profiles. <i>Pathogens and Immunity</i> , 2019, 4, 39.	1.4	16
1925	Melanoma immunotherapy dominates the field. <i>Annals of Translational Medicine</i> , 2016, 4, 269-269.	0.7	19
1926	Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma. <i>Current Medicinal Chemistry</i> , 2019, 26, 5968-5981.	1.2	6
1927	Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules. <i>Current Medicinal Chemistry</i> , 2020, 27, 2402-2448.	1.2	12
1928	B7-H3 Immune Checkpoint Protein in Human Cancer. <i>Current Medicinal Chemistry</i> , 2020, 27, 4062-4086.	1.2	50
1929	Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia. <i>Current Drug Targets</i> , 2017, 18, 315-331.	1.0	39
1930	Modulating Co-Stimulation During Antigen Presentation to Enhance Cancer Immunotherapy. <i>Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry</i> , 2012, 12, 224-235.	0.5	45
1931	Stimulation of Human CD4+ T Lymphocytes via TLR3, TLR5 and TLR7/8 Up-Regulates Expression of Costimulatory and Modulates Proliferation. <i>Open Microbiology Journal</i> , 2009, 3, 1-8.	0.2	17
1932	PD-L1 Expression Is a Prognostic Factor in Patients with Thoracic Esophageal Cancer Treated Without Adjuvant Chemotherapy. <i>Anticancer Research</i> , 2017, 37, 1433-1442.	0.5	30
1934	Immunoterapia z uÅ¼yciem przeciwciaÅ, monoklonalnych ukierunkowanych na szlak PD-1/PD-L1 w chorobach nowotworowych. <i>Acta Haematologica Polonica</i> , 2018, 49, 207-227.	0.1	5
1935	Immunomodulatory effects of Tim-3 and PD-1 on chronic hepatitis B virus infection. <i>Infection International</i> , 2018, 7, 6-11.	0.1	1
1936	Experimental advances in understanding allergic airway inflammation. <i>Frontiers in Bioscience - Scholar</i> , 2013, S5, 167-180.	0.8	3
1937	Diagnostic and prognostic utility of PD-1 in B cell lymphomas. <i>Disease Markers</i> , 2010, 29, 47-53.	0.6	53
1938	Hepatoma cells up-regulate expression of programmed cell death-1 on T cells. <i>World Journal of Gastroenterology</i> , 2008, 14, 6853.	1.4	11
1939	Costimulatory molecule programmed death-1 in the cytotoxic response during chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2009, 15, 5129.	1.4	18
1940	Viro-immune therapy: A new strategy for treatment of pancreatic cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 748.	1.4	16
1941	Specific CD8 <sup>+</sup> T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis. <i>World Journal of Gastroenterology</i> , 2016, 22, 6469.	1.4	53
1942	Programmed death ligand-1 expression and its prognostic role in esophageal squamous cell carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 8389.	1.4	22

#	ARTICLE	IF	CITATIONS
1944	Recombinant programmed cell death 1 inhibits psoriatic inflammation in imiquimod-treated mice. <i>International Journal of Molecular Medicine</i> , 2020, 46, 869-879.	1.8	8
1945	TNF-mediated epithelial-to-mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma. <i>Molecular Medicine Reports</i> , 2020, 21, 1849-1860.	1.1	19
1946	Immunotherapy a New Hope for Cancer Treatment: A Review. <i>Pakistan Journal of Biological Sciences</i> , 2018, 21, 135-150.	0.2	21
1947	Immunotherapy in lung cancer. <i>Translational Lung Cancer Research</i> , 2014, 3, 2-14.	1.3	53
1948	Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role. <i>Translational Lung Cancer Research</i> , 2015, 4, 728-42.	1.3	48
1949	Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer. <i>Translational Lung Cancer Research</i> , 2015, 4, 756-62.	1.3	8
1950	Predictive factors for immunotherapy in melanoma. <i>Annals of Translational Medicine</i> , 2015, 3, 208.	0.7	27
1951	Immunotherapy in breast cancer. <i>Journal of Carcinogenesis</i> , 2019, 18, 2.	2.5	56
1952	Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma. <i>Journal of Cancer Research and Therapeutics</i> , 2018, 14, 1167-1175.	0.3	51
1953	The Promise of PD-1 Signaling Pathway for Cancer Immunotherapy. <i>Journal of Clinical &amp; Cellular Immunology</i> , 2012, 03, .	1.5	2
1954	IFN- $\gamma$ , IL-4, IL-17, PD-1-Expressing T Cells and B Cells in Peripheral Blood from Tuberculosis Patients. <i>Advances in Microbiology</i> , 2012, 02, 426-435.	0.3	3
1955	Medical treatment for gastro-entero-pancreatic neuroendocrine tumours. <i>World Journal of Gastrointestinal Oncology</i> , 2016, 8, 389.	0.8	20
1956	Association of a PD-L2 Gene Polymorphism with Chronic Lymphatic Filariasis in a South Indian Cohort. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 100, 344-350.	0.6	3
1957	CD28/CTLA-4/B7 and CD40/CD40L costimulation and activation of regulatory T cells. <i>World Journal of Immunology</i> , 2014, 4, 63.	0.5	3
1958	B cells with regulatory properties in transplantation tolerance. <i>World Journal of Transplantation</i> , 2015, 5, 196.	0.6	23
1959	Assays for predicting and monitoring responses to lung cancer immunotherapy. <i>Cancer Biology and Medicine</i> , 2015, 12, 87-95.	1.4	35
1960	Effect of Programmed Death-Ligand 1 in Cancer-Associated Fibroblasts on Advanced Laryngeal Squamous Cell Carcinoma. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110464.	0.8	0
1962	Evolutionary transcriptomics implicates new genes and pathways in human pregnancy and adverse pregnancy outcomes. <i>ELife</i> , 2021, 10, .	2.8	23

#	ARTICLE	IF	CITATIONS
1963	Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer. <i>Cancers</i> , 2021, 13, 5225.	1.7	8
1964	Nature vs. Nurture: The Two Opposing Behaviors of Cytotoxic T Lymphocytes in the Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11221.	1.8	9
1965	Stem cells from exfoliated deciduous teeth transplantation ameliorates Sjögren's syndrome by secreting soluble PD-L1. <i>Journal of Leukocyte Biology</i> , 2022, 111, 1043-1055.	1.5	10
1966	Review of the recent clinical trials for PD-1/PD-L1 based lung cancer immunotherapy. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1355-1370.	1.1	6
1967	PD-L2 glycosylation promotes immune evasion and predicts anti-EGFR efficacy. , 2021, 9, e002699.		28
1968	Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. <i>Cell</i> , 2021, 184, 5309-5337.	13.5	588
1969	Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses. <i>Cancer Immunology Research</i> , 2021, 9, 1465-1475.	1.6	8
1970	Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets. <i>Molecular Biology Reports</i> , 2021, 48, 8075-8095.	1.0	40
1971	Immunotherapy of cancer tumors with inhibition of PD-1 membrane protein and its ligands interaction. <i>Acta Biomedica Scientifica</i> , 2021, 6, 146-159.	0.1	0
1972	Molecular and Genetic Immune Biomarkers of Primary and Immune-Therapy Induced Hypophysitis: From Laboratories to the Clinical Practice. <i>Journal of Personalized Medicine</i> , 2021, 11, 1026.	1.1	6
1973	The modulatory effect of crotoxin and its phospholipase A2 subunit from <i>Crotalus durissus terrificus</i> venom on dendritic cells interferes with the generation of effector CD4+ T lymphocytes. <i>Immunology Letters</i> , 2021, 240, 56-70.	1.1	5
1974	Development and Inhibition of Th2 Responses. <i>Lung Biology in Health and Disease</i> , 2002, , 247-291.	0.1	0
1975	Mast Cells. <i>Annual Review of Immunology</i> , 0, , .	9.5	0
1976	Costimulatory Molecules in T Cell Activation and Transplantation. , 2004, , 291-312.		0
1977	ORIGINS OF ANTINUCLEAR ANTIBODIES. , 2004, , 401-431.		5
1979	Co-stimulation Regulation of Immune Tolerance and Autoimmunity. , 2007, , 121-138.		0
1980	Harnessing the Power of Immunity to Battle Cancer: Much Ado about Nothing or All's Well That Ends Well?. , 2008, , 293-306.		0
1981	New Approaches for Optimizing Melanoma Vaccines. <i>Translational Medicine Series</i> , 2008, , 143-160.	0.0	1

#	ARTICLE	IF	CITATIONS
1982	Restoring Host Antitumoral Immunity: How Coregulatory Molecules Are Changing the Approach to the Management of Renal Cell Carcinoma. , 2009, , 367-403.		0
1983	Targeting Immunological Synapse: New Horizons in Immunotherapy for Cancer. , 2009, , 575-590.		0
1984	Immune Tolerance. , 2009, , 653-664.		0
1986	Transplantation Immunobiology. , 2009, , 1835-1866.		1
1987	Immune Cell Communication and Signaling Systems in Liver Disease. , 2010, , 117-146.		0
1989	The Role of T-Cell Costimulatory Pathways in Regulation of Autoimmune Diabetes. Journal of Clinical & Cellular Immunology, 2011, , .	1.5	0
1990	Cell Surface Co-signaling Molecules in the Control of Innate and Adaptive Cancer Immunity. , 2012, , 251-266.		0
1991	Developing Cancer Immunotherapies by the manipulation of Immune Checkpoints. IOSR Journal of Pharmacy, 2012, 2, 01-08.	0.1	0
1992	Immune Pathogenesis of Viral Hepatitis B and C. , 2012, , 111-128.		1
1993	Tolerogenic Dendritic Cells for Therapy of Immune-Mediated Inflammatory Diseases. , 0, , .		0
1994	The Role of Polymorphisms in Co-Signalling Moleculesâ€™ Genes in Susceptibility to B-Cell Chronic Lymphocytic Leukaemia. , 0, , .		1
1995	PD-1 Expression in LPS-Induced Raw264.7 Cells Is Regulated via Co-activation of Transcription Factor NF-Î²B and IRF-1. Korean Journal of Microbiology, 2013, 49, 301-308.	0.2	0
1996	Novel Targeted Therapies in Ovarian Cancer. Journal of Cancer Science & Therapy, 2014, 06, .	1.7	0
1997	PD-1. , 2014, , 1-7.		0
1998	Dendritic Cell-Based Cancer Vaccines. , 2014, , 69-87.		0
1999	Overcoming Cancer Tolerance with Immune Checkpoint Blockade. , 2015, , 87-129.		0
2000	Immunology of Pediatric Renal Transplantation. , 2015, , 1-51.		0
2001	Inflammation and Lung Cancer: Addressing Inflammation with Immunotherapy. , 2015, , 191-209.		0

#	ARTICLE	IF	CITATIONS
2002	Programmed Cell Death-1 Polymorphism rs11568821 is a predictor of Treatment Outcome in Chronic HCV Genotype 4 Infection. <i>Gastroenterology &amp; Hepatology (Bartlesville, Okla )</i> , 2015, 2, .	0.0	0
2003	Immune Microenvironment and its Therapeutic Implication in Non-Small Cell Lung Carcinoma: Literature Review. <i>Journal of Clinical &amp; Cellular Immunology</i> , 2015, 05, .	1.5	0
2004	Indoleamine 2,3-Dioxygenase-Competent Regulatory Dendritic Cells and Their Role in Alloimmune Regulation and Transplant Immune Tolerance. <i>Molecular and Integrative Toxicology</i> , 2015, , 335-360.	0.5	1
2005	T Cell Modulation: Anti-PD-1 Antibodies for the Treatment of Cancer. <i>Cancer Drug Discovery and Development</i> , 2015, , 231-244.	0.2	0
2006	Managing Advanced Melanoma: Targeting the PD-1 Pathway with Pembrolizumab. <i>Cancer Research Frontiers</i> , 2015, 1, 127-137.	0.2	0
2007	Immunology of Pediatric Renal Transplantation. , 2016, , 2457-2500.		0
2008	The Multifaceted Role of PD-1 in Health and Disease. , 2016, , 441-457.		0
2009	Responses and response evaluation of immune checkpoint inhibitors in lymphoma. <i>Annals of Lymphoma</i> , 0, 1, 1-1.	4.5	0
2010	Multipl miyelomâ€™da CD4+ regÃ¼latÃ¶r T hÃ¼crelerin rolÃ¼. <i>Åžukurova Åœniversitesi TÃ°p FakÃ¼ltesi Dergisi</i> , 2017, 42, 546-551.	0.0	0
2011	Immunotherapy Approaches to Breast Cancer. <i>Current Breast Cancer Reports</i> , 2017, 9, 227-235.	0.5	0
2012	Side Effects of Systemic Therapy and Their Clinical Management. , 2018, , 1-17.		0
2013	Programmed death-1 (PD-1) ligand 1 and PD-1 ligand 2 expressions and their clinical relevance in colorectal cancer. <i>Korean Journal of Clinical Oncology</i> , 2017, 13, 131-137.	0.1	0
2014	Front line of cancer immunotherapy development. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2017, 106, 2645-2658.	0.0	0
2015	Immunotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC). <i>Current Cancer Research</i> , 2018, , 365-396.	0.2	0
2016	New Development of Cancer Immunotherapy : History of Immunity Check Inhibitors Focusing on Programmed Death-1 (PD-1). <i>Japanese Journal of Neurosurgery</i> , 2018, 27, 712-722.	0.0	0
2017	Construction and Identification of Eukaryotic Expression Vector of Human Programmed Death Receptor 1. <i>Bioprocess</i> , 2018, 08, 55-60.	0.1	0
2018	PD-1. , 2018, , 1627-1632.		0
2020	The investigation of PD-L1 expression as a prognostic marker for uterine sarcoma.. <i>Morphologia</i> , 2018, 12, 62-71.	0.1	0

#	ARTICLE	IF	CITATIONS
2022	Innate and Adaptive Immune Responses to Cancer. , 2019, , 111-159.		3
2023	Immunotherapy in Breast Cancer. , 2019, , 541-552.		1
2024	Nivolumab (Opdivo). , 2019, , 255-283.		1
2025	A new strategy for fighting cancer, or how the "brake" of the immune system works. Visnik Nacional Noi Akademii Nauk Ukraini, 2019, , 44-57.	0.0	0
2026	PD-1 Research: History and Future Perspectives. Trends in the Sciences, 2019, 24, 2_8-2_14.	0.0	0
2028	Nivolumab-. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 1766-1771.	0.0	0
2029	GASTRIC CANCER IMMUNOTHERAPY. , 2019, 18, 6-16.	0.3	0
2030	Systemic Therapy for Esophageal Squamous Cell Carcinoma. Methods in Molecular Biology, 2020, 2129, 321-333.	0.4	1
2031	Immunotherapy in Pediatric Solid Tumors. Clinical Pediatric Hematology-Oncology, 2020, 27, 22-31.	0.0	1
2034	A REVIEW OF MODERN IMMUNOTHERAPY IN GASTROINTESTINAL MALIGNANT TUMORS. EurasianUnionofScientists, 2020, 6, 9-21.	0.0	0
2036	Overcoming Cancer Tolerance with Immune Checkpoint Blockade. , 2021, , 85-128.		0
2037	EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses. Pharmaceuticals, 2021, 14, 1081.	1.7	37
2038	Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis. Frontiers in Immunology, 2021, 12, 768957.	2.2	22
2039	The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10"IL-10R Pathways in Acute Myeloid Leukemia. Pharmaceuticals, 2021, 14, 1105.	1.7	6
2040	Programmed Cell Death Protein Ligand 2 Is a Potential Biomarker That Predicts the Efficacy of Immunotherapy. Disease Markers, 2021, 2021, 1-10.	0.6	2
2041	Stimulation of the PD-1 Pathway Decreases Atherosclerotic Lesion Development in Ldlr Deficient Mice. Frontiers in Cardiovascular Medicine, 2021, 8, 740531.	1.1	10
2043	Lentinan, a Shiitake Mushroom "Glucan, Downregulates the Enhanced PD-L1 Expression Induced by Platinum Compounds in Gastric Cancer Cells -. Journal of Analytical Oncology, 0, 9, 1-10.	0.1	2
2044	Companion Diagnostics and Clinical Biomarkers for Immunotherapy. , 2021, , 137-152.		0

#	ARTICLE	IF	CITATIONS
2045	Comprehensive assessment of PD-L1 and PD-L2 dysregulation in gastrointestinal cancers. <i>Epigenomics</i> , 2020, 12, 2155-2171.	1.0	4
2046	The Mechanism and Management of Adverse Cardiac Reactions Induced by Immune Checkpoint Inhibitors Therapy. <i>Cardiology Research and Practice</i> , 2020, 2020, 1-5.	0.5	0
2048	Immunotherapy and Radiosurgery. , 2020, , 423-436.		0
2049	Immune Targets in Colorectal Cancer. <i>Diagnostics and Therapeutic Advances in GI Malignancies</i> , 2020, , 205-230.	0.2	0
2050	Non-melanoma Skin Cancer and Cutaneous Melanoma from the Oncological Point of View. , 2020, , 41-68.		0
2051	Cancer immunotherapy. <i>Diagnostyka Laboratoryjna I Wiadomości PTDL</i> , 2020, 55, 61-66.	0.0	0
2052	Exploration of the personalized immune checkpoint atlas of plasma cell dyscrasias patients using high-dimensional single-cell analysis. <i>Oncology Reports</i> , 2020, 44, 224-240.	1.2	1
2053	Light-controlled elimination of PD-L1+ cells. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2021, 225, 112355.	1.7	5
2054	Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity. <i>Nature Communications</i> , 2021, 12, 6360.	5.8	23
2055	Moving towards the Future of Radio-Immunotherapy: Could We Tailor the Abscopal Effect on Head and Neck Cancer Patients?. <i>Immuno</i> , 2021, 1, 410-423.	0.6	1
2056	Co-Receptors in the Positive and Negative Regulation of T-Cell Immunity. , 2008, , 221-245.		0
2058	Contribution of B7-H1/PD-1 Co-inhibitory Pathway to T-Cell Dysfunction in Cancer. , 2008, , 29-40.		0
2059	T Cells and Antigen Recognition. , 2007, , 33-53.		0
2060	Tumor Immune Escape Mechanisms. , 2006, , 577-602.		2
2061	Immunogenetic Factors in Autoimmunity. , 2007, , 17-34.		0
2062	Immunoregulatory role of B7-H1 in chronicity of inflammatory responses. <i>Cellular and Molecular Immunology</i> , 2006, 3, 179-87.	4.8	65
2065	Finding Balance: T cell Regulatory Receptor Expression during Aging. , 2011, 2, 398-413.		16
2068	T cell coinhibition and immunotherapy in human breast cancer. <i>Discovery Medicine</i> , 2012, 14, 229-36.	0.5	28



#	ARTICLE	IF	CITATIONS
2069	T cell costimulation and coinhibition: genetics and disease. <i>Discovery Medicine</i> , 2011, 12, 119-28.	0.5	21
2070	Programmed Death 1 (PD-1) is involved in the development of proliferative diabetic retinopathy by mediating activation-induced apoptosis. <i>Molecular Vision</i> , 2015, 21, 901-10.	1.1	5
2071	Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 11084-91.	0.5	66
2072	PD-1, PD-L1 and PD-L2 expression in mouse prostate cancer. <i>American Journal of Clinical and Experimental Urology</i> , 2016, 4, 1-8.	0.4	22
2073	Prokaryotic expression of the extracellular domain of porcine programmed death 1 (PD-1) and its ligand PD-L1 and identification of the binding with peripheral blood mononuclear cells. <i>Canadian Journal of Veterinary Research</i> , 2017, 81, 147-154.	0.2	3
2075	Editors' Choice Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity. <i>Nagoya Journal of Medical Science</i> , 2019, 81, 1-18.	0.6	18
2076	Experimental model for the irradiation-mediated abscopal effect and factors influencing this effect. <i>American Journal of Cancer Research</i> , 2020, 10, 440-453.	1.4	6
2077	FRA1 contributes to MEK-ERK pathway-dependent PD-L1 upregulation by KRAS mutation in premalignant human bronchial epithelial cells. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 409-427.	0.0	7
2079	Editors' Choice Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity. <i>Nagoya Journal of Medical Science</i> , 2019, 81, 1-18.	0.6	18
2080	Impact of DNA Damage Response-Targeted Therapies on the Immune Response to Tumours. <i>Cancers</i> , 2021, 13, 6008.	1.7	5
2081	Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 5275-5291.	1.0	5
2082	Molecular and Clinical Characterization of a Novel Prognostic and Immunologic Biomarker GPSM3 in Low-Grade Gliomas. <i>Brain Sciences</i> , 2021, 11, 1529.	1.1	1
2083	Topical application of fucoïdan derived from <i>Cladosiphon okamuranus</i> alleviates atopic dermatitis symptoms through immunomodulation. <i>International Immunopharmacology</i> , 2021, 101, 108362.	1.7	5
2084	PD-L1 blockade exhibits anti-tumor effect on brain metastasis by activating CD8+ T cells in hematogenous metastasis model with lymphocyte infusion. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 335-344.	1.7	0
2085	Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorectal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 764618.	1.3	17
2086	Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 749064.	1.3	17
2087	PD-L1 and PD-L2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma. <i>Cancer Science</i> , 2022, 113, 399-410.	1.7	12
2088	Immune Checkpoints and Innate Lymphoid Cells—New Avenues for Cancer Immunotherapy. <i>Cancers</i> , 2021, 13, 5967.	1.7	11

#	ARTICLE	IF	CITATIONS
2090	An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 273-295.	0.8	1
2091	Pulmonary Toxicities of Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 357-375.	0.8	4
2092	Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer. <i>Cancers</i> , 2022, 14, 307.	1.7	20
2093	Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise. <i>Diagnostics</i> , 2022, 12, 124.	1.3	12
2094	The changing clinical spectrum of endocrine adverse events in cancer immunotherapy. <i>Trends in Endocrinology and Metabolism</i> , 2022, 33, 87-104.	3.1	11
2095	Neoadjuvant chemotherapy for upper tract urothelial carcinoma. <i>Translational Cancer Research</i> , 2020, 9, 6576-6582.	0.4	2
2096	PD1/PD-L1 pathway in psoriasis and psoriatic arthritis: a review. <i>Postepy Dermatologii I Alergologii</i> , 2021, 38, 925-930.	0.4	6
2097	Endocrine Complications of Biological Cancer Therapies. , 2022, , 1775-1778.		0
2098	Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases. <i>Frontiers in Pharmacology</i> , 2021, 12, 790963.	1.6	17
2099	A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy. <i>Applied Bionics and Biomechanics</i> , 2022, 2022, 1-6.	0.5	5
2100	Immunomodulatory potential of natural products from herbal medicines as immune checkpoints inhibitors: Helping to fight against cancer via multiple targets. <i>Medicinal Research Reviews</i> , 2022, 42, 1246-1279.	5.0	38
2101	Blocking the inhibitory receptor programmed cell death 1 prevents allergic immune response and anaphylaxis in mice. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 178-191.e9.	1.5	5
2102	Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on "Off-the-Shelf" T Cell Therapy Using iPSC Technology and Gene Editing. <i>Cells</i> , 2022, 11, 269.	1.8	10
2103	Combination of genetically engineered T cells and immune checkpoint blockade for the treatment of cancer. <i>Immunotherapy Advances</i> , 2022, 2, .	1.2	8
2104	Immune-related adverse events in various organs caused by immune checkpoint inhibitors. <i>Allergology International</i> , 2022, 71, 169-178.	1.4	34
2105	Soluble programmed cell death-1 predicts hepatocellular carcinoma development during nucleoside analogue treatment. <i>Scientific Reports</i> , 2022, 12, 105.	1.6	3
2106	B7 immune checkpoint family members as putative therapeutics in autoimmune disease: An updated overview. <i>International Journal of Rheumatic Diseases</i> , 2022, 25, 259-271.	0.9	4
2107	<sc>PD-L1</sc> overexpression correlates with <sc>JAK2</sc> mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2022, 97, 390-400.	2.0	8

#	ARTICLE	IF	CITATIONS
2108	Programmed death ligand 1 signals in cancer cells. <i>Nature Reviews Cancer</i> , 2022, 22, 174-189.	12.8	133
2109	Soluble PD-L1 as an early marker of progressive disease on nivolumab. , 2022, 10, e003527.		35
2110	Immune checkpoint inhibitors for the treatment of melanoma. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 563-576.	1.4	10
2111	Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 405-412.	0.9	35
2112	Immune Checkpoint Therapies and Atherosclerosis: Mechanisms and Clinical Implications. <i>Journal of the American College of Cardiology</i> , 2022, 79, 577-593.	1.2	34
2113	Molecular basis of PD-1 blockade by dostarlimab, the FDA-approved antibody for cancer immunotherapy. <i>Biochemical and Biophysical Research Communications</i> , 2022, 599, 31-37.	1.0	13
2114	A Randomized Phase II Study Comparing Nivolumab with Carboplatin + Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L). <i>Clinical Cancer Research</i> , 2022, 28, 893-902.	3.2	35
2115	T cell costimulation, checkpoint inhibitors and anti-tumor therapy. <i>Journal of Biosciences</i> , 2020, 45, .	0.5	6
2116	A New Standard of Care: Pembrolizumab in Programmed Death-ligand 1 Positive, Metastatic, Triple-negative Breast Cancer. <i>Touch Reviews in Oncology &amp; Haematology</i> , 2021, 17, 60.	0.1	0
2117	New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials. <i>International Journal of Biological Sciences</i> , 2022, 18, 2775-2794.	2.6	27
2118	Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy. <i>Immune Network</i> , 2022, 22, e2.	1.6	53
2119	Effects of PD-1 Signaling on Immunometabolic Reprogramming. <i>Immunometabolism</i> , 2022, 4, .	0.7	10
2120	Unraveling a Conserved Conformation of the FG Loop upon the Binding of Natural Ligands to the Human and Murine PD1. <i>Journal of Physical Chemistry B</i> , 2022, 126, 1441-1446.	1.2	1
2122	Immune checkpoint expression and relationships to anti-PD-L1 immune checkpoint blockade cancer immunotherapy efficacy in aged versus young mice. <i>Ageing and Cancer</i> , 2022, 3, 68-83.	0.5	5
2123	Tumor Microenvironment and Microvascular Density in Follicular Lymphoma. <i>Journal of Clinical Medicine</i> , 2022, 11, 1257.	1.0	5
2124	Anti-PD-1 Monoclonal Antibody Combined With Anti-VEGF Agent Is Safe and Effective in Patients With Recurrent/Metastatic Head and Neck Squamous Cancer as Second-Line or Beyond Treatment. <i>Frontiers in Oncology</i> , 2022, 12, 781348.	1.3	6
2125	Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. <i>Journal of Hematology and Oncology</i> , 2022, 15, 24.	6.9	136
2126	Programmed Cell Death-1 and Its Ligands as Targets for Therapy of Multiple Myeloma Patients. <i>Cancer Management and Research</i> , 2022, Volume 14, 1267-1281.	0.9	0

#	ARTICLE	IF	CITATIONS
2127	A novel peptide-based probe <sup>99m</sup> Tc-PEG6-RD-PDP2 for the molecular imaging of tumor PD-L2 expression. <i>Chinese Chemical Letters</i> , 2022, 33, 3497-3501.	4.8	2
2128	Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-“programmed cell death protein-1 (PD-1) antibody, in human cancer models. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 515-527.	1.1	7
2129	Nanotechnology in Immunotherapy for Type 1 Diabetes: Promising Innovations and Future Advances. <i>Pharmaceutics</i> , 2022, 14, 644.	2.0	3
2131	Checkpoint Inhibitor Pneumonitis Induced by Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer: Occurrence and Mechanism. <i>Frontiers in Immunology</i> , 2022, 13, 830631.	2.2	28
2132	Dendritic cell-based cancer immunotherapy in the era of immune checkpoint inhibitors: From bench to bedside. <i>Life Sciences</i> , 2022, 297, 120466.	2.0	18
2133	Formation of necrotizing vasculitis in the patient with diffuse B-cell large cell lymphoma on immune checkpoint inhibitor (PD-1) therapy. <i>HERALD of North-Western State Medical University Named After I I Mechnikov</i> , 2021, 13, 83-90.	0.1	0
2134	Structural basis of HLX10 PD-1 receptor recognition, a promising anti-PD-1 antibody clinical candidate for cancer immunotherapy. <i>PLoS ONE</i> , 2021, 16, e0257972.	1.1	15
2135	What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?. <i>Frontiers in Immunology</i> , 2021, 12, 773168.	2.2	18
2136	Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment. <i>Cancers</i> , 2021, 13, 6231.	1.7	13
2137	Advances in targeting programmed cell death 1/programmed cell death-ligand 1 therapy for hematological malignancies. <i>Aging Pathobiology and Therapeutics</i> , 2021, 3, 84-94.	0.3	0
2138	The foundations of immune checkpoint blockade and the ipilimumab approval decennial. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 509-528.	21.5	201
2139	Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer. <i>Cells</i> , 2021, 10, 3408.	1.8	4
2140	Immunotherapy Resistance in Glioblastoma. <i>Frontiers in Genetics</i> , 2021, 12, 750675.	1.1	13
2141	Blockade of B7-H1 and PD-1 by Monoclonal Antibodies Potentiates Cancer Therapeutic Immunity. <i>Cancer Research</i> , 2005, 65, 1089-1096.	0.4	819
2142	Autoimmunity regulation within the tumor microenvironment. , 2022, , 51-71.		0
2143	Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	0.6	1
2144	A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2022, 63, 2161-2170.	0.6	12
2145	The role of cellular proteostasis in antitumor immunity. <i>Journal of Biological Chemistry</i> , 2022, 298, 101930.	1.6	6

#	ARTICLE	IF	CITATIONS
2177	Melanoma: An immunotherapy journey from bench to bedside. <i>Cancer Treatment and Research</i> , 2022, 183, 49-89.	0.2	0
2178	Current situation of programmed cell death protein 1/programmed cell death ligand 1 inhibitors in advanced triple-negative breast cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2022, 34, 117-130.	0.7	2
2179	Role of Programmed Cell Death Protein-1 and Lymphocyte Specific Protein Tyrosine Kinase in the Aryl Hydrocarbon Receptor-Mediated Impairment of the IgM Response in Human CD5+ Innate-Like B Cells. <i>Frontiers in Immunology</i> , 2022, 13, 884203.	2.2	1
2180	A Systematic Review and Meta-Analysis of the role of immune checkpoint inhibitors (ICI) as adjuvant treatment for Localized High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC). <i>Clinical Genitourinary Cancer</i> , 2022, , .	0.9	1
2181	Over-expression of Programmed Death Ligand 1 (PD-L1) in Refractory Inflammatory Bowel Disease (IBD). <i>Human Pathology</i> , 2022, , .	1.1	3
2182	Advanced materials for management of immune-related adverse events induced by immune checkpoint inhibitors. <i>Materials and Design</i> , 2022, 219, 110738.	3.3	0
2183	The mutual relationship between the host immune system and radiotherapy: stimulating the action of immune cells by irradiation. <i>International Journal of Clinical Oncology</i> , 2023, 28, 201-208.	1.0	1
2184	Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177 <sup>66</sup> -Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 1136-1148.	1.9	5
2185	Preclinical Studies of a Novel Human PD-1 B-Cell Peptide Cancer Vaccine PD1-Vaxx From BALB/c Mice to Beagle Dogs and to Non-Human Primates (Cynomolgus Monkeys). <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	11
2186	Safety and potential increased risk of toxicity of radiotherapy combined immunotherapy strategy. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2023, 19, 35-50.	0.7	2
2187	Tissue and circulating PD-L2: moving from health and immune-mediated diseases to head and neck oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 175, 103707.	2.0	8
2188	Characterization and function of biomarkers in sunitinib-resistant renal carcinoma cells. <i>Gene</i> , 2022, 832, 146514.	1.0	4
2189	The role of the BTLA-HVEM complex in the pathogenesis of autoimmune diseases. <i>Cellular Immunology</i> , 2022, 376, 104532.	1.4	14
2190	Multicenter Joint Retrospective Study on the Onset of Immune-related Adverse Events by TPS in Patients Indicated for Non-small Cell Lung Cancer Pembrolizumab Monotherapy. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , 2021, 47, 239-249.	0.0	0
2191	Evolution of Medical Approaches and Prominent Therapies in Breast Cancer. <i>Cancers</i> , 2022, 14, 2450.	1.7	4
2192	Extracellular Plasmablasts Present in the Acute Phase of Infections Express High Levels of PD-L1 and Are Able to Limit T Cell Response. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	1
2193	The $\hat{\pm}5$ -nAChR/PD-L1 axis facilitates lung adenocarcinoma cell migration and invasion. <i>Human Cell</i> , 2022, 35, 1207-1218.	1.2	8
2194	The role of neoantigens in tumor immunotherapy. <i>Biomedicine and Pharmacotherapy</i> , 2022, 151, 113118.	2.5	17

#	ARTICLE	IF	CITATIONS
2195	Tumoral and Stromal Pdl1 and Pdl2 Checkpoints Immunohistochemical Expression in Pancreatic Ductal Adenocarcinoma, a Promising Field Of Study. Open Access Macedonian Journal of Medical Sciences, 2022, 10, 775-781.	0.1	0
2196	When Less May Be Enough: Dose Selection Strategies for Immune Checkpoint Inhibitors Focusing on AntiPD-(L)1 Agents. Targeted Oncology, 2022, 17, 253-270.	1.7	5
2197	Review of the Clinical Pharmacokinetics, Efficacy and Safety of Pembrolizumab. Current Drug Metabolism, 2022, 23, 460-472.	0.7	6
2198	Key differences between anti-PD-1/PD-L1 inhibitors. Meditsinskiy Sovet, 2022, , 22-28.	0.1	0
2199	Transcriptional Profiling of Leishmania infantum Infected Dendritic Cells: Insights into the Role of Immunometabolism in Host-Parasite Interaction. Microorganisms, 2022, 10, 1271.	1.6	6
2200	PD-1/PD-L Axis in Neuroinflammation: New Insights. Frontiers in Neurology, 0, 13, .	1.1	16
2201	Immunotherapy in Advanced Non-Small Cell Lung Cancers: Current Status and Updates. Cancer Management and Research, 0, Volume 14, 2079-2090.	0.9	3
2202	Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis. Biomedicines, 2022, 10, 1334.	1.4	5
2203	ALOX12: A Novel Insight in Bevacizumab Response, Immunotherapy Effect, and Prognosis of Colorectal Cancer. Frontiers in Immunology, 0, 13, .	2.2	1
2204	Leveraging structural and 2D-QSAR to investigate the role of functional group substitutions, conserved surface residues and desolvation in triggering the small molecule-induced dimerization of hPD-L1. BMC Chemistry, 2022, 16, .	1.6	3
2205	Tumor immunotherapy: Mechanisms and clinical applications. , 2022, 1, .		2
2206	Multi-modal molecular programs regulate melanoma cell state. Nature Communications, 2022, 13, .	5.8	9
2207	Novel LncRNA ZFH4-AS1 as a Potential Prognostic Biomarker That Affects the Immune Microenvironment in Ovarian Cancer. Frontiers in Oncology, 0, 12, .	1.3	7
2208	Genomic and immune microenvironment profiling in a case of metastatic intrathyroid thymic carcinoma. Clinical Case Reports (discontinued), 2022, 10, .	0.2	3
2209	PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas. Biomedicines, 2022, 10, 1587.	1.4	6
2210	The Neonatal Innate Immune Response to Sepsis: Checkpoint Proteins as Novel Mediators of This Response and as Possible Therapeutic/Diagnostic Levers. Frontiers in Immunology, 0, 13, .	2.2	1
2211	Chromatin Separation Regulators Predict the Prognosis and Immune Microenvironment Estimation in Lung Adenocarcinoma. Frontiers in Genetics, 0, 13, .	1.1	1
2212	Effects of high-fat diet on thyroid autoimmunity in the female rat. BMC Endocrine Disorders, 2022, 22, .	0.9	1

#	ARTICLE	IF	CITATIONS
2213	The Potential Predictive Biomarkers for Advanced Hepatocellular Carcinoma Treated With Anti-Angiogenic Drugs in Combination With PD-1 Antibody. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
2214	Normalization of tumor vasculature: A potential strategy to increase the efficiency of immune checkpoint blockades in cancers. <i>International Immunopharmacology</i> , 2022, 110, 108968.	1.7	2
2215	Lentivirus-mediated PD-L1 overexpression in bone marrow-derived dendritic cells induces immune tolerance in a rat keratoplasty model. <i>Transplant Immunology</i> , 2022, 74, 101654.	0.6	0
2216	Single-cell immune profiling reveals long-term changes in myeloid cells and identifies a novel subset of CD9 monocytes associated with COVID-19 hospitalization. <i>Journal of Leukocyte Biology</i> , 0, , .	1.5	5
2217	Combinatorial Strategies With PD-1/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	1
2218	Recent Advances in Immunotherapy for the Treatment of Malignant Melanoma. <i>Current Pharmaceutical Design</i> , 2022, 28, 2363-2374.	0.9	3
2220	Role of the PD-1 and PD-L1 axis in COVID-19. <i>Future Microbiology</i> , 2022, 17, 985-988.	1.0	7
2221	Micro-hydrogel injectables that deliver effective CAR-T immunotherapy against 3D solid tumor spheroids. <i>Translational Oncology</i> , 2022, 24, 101477.	1.7	9
2222	PD-L1 expression in EBV-associated gastric carcinomas. <i>Arkhiv Patologii</i> , 2022, 84, 5.	0.0	2
2223	Crosstalk Between Programmed Death Ligand 1, Ki-67 Labelling Index, and Tumor-Infiltrating Lymphocytes in Invasive Breast Cancer and Clinicopathological Correlations in a Tertiary Care Center in Western India. <i>Iranian Journal of Pathology</i> , 2022, 17, 314-322.	0.2	1
2224	Prognostic significance of programmed death-1 and programmed death ligand-1 proteins in breast cancer. <i>Human Antibodies</i> , 2022, , 1-20.	0.6	0
2225	Evolving Understanding of T-cell Cosignaling Pathways. <i>Transplantation</i> , 2022, 106, e388-e390.	0.5	1
2226	Monocyte biology conserved across species: Functional insights from cattle. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
2227	Targetability of the neurovascular unit in inflammatory diseases of the central nervous system. <i>Immunological Reviews</i> , 2022, 311, 39-49.	2.8	13
2228	Polysome-CAGE of TCL1-driven chronic lymphocytic leukemia revealed multiple N-terminally altered epigenetic regulators and a translation stress signature. <i>ELife</i> , 0, 11, .	2.8	0
2229	Development of a human phage display-derived anti-PD-1 scFv antibody: an attractive tool for immune checkpoint therapy. <i>BMC Biotechnology</i> , 2022, 22, .	1.7	10
2230	Efficacy and safety of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for locally advanced stages of esophageal cancer: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
2231	Immune Checkpoint Inhibitors: Recent Clinical Advances and Future Prospects. <i>Current Medicinal Chemistry</i> , 2023, 30, 3215-3237.	1.2	3

#	ARTICLE	IF	CITATIONS
2232	A Comparison of Murine PD-1 and PD-L1 Monoclonal Antibodies. <i>Monoclonal Antibodies in Immunodiagnosis and Immunotherapy</i> , 2022, 41, 202-209.	0.8	5
2233	Progress in programmed cell death-1/programmed cell death-ligand 1 pathway inhibitors and binding mode analysis. <i>Molecular Diversity</i> , 0, , .	2.1	1
2234	Identification of OTUD6B as a new biomarker for prognosis and immunotherapy by pan-cancer analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
2235	Beyond Cancer: Regulation and Function of PD-L1 in Health and Immune-Related Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8599.	1.8	10
2236	The changes in peripheral blood Th17 and Treg ratios in Hashimoto's thyroiditis are accompanied by differential PD-1/PD-L1 expression. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	1
2237	Immunohistochemical Phenotype of T Cells Invading Muscle in Inclusion Body Myositis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2022, 81, 825-835.	0.9	5
2238	A Bright Horizon: Immunotherapy for Pediatric T-Cell Malignancies. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8600.	1.8	6
2239	Hepatocytes infected with hepatitis C virus change immunological features in the liver microenvironment. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 65-76.	4.5	9
2240	A review of PD-1/PD-L1 siRNA delivery systems in immune T cells and cancer cells. <i>International Immunopharmacology</i> , 2022, 111, 109022.	1.7	3
2241	Design, synthesis and biological evaluation of PD-1 derived peptides as inhibitors of PD-1/PD-L1 complex formation for cancer therapy. <i>Bioorganic Chemistry</i> , 2022, 128, 106047.	2.0	8
2242	Treatment of refractory/relapsed extranodal NK/T cell lymphoma with decitabine plus anti-PD-1: A case report. <i>World Journal of Clinical Cases</i> , 0, 10, 10193-10200.	0.3	1
2243	Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 73, 117001.	1.4	9
2244	Polymeric micelles as delivery systems for anticancer immunotherapy. , 2022, , 175-197.		0
2245	Current Trends in Immuno-Oncology. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2023, 21, 96-107.	0.4	1
2246	An Extended PD-L2 Cytoplasmic Domain Results From Alternative Splicing in NSCLC Cells. <i>Journal of Immunotherapy</i> , 2022, 45, 379-388.	1.2	4
2247	Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	97
2248	Boosting the Immune Response"Combining Local and Immune Therapy for Prostate Cancer Treatment. <i>Cells</i> , 2022, 11, 2793.	1.8	3
2249	Functional Downregulation of PD-L1 and PD-L2 by CpG and non-CpG Oligonucleotides in Melanoma Cells. <i>Cancers</i> , 2022, 14, 4698.	1.7	0



#	ARTICLE	IF	CITATIONS
2250	Soluble programmed cell death-ligand 1 as a new potential biomarker associated with acute coronary syndrome. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
2252	PD-L1 Status in Tenosynovial Giant Cell Tumors. <i>Medicina (Lithuania)</i> , 2022, 58, 1270.	0.8	1
2253	A change of PD-1/PD-L1 expression on peripheral T cell subsets correlates with the different stages of Alzheimer's Disease. <i>Cell and Bioscience</i> , 2022, 12, .	2.1	6
2254	Costimulation blockade and Tregs in solid organ transplantation. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
2255	Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	33
2256	A "Cell Space Station" for Spatiotemporal Molecular Manipulation of Immune Checkpoint. <i>ACS Nano</i> , 2022, 16, 16332-16342.	7.3	1
2257	Immune Checkpoint Inhibitors in Gastroesophageal Junction or Gastric Cancer. , 2022, , 1-25.		0
2258	The Clinicopathological Significance and Prognostic Value of PD-L2 in Patients with HCC, ICC and PAAD: A Meta-Analysis. <i>International Journal of Surgery Oncology</i> , 2022, 7, 81-89.	0.2	0
2259	AKT Isoforms in the Immune Response in Cancer. <i>Current Topics in Microbiology and Immunology</i> , 2022, , 349-366.	0.7	0
2260	Bioengineering and computational analysis of programmed cell death ligand-1 monoclonal antibody. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
2261	Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis. <i>Nature Communications</i> , 2022, 13, .	5.8	12
2262	Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12067.	1.8	15
2263	Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels. <i>Annals of Hematology</i> , 0, , .	0.8	0
2264	Identification of Two Novel Immune Subtypes Characterized by Distinct Prognosis and Tumor Microenvironment in Osteosarcoma. <i>Journal of Immunology Research</i> , 2022, 2022, 1-12.	0.9	1
2265	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	59
2266	Dendritic Cells or Macrophages? The Microenvironment of Human Clear Cell Renal Cell Carcinoma Imprints a Mosaic Myeloid Subtype Associated with Patient Survival. <i>Cells</i> , 2022, 11, 3289.	1.8	2
2267	Tumor immune microenvironment in therapy-naïve esophageal adenocarcinoma could predict the nodal status. <i>Cancer Medicine</i> , 2023, 12, 5526-5535.	1.3	4
2268	The PD-1/PD-L1 Pathway: A Perspective on Comparative Immuno-Oncology. <i>Animals</i> , 2022, 12, 2661.	1.0	2

#	ARTICLE	IF	CITATIONS
2269	Immune checkpoint inhibitors in osteosarcoma: A hopeful and challenging future. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	11
2270	Phenotypic profiling of <scp>CD279</scp> and <scp>CD185</scp> level on helper T cells in patients with autoimmune hepatitis. <i>Scandinavian Journal of Immunology</i> , 0, , .	1.3	0
2271	Expression profile of immunoregulatory factors in canine tumors. <i>Veterinary Immunology and Immunopathology</i> , 2022, 253, 110505.	0.5	0
2272	Loss of LFN promotes macrophage M2 polarization and PD-L2 expression contributing cancer immune-escape in mice. <i>Cell Death Discovery</i> , 2022, 8, .	2.0	2
2273	The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
2274	Fetus, as an allograft, evades the maternal immunity. <i>Transplant Immunology</i> , 2022, 75, 101728.	0.6	2
2275	The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors. <i>Life Sciences</i> , 2022, 310, 121138.	2.0	14
2276	Immunotherapy in gynecologic malignancies. , 2023, , 506-520.e7.		0
2277	Qualitative analysis and numerical simulations of new model describing cancer. <i>Journal of Computational and Applied Mathematics</i> , 2023, 422, 114899.	1.1	12
2278	Immune Checkpoint Inhibitors in Hodgkin Lymphoma and Non-Hodgkin Lymphoma. , 0, , .		0
2279	Evolving therapeutic landscape of advanced hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 203-222.	8.2	113
2281	The effect of organ-specific tumor microenvironments on response patterns to immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
2283	Expression and T cell regulatory action of the PD-1 immune checkpoint in the ovary and fallopian tube. <i>American Journal of Reproductive Immunology</i> , 2023, 89, .	1.2	1
2284	Current studies and future promises of PD-1 signal inhibitors in cervical cancer therapy. <i>Biomedicine and Pharmacotherapy</i> , 2023, 157, 114057.	2.5	5
2285	Inflammation-mediated tissue damage in pulmonary tuberculosis and host-directed therapeutic strategies. <i>Seminars in Immunology</i> , 2023, 65, 101672.	2.7	23
2286	The Use of Immunotherapy in Cancer Patients with Autoimmune Diseases. , 2023, , 267-286.		0
2287	Suppression of CD56 <sup>bright</sup> NK cells in breast cancer patients is associated with the PD-1 and TGF- $\beta$ 2R11 expression. <i>Clinical and Translational Oncology</i> , 2023, 25, 841-851.	1.2	2
2288	The tumor microenvironment and immune targeting therapy in pediatric renal tumors. <i>Pediatric Blood and Cancer</i> , 0, , .	0.8	3

#	ARTICLE	IF	CITATIONS
2289	B7 Family Members in Pancreatic Ductal Adenocarcinoma: Attractive Targets for Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15005.	1.8	1
2290	The Glycosylation of Immune Checkpoints and Their Applications in Oncology. <i>Pharmaceuticals</i> , 2022, 15, 1451.	1.7	3
2291	Cancer immunosurveillance in respiratory diseases. , 2022, , 1-14.		2
2292	Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGF $\beta$ 2 and PD-1/PD-L1. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 1187-1202.	1.9	1
2293	Reprogramming immune cells activity by furin-like enzymes as emerging strategy for enhanced immunotherapy in cancer. <i>British Journal of Cancer</i> , 0, , .	2.9	0
2294	B7 family protein glycosylation: Promising novel targets in tumor treatment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
2296	Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
2297	Immunotherapeutics in lung cancers: from mechanistic insight to clinical implications and synergistic perspectives. <i>Molecular Biology Reports</i> , 0, , .	1.0	0
2298	Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in treating non-Hodgkin lymphoma: A systematic review and meta-analysis of clinical trials. <i>Medicine (United States)</i> , 2022, 101, e32333.	0.4	5
2299	In or out of control: Modulating regulatory T cell homeostasis and function with immune checkpoint pathways. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
2300	Identification, binding, and structural characterization of single domain anti-PD-L1 antibodies inhibitory of immune regulatory proteins PD-1 and CD80. <i>Journal of Biological Chemistry</i> , 2023, 299, 102769.	1.6	4
2301	Preconditioning Strategies to Limit Graft Immunogenicity and Cold Ischemic Organ Injury. <i>Journal of Investigative Medicine</i> , 2004, 52, 323-329.	0.7	7
2302	PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection (TUM2P.881). <i>Journal of Immunology</i> , 2014, 192, 71.5-71.5.	0.4	0
2303	The effect of Wnt/ $\beta$ -catenin signaling on PD-1/PDL-1 axis in HPV-related cervical cancer. <i>Oncology Research</i> , 2022, 30, 99-116.	0.6	7
2304	PD-L1 Biomolecules Associated with Clinical Features in Non-Melanoma Skin Cancer. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 0, Volume 16, 1-8.	0.8	0
2305	Reactivation of natural killer cells with monoclonal antibodies in the microenvironment of malignant neoplasms. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	1
2306	Immune checkpoint inhibitors and reproductive failures. <i>Journal of Reproductive Immunology</i> , 2023, 156, 103799.	0.8	11
2307	Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7

#	ARTICLE	IF	CITATIONS
2308	Spatial and single-cell transcriptomics decipher the cellular environment containing HLA-G+ cancer cells and SPP1+ macrophages in colorectal cancer. <i>Cell Reports</i> , 2023, 42, 111929.	2.9	25
2309	Strahlentherapie und Immuntherapie. <i>Springer Reference Medizin</i> , 2023, , 1-20.	0.0	0
2310	The role of check point inhibitors in autoimmune diseases; similarities and differences to cancer. <i>Critical Reviews in Immunology</i> , 2023, , .	1.0	0
2311	An immune risk score predicts survival of patients with diffuse large B-cell lymphoma. <i>Leukemia Research</i> , 2023, 125, 107008.	0.4	0
2312	Cbl-b inhibited CD4+ T cell activation by regulating the expression of miR-99a/miR-125b. <i>International Immunopharmacology</i> , 2023, 115, 109677.	1.7	1
2313	Laboratory predictors to intravesical BCG therapy response in patients with non-muscle invasive bladder cancer. <i>Urology Herald</i> , 2023, 10, 155-164.	0.1	2
2314	Prognostic value of PD-L2 in lung adenocarcinoma. <i>Asian Journal of Surgery</i> , 2022, , .	0.2	0
2315	Construction and Preclinical Evaluation of a <sup>124</sup> I-Labeled Specific Antibody Targeting PD-L2 in Lung Cancer. <i>Molecular Pharmaceutics</i> , 2023, 20, 1365-1374.	2.3	1
2316	NCAPD2 is a novel marker for the poor prognosis of lung adenocarcinoma and is associated with immune infiltration and tumor mutational burden. <i>Medicine (United States)</i> , 2023, 102, e32686.	0.4	1
2317	Therapeutic cancer vaccination against telomerase: clinical developments in melanoma. <i>Current Opinion in Oncology</i> , 2023, 35, 100-106.	1.1	0
2319	The role of immune checkpoint inhibitors (ICI) as adjuvant treatment in renal cell carcinoma (RCC): A systematic review and meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2023, 21, 324-333.	0.9	4
2320	High expression of TMEM200A is associated with a poor prognosis and immune infiltration in gastric cancer. <i>Pathology and Oncology Research</i> , 0, 29, .	0.9	3
2321	Treatment of HPV-Related Uterine Cervical Cancer with a Third-Generation Oncolytic Herpes Simplex Virus in Combination with an Immune Checkpoint Inhibitor. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1988.	1.8	4
2323	PD-1/PD-L1 and DNA Damage Response in Cancer. <i>Cells</i> , 2023, 12, 530.	1.8	12
2324	&lt;i>Dictyostelium</i> Differentiation-inducing Factor Derivatives Reduce the Glycosylation of PD-L1 in MDA-MB-231 Human Breast Cancer Cells. <i>Juntendo Medical Journal</i> , 2023, , .	0.1	0
2325	Neopeptide load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	1
2326	Nivolumab plus ipilimumab combination therapy in cancer: Current evidence to date. <i>International Immunopharmacology</i> , 2023, 117, 109881.	1.7	8
2327	The implication of anti-PD-1 therapy in cancer patients for the vaccination against viral and other infectious diseases. , 2023, 245, 108399.		8

#	ARTICLE	IF	CITATIONS
2328	The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapy. <i>Biomedicine and Pharmacotherapy</i> , 2023, 162, 114646.	2.5	7
2330	Checkpoint Blockade in Hematologic Malignancies. , 2022, , 1-42.		0
2331	Ocular immune privilege and retinal pigment epithelial cells. <i>Journal of Leukocyte Biology</i> , 2023, 113, 288-304.	1.5	8
2332	New Fractional Cancer Mathematical Model via IL-10 Cytokine and Anti-PD-L1 Inhibitor. <i>Fractal and Fractional</i> , 2023, 7, 151.	1.6	5
2333	Boosting Checkpoint Immunotherapy with Biomaterials. <i>ACS Nano</i> , 2023, 17, 3225-3258.	7.3	20
2334	Regulatory B cells are reduced in the blood in patients with granulomatosis with polyangiitis, and fail to regulate T-cell IFN- $\gamma$ production. <i>Clinical and Experimental Immunology</i> , 2023, 213, 190-201.	1.1	1
2335	Radiotherapy, PARP Inhibition, and Immune-Checkpoint Blockade: A Triad to Overcome the Double-Edged Effects of Each Single Player. <i>Cancers</i> , 2023, 15, 1093.	1.7	4
2336	Functional characterization of TSPAN7 as a novel indicator for immunotherapy in glioma. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
2338	Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer. <i>Expert Opinion on Biological Therapy</i> , 2023, 23, 227-233.	1.4	2
2339	Advances in the Study of Hyperprogression of Different Tumors Treated with PD-1/PD-L1 Antibody and the Mechanisms of Its Occurrence. <i>Cancers</i> , 2023, 15, 1314.	1.7	2
2340	The role of LncRNAs in tumor immunotherapy. <i>Cancer Cell International</i> , 2023, 23, .	1.8	11
2341	Immunotherapy of Cancer: Towards a New Era. <i>European Medical Journal Oncology</i> , 0, , 76-82.	0.0	0
2342	Shaping of the Clinical Landscape of Immunotherapy by PD-L1 Expression in Breast Cancer. , 2023, , 1-20.		0
2343	Thyroid cells from normal and autoimmune thyroid glands suppress T lymphocytes proliferation upon contact revealing a new regulatory inhibitory type of interaction independent of PD1/PDL1. <i>Journal of Autoimmunity</i> , 2023, 136, 103013.	3.0	1
2344	Analysis of factors affecting testicular spermatogenesis capacity by using the tissue transcriptome data from GTEx. <i>Reproductive Toxicology</i> , 2023, 117, 108359.	1.3	0
2345	iATMEcell: identification of abnormal tumor microenvironment cells to predict the clinical outcomes in cancer based on cell-cell crosstalk network. <i>Briefings in Bioinformatics</i> , 2023, 24, .	3.2	1
2347	Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy. <i>Theranostics</i> , 2023, 13, 1520-1544.	4.6	19
2348	Safety and efficacy of radiotherapy/chemoradiotherapy combined with immune checkpoint inhibitors for non-small cell lung cancer: A systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3

#	ARTICLE	IF	CITATIONS
2349	IFN- $\gamma$ signature enables selection of neoadjuvant treatment in patients with stage III melanoma. <i>Journal of Experimental Medicine</i> , 2023, 220, .	4.2	19
2350	Pan-cancer analysis identifies PD-L2 as a tumor promotor in the tumor microenvironment. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
2351	Predictive Factors for Response and Resistance to Anti-PD-1 Immunotherapy in Melanoma. , 2023, , 1-19.		0
2352	Immunotherapy for hepatocellular carcinoma: Recent advances and future targets. , 2023, 244, 108387.		12
2353	Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers. <i>Molecular Cancer</i> , 2023, 22, .	7.9	32
2354	Boron Derivatives Inhibit the Proliferation of Breast Cancer Cells and Affect Tumor-Specific T Cell Activity In Vitro by Distinct Mechanisms. <i>Biological Trace Element Research</i> , 2023, 201, 5692-5707.	1.9	5
2355	Immunotherapy in Gastrointestinal Malignancies. , 2023, , 1-23.		0
2356	The predictive values of soluble B7-DC in children with refractory mycoplasma pneumoniae pneumonia. <i>Translational Pediatrics</i> , 2023, 12, 396-404.	0.5	3
2357	APC mutation correlated with poor response of immunotherapy in colon cancer. <i>BMC Gastroenterology</i> , 2023, 23, .	0.8	1
2358	Novel technologies for applying immune checkpoint blockers. <i>International Review of Cell and Molecular Biology</i> , 2024, , 1-101.	1.6	2
2360	Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice. <i>Biomedicines</i> , 2023, 11, 1071.	1.4	27
2361	Immunophenotypic and Functional Characterization of Eosinophil and Migratory Dendritic Cell Subsets during Filarial Manifestation of Tropical Pulmonary Eosinophilia. <i>ACS Infectious Diseases</i> , 2023, 9, 1105-1122.	1.8	4
2362	PCSK9, a novel immune and ferroptosis related gene in abdominal aortic aneurysm neck. <i>Scientific Reports</i> , 2023, 13, .	1.6	6
2363	Novel strategies for cancer immunotherapy: counter-immunoediting therapy. <i>Journal of Hematology and Oncology</i> , 2023, 16, .	6.9	14
2364	Immunotherapy and Cancer Stem Cells. , 2023, , 165-235.		0
2365	Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 7640.	1.8	5
2366	Therapeutic potential for coxib-nitric oxide releasing hybrids in cancer treatment. , 2023, , 57-115.		0
2367	Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review. <i>World Journal of Gastrointestinal Surgery</i> , 0, 15, 495-519.	0.8	12

#	ARTICLE	IF	CITATIONS
2397	Checkpoint blockade meets gene therapy: Opportunities to improve response and reduce toxicity. <i>International Review of Cell and Molecular Biology</i> , 2023, , 43-86.	1.6	1
2432	Microbiota-dependent regulation of costimulatory and coinhibitory pathways via innate immune sensors and implications for immunotherapy. <i>Experimental and Molecular Medicine</i> , 2023, 55, 1913-1921.	3.2	3
2457	Prognostic Factors in Advanced Renal Cell Carcinoma. , 2023, , 233-250.		0
2459	Plasmablastic Lymphoma. , 2023, , .		0
2466	PD-1 receptor outside the main paradigm: tumour-intrinsic role and clinical implications for checkpoint blockade. <i>British Journal of Cancer</i> , 2023, 129, 1409-1416.	2.9	4
2467	Beyond Inhibition Against PD-1/PD-L1 Pathway: Development of PD-L1 Inhibitors Targeting Internalization and Degradation of PD-L1. <i>RSC Medicinal Chemistry</i> , 0, , .	1.7	0
2478	Cancer immunotherapy-associated endocrine complications and treatment strategies. , 2024, , 199-221.		0
2487	Immune Checkpoint Molecules and Maternalâ€Fetal Immunity. <i>Current Obstetrics and Gynecology Reports</i> , 2024, 13, 37-45.	0.3	0
2498	Immune-oncological drug atezolizumab. , 2024, , 89-101.		0
2502	Molecular Imaging of PD-1 Unveils Unknown Characteristics of PD-1 Itself by Visualizing â€œPD-1 Microclustersâ€¸ <i>Advances in Experimental Medicine and Biology</i> , 2024, , 197-205.	0.8	0